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SUMMARY 
Coronary artery disease (CAD) is the major cause of morbidity and mortality 
worldwide.  Myocardial infarction (MI), namely heart attack, is a more severe 
phenotype of CAD.  The etiology of CAD is largely contributed by genetics 
and environmental exposures.  With an increasing number of studies on the 
impact of environmental exposures, several guidelines have been proposed 
and a reduced risk of CAD has been documented in individuals who adhere to 
the guidelines.  However, much less is known about the genetic basis of CAD.  
Genome wide association analysis, which is a powerful tool to identify genetic 
variants, is commonly employed to identify novel genetic variants currently.  
Most genome wide association studies (GWAS) have been conducted in 
Caucasians while few were carried out in Asia.  The overall aim of this 
dissertation was to elucidate the genetic basis in relation to CAD and its 
associated quantitative intermediate traits, high density lipoprotein cholesterol 
(HDL-C), low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) 
in Singaporean Chinese populations. 
 
We first assembled 1,136 myocardial infarction (MI) cases and 1,243 controls 
from existing Singaporean Chinese cohorts to conduct GWAS, with the aim of 
discovering new susceptibility loci for CAD.  We did not observe any new 
genetic variants to be associated with MI but there were suggestive 
associations in several genes that are implicated in the biology of CAD such as 
vascular endothelial growth factor A.  We next conducted GWAS and meta-
analyses on the intermediate quantitative traits of CAD, namely HDL-C, LDL-
ix 
 
C and TG in 2,003 Singaporean Chinese with stratification by their MI status.  
In this study, 66 of the 174 genetic variants that were previously reported in 
Caucasians have been successfully replicated in the Singaporean Chinese, thus 
demonstrating the transferability of these genetic variants across ethnic groups.  
Significant novel genome wide associations have also been discovered in 11 
genetic variants for HDL-C, 18 for LDL-C and 22 for TG.  To determine the 
independent roles of these newly identified variants, conditional analysis was 
carried out to adjust the effect of index variants.  We found no evidence of 
genome wide significant associations for these variants after the conditioning.   
 
A situation of missing heritability is encountered when individual genes 
cannot fully account for all the heritability of diseases that is expected to be 
contributed by genetic factors.  Like most if not all complex diseases, CAD is 
not spared from this phenomenon.  To address this issue, a gene-gene 
interaction study was carried out for peroxisome proliferator activated 
receptors (PPARs), which are the key upstream regulators in the HDL-C 
metabolic pathway.  A statistically significant interaction influencing HDL-C 
has been detected between PPARδ variant rs2267668 and epithelial membrane 
protein 2 downstream variant rs7191411 (β=-0.19, P=1.19x10-10) after 
multiple-testing correction (corrected P significance threshold: 1.18x10
-9
).  
The interaction has been successfully replicated (meta-analysis β=-0.13,  
P=3.72x10
-11
) in two independent Chinese populations (N=1,872 and N=1,928) 
but not in the Malays and Indians.   
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These findings highlight the global transferability of the majority of genetic 
variants and the potential new susceptibility of several loci for CAD.  The 
significant gene-gene interaction, identified for the first time, provides new 
insight into the potentially new mechanisms influencing circulating HDL-C.  
xi 
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Chapter 1: Introduction 
1.1 Overview of coronary artery disease 
Coronary artery disease (CAD) is the most common type of heart disease and the 
number two killer of death after cancer.  It is characterized by the blockage of 
coronary arteries.  The development of CAD begins with fatty acids depositing 
(also called plaques) in the vessels, grows gradually with plagues building up 
inside the arteries and results in difficult blood flow.  Patients with CAD may 
experience a discomfort (called angina) caused by lack of oxygen in heart muscles.  
Sometimes a more severe consequence, myocardial infarction (MI) or heart attack 
will occur when plaques rupture and occlude the coronary arteries, causing death 
of heart muscles.  The main problem is that many people are unconscious of their 
disease status until they have angina or heart attack.  Therefore, it is important to 
study the etiology of CAD to facilitate the prediction and prevention of CAD. 
 
1.2 Overview of the epidemiology of coronary artery disease 
Cardiovascular disease is the leading cause of morbidity and mortality worldwide.  
The number of people who die annually from cardiovascular disease is higher 
than that from any other diseases [1].  According to the 2013 Fact Sheet of World 
Health Organization, approximately 17.3 million people died from cardiovascular 
disease in 2008, which represents 30% of the global deaths[1].  Of these deaths, 
6.2 million people died from stroke and 7.3 million people died from coronary 
artery disease[2].  It is estimated that the number of people who die from 
cardiovascular disease will increase to 23.3 million by 2030 and it will remain the 
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leading cause of death [3].  In future, cardiovascular disease would be the largest 
single contributor to global morbidity and mortality and will continue to remain 
so [4].  Therefore, studies in CAD need to be carried out to address such a health 
burden.  
 
Benefiting from the effective interventions and treatments for cardiovascular 
disease, the trend of mortality in developed countries declines slightly [5].  
However, the mortality rate of cardiovascular disease in developing countries 
increases rapidly.  Currently, over 80% of the world’s deaths have occurred in 
developing countries[1].  Several factors could be contributed to the increase.  
First, people in developing countries are more exposed to environmental risk 
factors such as tobacco.  Second, effective health care service is less accessible 
for them.  Likewise, prediction and prevention programs that they can benefit 
from are also less accessible compared to those in developed countries.  Third, big 
changes in diet and physical activities due to urbanization and globalization could 
play a particularly important role in the rise of cardiovascular disease in 
developing countries.  As a result, people in developing countries have a younger 
age of onset and higher incidence rate.  Asia, in which the majority of countries 
are developing countries, also experiences high cardiovascular burden and 
mortality rate.  Therefore, it is imperative that studies of coronary artery disease 
in Asia are conducted to address this increasing burden. 
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1.3 Overview of the etiology of coronary artery disease 
The etiology of CAD is multifactorial, involving environmental and genetic 
factors, as well as their interactions with each other.  Life style factors and various 
other environmental factors such as diet, smoking and physical activities have 
been repeatedly reported in epidemiological studies of CAD.  Smoking is the 
strongest environmental risk factor.  CAD patients who smoked more than 12 
cigarettes per day were observed to have a higher relative risk of 5.48 compared 
to nonsmokers[6].  The risk ratios of other environmental factors, such as body 
mass index, physical activities and diet score, remain high ranging from 1.41 to 
1.90.  A growing body of interventional studies have been conducted and showed 
that modification of lifestyle, diet and smoking would reduce the risk of 
cardiovascular mortality.  One of the significant examples was that a 30% 
reduction in CAD-related mortality was observed when 36% of cardiac patients 
stopped smoking [7].   
 
Genetic factors also play an important role in the etiology of CAD.  It has been 
reported that a2-fold increase of CAD risk was observed in subjects with family 
history of premature disease, and that this cannot be explained by environmental 
factors [4].  Table 1 reviews the genes that are involved in the CAD-related 
metabolic pathways, such as lipid metabolism, blood pressure regulation and 
insulin sensitivity [8-10].  The genetic variants in such genes can potentially 
affect protein expression and biological processes that underlie the onset of CAD. 
For example, genetic variants may elevate triglycerides and decrease high density 
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lipoprotein level, leading to increased risk of CAD [5].  Moreover, many 
Mendelian disorders can lead to CAD or have features of CAD. In Online 
Mendelian Inheritance in Man (OMIM)[11], an online catalog of human genes 
and genetic disorders, 200 Mendelian disorders with features of CAD have been 
recorded (Table 2).  Among them, 181 Mendelian disorders have known genetic 
basis, which is the fundamental cause of these Mendelian disorders that can lead 
to CAD or have features of CAD. The heritability of CAD has been evaluated in 
20,966 Swedish twins and has shown a high value of 0.57 in men and 0.38 in 
women [12].All the above evidences imply the important role of genetics in the 
onset of CAD. Furthermore, genetic factors can interact with genes and 
environmental factors to influence the final outcome on CAD.  For example, it 
has been demonstrated that apolipoprotein E ἐ4 carriers had 2 to 3 times higher 
risk of CAD in smokers than nonsmokers [13].  However, it is challenging to 
unveil genetic determinants that interact with environmental factors or genes 
when the genetic variant exhibits opposite effects on CAD for different 
environmental conditions and different genotypes. For example, subjects with CC 
genotypes of PPARγ had higher CAD incidence in apoε4 carriers than non-apoε4 
carriers but subjects with CT genotypes of PPARγ had lower CAD incidence in 
apoε4 carriers than non-apoE4 carriers [14]. Therefore, it is highly imperative to 
uncover the genetic basis of CAD and investigate how these genetic determinants 
interact within themselves or with environmental factors. 
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Table 1 Genes associated with increased risk for CAD/MI. A summary of three review 
papers [8-10] 
Genes OMIM No. References 
Lipid metabolism 
  
ATP-binding cassette, subfamily a, member 1 600046 [15, 16] 
ATP-binding cassette, subfamily g, member 1 603076 [17, 18] 
Apolipoprotein (a) 152200 [19] 
Apolipoprotein B 107730 [20] 
Apolipoprotein C-I 107710 [21] 
Apolipoprotein E 107741 [22-28] 
Cholesterol ester transfer protein 118470 [29-32] 
LDL receptor 606945 [33] 
Lecithin cholesterol acetyl transferase 606961 [34] 
Lipoprotein lipase 238600 [35, 36] 
Blood pressure regulation 
  
Alpha-adducin 102680 [37] 
Angiotensin converting enzyme 106180 [38, 39] 
Angiotensin II receptor, type 1 106165 [40, 41] 
Angiotensinogen 106150 [40, 42, 43] 
Insulin sensitivity 
  
Insulin receptor substrate-1 147545 [44] 
Homocysteine metabolism 
  
Cystathionine beta synthase 236200 [45-47] 
Methylene tetrahydrofolate reductase 607093 [48-51] 
Thrombosis 
  
Factor II (Prothrombin) 176930 [52] 
Factor V (Factor V Leiden) 227400 [53, 54] 
Factor VII 227500 [55-57] 
Thrombospondin genes 188060 [58] 
 
188061 
 
 
188062 
 
Fibrinolysis 
  
Fibrinogen genes 134820 [59-62] 
 
134830 
 
 
134850 
 
Plasminogen activator inhibitor-1 173360 [63, 64] 
Thrombin-activatable fibrinolysis inhibitor 603101 [65] 
Platelet function 
  
Glycoprotein Ia/IIa receptor 192974 [66] 
Glycoprotein IIIa receptor 173470 [67-69] 
Endothelial/vessel function 
  
Connexin 37 121012 [64] 
Endothelial nitric oxide synthase 163729 [69] 
Matrix Gla protein 154870 [70] 
Matrix metalloproteinase 9 120361 [71] 
Stomelysin-1 185250 
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Table 1(continued) Genes associated with increased risk for CAD/MI. A summary of three 
review papers [8-10] 
Genes OMIM No. References 
Inflammatory response 
  
Endothelial leukocyte adhesion molecule-1 (E-selectin) 131210 [72, 73] 
Arachidonate 5-lipoxygenase 152390 [74] 
Arachidonate 5-lipoxygenase-activating protein 603700 [74] 
Granule membrane protein (P-selectin) 173610 [75, 76] 
Interleukin-6 147620 [77] 
Paraoxonase 168820 [78, 79] 
Miscellaneous 
  
Adenosine monophosphate deaminase-1 102770 [80] 
Alcohol dehydrogenase type 3 103730 [81] 
Ataxia-telangiectasia locus 607585 [82] 
Cytochrome b(-245), alpha subunit 608508 [83-85] 
Werner syndrome locus 604611 [86] 
Obesity/Diabetes 
  
Leptin receptor 601007 [87] 
Peroxisome proliferator-activated receptor gamma 601487 [88, 89] 
Coagulation 
  
Thrombospondin II 188061 [90, 91] 
Thrombospondin IV 600715 [90] 
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Table 2 Mendelian disorders featuring coronary artery disease or myocardial infarction in 
OMIM[11] 
No. MIM No. Mendelian disorders featuring coronary artery disease or myocardial infarction 
1 #615812 ABDOMINAL OBESITY-METABOLIC SYNDROME 3; AOMS3 
2 #118450 ALAGILLE SYNDROME 1; ALGS1 
3 #300600 ALAND ISLAND EYE DISEASE; AIED 
4 #203450 ALEXANDER DISEASE 
5 #203500 ALKAPTONURIA; AKU 
6 #502500 ALZHEIMER DISEASE, SUSCEPTIBILITY TO, MITOCHONDRIAL 
7 #132900 AORTIC ANEURYSM, FAMILIAL THORACIC 4; AAT4 
8 #615436 AORTIC ANEURYSM, FAMILIAL THORACIC 8; AAT8 
9 #614823 AORTIC VALVE DISEASE 2; AOVD2 
10 #107970 ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 1; ARVD1 
11 #610193 
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 10; 
ARVD10 
12 #610476 
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 11; 
ARVD11 
13 #611528 
ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 12; 
ARVD12 
14 #600996 ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 2; ARVD2 
15 #609040 ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA, FAMILIAL, 9; ARVD9 
16 #208000 ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 1; GACI1 
17 #614473 ARTERIAL CALCIFICATION, GENERALIZED, OF INFANCY, 2; GACI2 
18 #614475 ATRIAL SEPTAL DEFECT 9; ASD9 
19 #615745 ATRIAL STANDSTILL 2; ATRST2 
20 #615952 AUTOIMMUNE DISEASE, MULTISYSTEM, INFANTILE-ONSET; ADMIO 
21 #613385 
AUTOIMMUNE DISEASE, MULTISYSTEM, WITH FACIAL DYSMORPHISM; 
ADMFD 
22 #607595 
BRAIN SMALL VESSEL DISEASE WITH OR WITHOUT OCULAR ANOMALIES; 
BSVD 
23 #211800 CALCIFICATION OF JOINTS AND ARTERIES; CALJA 
24 #131300 CAMURATI-ENGELMANN DISEASE; CAEND 
25 #115200 CARDIOMYOPATHY, DILATED, 1A; CMD1A 
26 #615235 CARDIOMYOPATHY, DILATED, 1JJ; CMD1JJ 
27 #613873 CARDIOMYOPATHY, FAMILIAL HYPERTROPHIC, 17; CMH17 
28 #608836 CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY, LETHAL NEONATAL 
29 #605714 CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED 
30 #125310 
CEREBRAL ARTERIOPATHY, AUTOSOMAL DOMINANT, WITH SUBCORTICAL 
INFARCTS AND LEUKOENCEPHALOPATHY; CADASIL 
31 #213700 CEREBROTENDINOUS XANTHOMATOSIS; CTX 
32 #609260 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2A2; CMT2A2 
33 #600882 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2B; CMT2B 
34 #607684 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2E; CMT2E 
35 #607677 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2I; CMT2I 
36 #613287 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2N; CMT2N 
37 #614228 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2O; CMT2O 
38 #614436 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2P; CMT2P 
39 #615025 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2Q; CMT2Q 
40 #615490 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2R; CMT2R 
41 #616155 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2S; CMT2S 
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Table 2 (continued) Mendelian disorders featuring coronary artery disease or myocardial 
infarction in OMIM [11] 
No. MIM No. Mendelian disorders featuring coronary artery disease or myocardial infarction 
42 #616233 CHARCOT-MARIE-TOOTH DISEASE, AXONAL, TYPE 2T; CMT2T 
43 #601098 CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1C; CMT1C 
44 #607678 CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 1D; CMT1D 
45 #614895 CHARCOT-MARIE-TOOTH DISEASE, DEMYELINATING, TYPE 4F; CMT4F 
46 #608323 CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE C; CMTDIC 
47 #614455 CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE E; CMTDIE 
48 #615185 CHARCOT-MARIE-TOOTH DISEASE, DOMINANT INTERMEDIATE F; CMTDIF 
49 #608340 CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE A; CMTRIA 
50 #613641 CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB 
51 #615376 CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE C; CMTRIC 
52 #616039 CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE D; CMTRID 
53 #604563 CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B2; CMT4B2 
54 #615284 CHARCOT-MARIE-TOOTH DISEASE, TYPE 4B3; CMT4B3 
55 #601596 CHARCOT-MARIE-TOOTH DISEASE, TYPE 4C; CMT4C 
56 #611228 CHARCOT-MARIE-TOOTH DISEASE, TYPE 4J; CMT4J 
57 #302800 CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 1; CMTX1 
58 #300905 CHARCOT-MARIE-TOOTH DISEASE, X-LINKED DOMINANT, 6; CMTX6 
59 #311070 CHARCOT-MARIE-TOOTH DISEASE, X-LINKED RECESSIVE, 5; CMTX5 
60 #246700 CHYLOMICRON RETENTION DISEASE; CMRD 
61 #615522 COLE DISEASE; COLED 
62 #280000 
COLOBOMA, CONGENITAL HEART DISEASE, ICHTHYOSIFORM DERMATOSIS, 
MENTAL RETARDATION, AND EAR ANOMALIES SYNDROME; CHIME 
63 #610947 CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT 2; ADCAD2 
64 #608320 CORONARY ARTERY DISEASE, AUTOSOMAL DOMINANT, 1; ADCAD1 
65 #614437 CUTIS LAXA, AUTOSOMAL RECESSIVE, TYPE IB; ARCL1B 
66 #300257 DANON DISEASE 
67 #300009 DENT DISEASE 1 
68 #300555 DENT DISEASE 2 
69 #135290 DESMOID DISEASE, HEREDITARY 
70 #112250 
DIAPHYSEAL MEDULLARY STENOSIS WITH MALIGNANT FIBROUS 
HISTIOCYTOMA; DMSMFH 
71 #615327 DOWLING-DEGOS DISEASE 2; DDD2 
72 #615696 DOWLING-DEGOS DISEASE 4; DDD4 
73 #223800 DYGGVE-MELCHIOR-CLAUSEN DISEASE; DMC 
74 #609638 EPIDERMOLYSIS BULLOSA, LETHAL ACANTHOLYTIC; EBLA 
75 #133100 ERYTHROCYTOSIS, FAMILIAL, 1; ECYT1 
76 #615363 ESTROGEN RESISTANCE; ESTRR 
77 #301500 FABRY DISEASE 
78 #136120 FISH-EYE DISEASE; FED 
79 #600803 GALLBLADDER DISEASE 1; GBD1 
80 #608013 GAUCHER DISEASE, PERINATAL LETHAL 
81 #230800 GAUCHER DISEASE, TYPE I 
82 #230900 GAUCHER DISEASE, TYPE II 
83 #231000 GAUCHER DISEASE, TYPE III 
84 #231005 GAUCHER DISEASE, TYPE IIIC 
85 #137440 GERSTMANN-STRAUSSLER DISEASE; GSD 
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Table 2 (continued) Mendelian disorders featuring coronary artery disease or myocardial 
infarction in OMIM [11] 
No. MIM No. Mendelian disorders featuring coronary artery disease or myocardial infarction 
86 #240600 GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A 
87 #611556 GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B 
88 #232200 GLYCOGEN STORAGE DISEASE Ia; GSD1A 
89 #232220 GLYCOGEN STORAGE DISEASE Ib; GSD1B 
0 #232240 GLYCOGEN STORAGE DISEASE Ic 
91 #232300 GLYCOGEN STORAGE DISEASE II; GSD2 
92 #232400 GLYCOGEN STORAGE DISEASE III; GSD3 
93 #232500 GLYCOGEN STORAGE DISEASE IV; GSD4 
94 #306000 GLYCOGEN STORAGE DISEASE IXa1; GSD9A1 
95 #613027 GLYCOGEN STORAGE DISEASE IXc; GSD9C 
96 #261740 GLYCOGEN STORAGE DISEASE OF HEART, LETHAL CONGENITAL 
97 #232600 GLYCOGEN STORAGE DISEASE V; GSD5 
98 #232700 GLYCOGEN STORAGE DISEASE VI; GSD6 
99 #232800 GLYCOGEN STORAGE DISEASE VII; GSD7 
100 #612933 GLYCOGEN STORAGE DISEASE XI; GSD11 
101 #611881 GLYCOGEN STORAGE DISEASE XII; GSD12 
102 #612932 GLYCOGEN STORAGE DISEASE XIII; GSD13 
103 #613507 GLYCOGEN STORAGE DISEASE XV; GSD15 
104 #300559 GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D 
105 #233690 
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 
CYTOCHROME b-NEGATIVE 
106 #233700 
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 
CYTOCHROME b-POSITIVE, TYPE I 
107 #233710 
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 
CYTOCHROME b-POSITIVE, TYPE II 
108 #613960 
GRANULOMATOUS DISEASE, CHRONIC, AUTOSOMAL RECESSIVE, 
CYTOCHROME b-POSITIVE, TYPE III 
109 #306400 GRANULOMATOUS DISEASE, CHRONIC, X-LINKED; CGD 
110 #612356 HEPARIN COFACTOR II DEFICIENCY 
111 #235550 HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY; VODI 
112 #142623 HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1; HSCR1 
113 #236200 HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY 
114 #143100 HUNTINGTON DISEASE; HD 
115 #603218 HUNTINGTON DISEASE-LIKE 1; HDL1 
116 #607014 HURLER SYNDROME 
117 #143890 HYPERCHOLESTEROLEMIA, FAMILIAL 
118 #243700 HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL RECESSIVE 
119 #146255 
HYPOPARATHYROIDISM, SENSORINEURAL DEAFNESS, AND RENAL DISEASE; 
HDR 
120 #167320 
INCLUSION BODY MYOPATHY WITH EARLY-ONSET PAGET DISEASE WITH OR 
WITHOUT FRONTOTEMPORAL DEMENTIA 1; IBMPFD1 
121 #612567 INFLAMMATORY BOWEL DISEASE 25, AUTOSOMAL RECESSIVE; IBD25 
122 #613148 INFLAMMATORY BOWEL DISEASE 28, AUTOSOMAL RECESSIVE; IBD28 
123 #614328 INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 1; NISBD1 
124 #616069 INFLAMMATORY SKIN AND BOWEL DISEASE, NEONATAL, 2; NISBD2 
125 #609242 KANZAKI DISEASE 
126 #245200 KRABBE DISEASE 
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Table 2 (continued) Mendelian disorders featuring coronary artery disease or myocardial 
infarction in OMIM [11] 
No. MIM No. Mendelian disorders featuring coronary artery disease or myocardial infarction 
127 #611722 KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY 
128 #613485 LONG QT SYNDROME 13; LQT13 
129 #248600 MAPLE SYRUP URINE DISEASE; MSUD 
130 #155100 MAY-HEGGLIN ANOMALY; MHA 
131 #309350 MELNICK-NEEDLES SYNDROME; MNS 
132 #309400 MENKES DISEASE 
133 #300845 
MOYAMOYA DISEASE 4 WITH SHORT STATURE, HYPERGONADOTROPIC 
HYPOGONADISM, AND FACIAL DYSMORPHISM; MYMY4 
134 #615750 MOYAMOYA DISEASE 6 WITH ACHALASIA; MYMY6 
135 #252700 MUCOPOLYSACCHARIDOSES, UNCLASSIFIED TYPES 
136 #253010 MUCOPOLYSACCHARIDOSIS TYPE IVB 
137 #253250 MULIBREY NANISM 
138 #613834 MULTISYSTEMIC SMOOTH MUSCLE DYSFUNCTION SYNDROME 
139 #253800 
MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH 
BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4 
140 #256700 NEUROBLASTOMA, SUSCEPTIBILITY TO 
141 #610717 NEUTRAL LIPID STORAGE DISEASE WITH MYOPATHY; NLSDM 
142 #607616 NIEMANN-PICK DISEASE, TYPE B 
143 #607625 NIEMANN-PICK DISEASE, TYPE C2; NPC2 
144 #310600 NORRIE DISEASE; ND 
145 #239000 PAGET DISEASE, JUVENILE 
146 #168601 PARKINSON DISEASE 1, AUTOSOMAL DOMINANT; PARK1 
147 #612953 PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14 
148 #614203 PARKINSON DISEASE 17; PARK17 
149 #614251 PARKINSON DISEASE 18; PARK18 
150 #615528 PARKINSON DISEASE 19, JUVENILE-ONSET; PARK19 
151 #615530 PARKINSON DISEASE 20, EARLY-ONSET; PARK20 
152 #605909 PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK6 
153 #606324 PARKINSON DISEASE 7, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK7 
154 #607060 PARKINSON DISEASE 8, AUTOSOMAL DOMINANT; PARK8 
155 #168600 PARKINSON DISEASE, LATE-ONSET; PD 
156 #312080 PELIZAEUS-MERZBACHER DISEASE; PMD 
157 #610489 PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 1; PPNAD1 
158 #610475 PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 2; PPNAD2 
159 #615830 PIGMENTED NODULAR ADRENOCORTICAL DISEASE, PRIMARY, 4; PPNAD4 
160 #615688 POLYARTERITIS NODOSA, CHILDHOOD-ONSET; PAN 
161 #263300 POLYCYTHEMIA VERA; PV 
162 #177850 PSEUDOXANTHOMA ELASTICUM, FORME FRUSTE 
163 #264800 PSEUDOXANTHOMA ELASTICUM; PXE 
164 #234810 PULMONARY VENOOCCLUSIVE DISEASE 2, AUTOSOMAL RECESSIVE; PVOD2 
165 #606072 RIPPLING MUSCLE DISEASE; RMD 
166 #604369 SALLA DISEASE; SD 
167 #609241 SCHINDLER DISEASE, TYPE I 
168 #260400 SHWACHMAN-DIAMOND SYNDROME; SDS 
169 #248200 STARGARDT DISEASE 1; STGD1 
170 #205400 TANGIER DISEASE; TGD 
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Table 2 (continued) Mendelian disorders featuring coronary artery disease or myocardial 
infarction in OMIM [11] 
No. MIM No. Mendelian disorders featuring coronary artery disease or myocardial infarction 
171 #615542 
TESTICULAR ANOMALIES WITH OR WITHOUT CONGENITAL HEART DISEASE; 
TACHD 
172 #614521 THROMBOCYTHEMIA 3; THCYT3 
173 #612304 
THROMBOPHILIA DUE TO PROTEIN C DEFICIENCY, AUTOSOMAL RECESSIVE; 
THPH4 
174 #608808 TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 1; DTGA1 
175 #613853 TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 2; DTGA2 
176 #613854 TRANSPOSITION OF THE GREAT ARTERIES, DEXTRO-LOOPED 3; DTGA3 
177 #191100 TUBEROUS SCLEROSIS 1; TSC1 
178 #613254 TUBEROUS SCLEROSIS 2; TSC2 
179 #607636 VAN BUCHEM DISEASE, TYPE 2 
180 #613554 VON WILLEBRAND DISEASE, TYPE 2; VWD2 
181 #194050 WILLIAMS-BEUREN SYNDROME; WBS 
182 %612726 HARDIKAR SYNDROME 
183 %608600 LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 1; FPLD1 
184 %602248 MALIGNANT ATROPHIC PAPULOSIS 
185 %252350 MOYAMOYA DISEASE 1; MYMY1 
186 %180000 RETINAL ARTERIES, TORTUOSITY OF 
187 +152200 APOLIPOPROTEIN(a); LPA 
188 *108000 ARTERIES, ANOMALIES OF 
189 *209010 
ATHEROSCLEROSIS, PREMATURE, WITH DEAFNESS, NEPHROPATHY, 
DIABETES MELLITUS, PHOTOMYOCLONUS, AND DEGENERATIVE 
NEUROLOGIC DISEASE 
190 *116870 
CELIAC ARTERY STENOSIS FROM COMPRESSION BY MEDIAN ARCUATE 
LIGAMENT OF DIAPHRAGM 
191 *122455 CORONARY ARTERY DISSECTION, SPONTANEOUS 
192 *124950 
DEAFNESS, SENSORINEURAL, WITH PERIPHERAL NEUROPATHY AND 
ARTERIAL DISEASE 
193 *128950 EARLOBE CREASE 
194 *135580 FIBROMUSCULAR DYSPLASIA OF ARTERIES 
195 *231100 HEMOCHROMATOSIS, NEONATAL 
196 *243100 INTERNAL CAROTID ARTERIES, HYPOPLASIA OF 
197 *147820 INTERNAL CAROTID ARTERY, SPONTANEOUS DISSECTION OF 
198 *606519 PHACE ASSOCIATION 
199 *180080 RETINAL VENOUS BEADING 
200 *610338 RIGHT PULMONARY ARTERY, ANOMALOUS ORIGIN OF, FAMILIAL 
#Phenotype description with known genetic basis 
%Phenotype description or locus with unknown genetic basis 
+Phenotype description combined with genetic basis 
*Other, mainly phenotypes with suspected Mendelian basis 
12 
 
1.4 Research objectives and significances 
Study I: Genome wide scan of single nucleotide polymorphisms 
associated with myocardial infarction –Chapter 4 
Genome wide association analysis is a powerful tool to identify genetic 
determinants, especially for common diseases.  Genome wide association 
studies (GWAS) have uncovered multiple variants associated with CAD or MI 
in Caucasians.  It is thus desirable to extend the method to the genetic studies 
of Asians.  Such studies can also provide Asian-specific genetic information 
of CAD.  Until 2014, two GWAS in Chinese have been conducted and 
identified five new susceptibility loci for CAD.  Hence, we aimed to  
i) Discover genetic variants associated with CAD by genome wide 
association analysis  
ii) Replicate the susceptibility loci reported in the two Chinese GWAS 
 
Study II: Genome wide scan of single nucleotide polymorphisms 
associated with serum lipid concentrations–Chapter 5 
Serum lipid concentrations, including high density lipoprotein (HDL), low 
density lipoprotein (LDL-C) and triglycerides (TG) are important risk factors 
of CAD and MI.  They are independently associated with CAD and 
considered as intermediate traits of CAD.  The discovery and identification of 
lipid traits associated loci may facilitate the control and therapy of 
cardiovascular disease.  Given the same sample size, it has a higher power to 
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detect variants associated with intermediate traits compared to GWAS of 
CAD.  In this study, we aimed to  
i) Identify new susceptibility loci associated with three lipid traits—
HDL-C, LDL-C, TG. 
ii) Replicate index variants reported in the literature to examine the 
transferability of index variants to the Chinese population. 
iii) Examine the causality of lipid trait for CAD/MI 
 
Study III: Interactions between genetic variants of peroxisome 
proliferator activated receptor delta and epithelial membrane protein 2 
on high density lipoprotein cholesterol levels in the Singaporean 
Chinese—Chapter 6 
Although many GWAS have been conducted to identify novel loci associated 
with CAD, the identified variants cannot fully explain the heritability of CAD.  
Gene-gene interaction is one of the important factors that account for the 
missing heritability, which is of importance to understand the etiology of 
CAD/MI.  However, it is difficult to identify gene-gene interactions in a small 
population on a genome-wide scale.  A more feasible option is to select 
candidate genes that are biologically related with traits of interest.  In our 
study, genetic variants from the peroxisome proliferator activated receptors 
(PPARs) were selected due to the instrumental role that these 
receptors/transcription factors play in HDL-C metabolism.  Hence, we aimed 
to  
i) Identify new variants in PPARs that associate with HDL-C 
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ii) Discover significant gene-gene interactions influencing HDL-C 
iii) Validate the interactions in additional cohorts 
 
We believe investigations of CAD in Asians would provide insights into Asian 
genetics, extend our understanding of genetic basis of CAD, and facilitate the 
discovery of new avenues for novel therapeutic strategies for combating CAD. 
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Chapter 2 Literature review 
This chapter presents a survey of literature pertinent to studies on CAD with 
particular references to genetic basis of CAD.  The pathology of CAD is reviewed.  
In addition, previous studies that have attempted to develop methods for 
elucidating the genetic basis of CAD are presented.  Studies using association 
analysis to explain genetic basis of CAD are reviewed.  To obtain a better 
understanding of GWAS conducted in the present study, the potential drawbacks 
of GWAS are evaluated and corresponding strategies of GWAS are discussed. 
 
2.1 Pathology of coronary artery disease 
2.1.1 Atherosclerosis 
Atherosclerosis is the primary cause of heart disease.  It is characterized by 
the accumulation of lipids, inflammatory responses and fibrosis in the arteries.  
The process of atherosclerosis consists of four steps: lesion initiation, 
inflammation, foam cell formation and fibrous plaques [92]. 
 
Lesion initiation 
The process of atherosclerosis begins with the changes inendothelial 
permeability.The endothelium is the selectively permeable barrier between 
blood and tissues which functions as a sensory and executive center that can 
generate regulating molecules of inflammation, thrombosis and vascular 
remodeling[93].  When the endothelium shows increased permeability, 
macromolecules such as LDL-C easily deposit in the sub-endothelial matrix 
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and therefore the macromolecules accumulate in the sub-endothelial matrix 
and grow gradually.  These trapped macromolecules can undergo 
modifications at the vessel wall [94], including oxidation, lipolysis, and 
proteolysis which greatly contribute to the resulting process of inflammation 
and foam-cell formation. 
 
Inflammation 
Inflammation is triggered by the accumulation of minimally oxidized LDL, 
which stimulates the endothelium to produce numerous pro-inflammatory 
molecules, including growth factors and adhesion molecules such as P- and E-
selectins, as well as vascular cell adhesion molecules.  These factors mediate 
the entry of leukocytes through the arterial wall and the binding of monocytes 
to the endothelium [95, 96].  As a result, monocytes, lymphocytes and 
macrophages accumulate in the artery wall. 
 
Foamcell formation 
Macrophages are the key players in the foam cell formation.  On one hand, it 
can actively secrete apolipoprotein E, which may promote cholesterol efflux 
to high density lipoprotein (HDL) and therefore inhibit the formation of foam 
cell.  On the other hand, macrophages are able to recognize extensively 
oxidized LDL but not minimally oxidized LDL. The rapid uptake of 
extensively oxidized LDL leads to the formation of foam cells.  The process is 
mediated by a group of scavenger receptors such as macrophage scavenger 
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receptor class A and fatty acid translocase/CD36.  Their expression is 
regulated by nuclear transcription factor peroxisome proliferator activated 
receptor γ (PPARγ) and cytokines such as tumor necrosis factor α and 
interferon γ [97]. 
 
Fibrous plaques 
Due to the effects of the cytokines and growth factors secreted by 
macrophages and T cells, smooth muscle cells migrate, proliferate and secrete 
extracellular matrix at the sites of foam cells.  With the accumulation of 
extracellular lipid, mainly cholesterol and its ester, fibrous plaques are thus 
formed.  The inflammatory cells and the extracellular matrix and lipids will 
gradually grow and form a protuberance, known as a fibrous cap.  In this way, 
fibrous plaques block arteries and may result in rupture, leading to coronary 
artery disease or myocardial infarction. 
 
2.1.2 Biochemistry of plasma cholesterols 
Cholesterol uptake 
Diet is an important source of cholesterol.  In the intestines, the mixture of 
dietary fat is transformed to triacylglycerol and lipid digestion products by 
bile salts.  They are further packaged into lipoprotein particles with 
apolipoprotein E (APOE), apolipoprotein CII (APOCII) and apolipoprotein 
B48 (APOB48) called chylomicrons.  Chylomicron is a vehicle unit that 
transports dietary triacylglycerol to muscles and adipose tissues and dietary 
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cholesterol to the liver.  Chylomicron is released into blood stream through 
capillaries and ends up on the endothelium of capillaries in muscles and 
adipose tissues, where the triacylglycerol is hydrolyzed by APOCII activated 
lipoprotein lipase (LPL).  The tissues then take up the hydrolysis products and 
the chylomicrons shrink to cholesterol-enriched chylomicron remnants.  These 
chylomicron remnants with apolipoprotein E and apolipoprotein B48 circulate 
in blood stream and are subsequently taken up by the liver.  In the liver, 
chylomicron remnants are recognized by remnant receptors and re-packed into 
very low density lipoproteins.  The very low density lipoprotein is 
transformed to LDL by lecithin-cholesterol acyltransferase (LCAT) in 
circulation.  LDL subsequently delivers cholesterol to tissues by LDL 
receptors[98].The cholesterol uptake by cell is controlled by the expression of 
LDL receptors. 
 
Reverse cholesterol transportation (RCT) 
The concept of reverse cholesterol transportation is to transport cholesterol 
from peripheral cells and tissues to the liver.  It includes the cholesterol efflux 
from cell, transportation from cell to liver, transformation of cholesterol into 
bile acids in the liver and elimination of cholesterol from the body[99].  RCT 
may prevent the plaque formation and the development of atherosclerosis by 
decreasing the cholesterol levels in blood plasma.  A typical RCT model 
comprises a caveolae transport center, an intracellular trafficking system of 
caveolin-1 complex, two transmembrane trafficking systems of ATP-binding 
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cassette, sub-family A member 1 (ABCA1) and scavenger receptor class B 
member 1 (SR-B1) and a extracellular trafficking system of 
HDL/apoA1(Figure 1 )[99]. 
 
 
Figure 1 Working model of cellular reverse cholesterol transport 
 
Caveolae is a flask shaped plasma invagination, rich in cholesterol and 
phosphosphingolipids.  They act not only as a cholesterol storage pool but 
also a regulation center of transmembrane cholesterol transportation, 
endocytosis and transcytosis of lipoprotein [100, 101].  Its function is enabled 
by the presence of many receptors in caveolae, such as low density lipoprotein 
receptors (LDLR), scavenger receptor class B member 1(SR-B1), ATP-
binding cassette, sub-family A member 1 (ABCA-1), which are all key 
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molecules for the trafficking of lipids.  The formation and maintenance of 
caveolae is regulated by caveolin, the main protein component of caveolae. 
Caveolin-1 is the most important member of the caveolin family.  It is the key 
component of the intracellular trafficking system.  Caveolin-1 in the 
endoplasmic membrane can promote the formation of caveolar vesicles and 
carry free cholesterol from endoplasmic membrane to caveolae[102].  It also 
forms a complex with cyclophilin A, cyclophilin 40 and heat shock protein 56 
(HSP56) [103], transporting free cholesterol from cytoplasm to cell membrane.  
The expression of caveolin-1 is regulated by sterol regulatory element binding 
proteins [104] and peroxisome proliferator activated receptors (PPARs)[105]. 
 
The transmembrane trafficking is mediated by HDL specific receptor SR-B1 
and integrated membrane protein ABCA1.  The SR-B1 mediated cholesterol 
transportation is a passive process.  The transportation direction is determined 
by the density gradient of cholesterol between HDL and the cell surface [99].  
The extracellular domain of SR-BI will form a hydrophobic channel for 
cholesterol esters and up to 80% of cholesterol esters will accumulate in 
caveolae [106].  When the cholesterol concentration in plasma exceeds 20%, 
SR-B1-dependent cholesterol efflux is blocked [107].  In contrast to SR-BI 
mediated cholesterol transportation, ABCA1 mediated cholesterol 
transportation is an active process using energy provided by ATP.  The 
transportation is a two-step mechanism.  The first step is to transport 
phospholipids from caveolae to apolipoprotein A1, which is the key 
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component of extracellular trafficking system and the main transporter of 
HDL.  The second step is to transport cholesterol to the complex formed in 
first step, leading to the formation of nascent HDL and promoting cholesterol 
efflux [108].  SR-B1 and ABCA1 both mediate the cholesterol efflux and they 
are regulated by different factors such as cholesterol concentrations, HDL size, 
and ABCA1 expression level.  The expression of SR-BI and ABCA1 is 
regulated by sterol regulatory element binding proteins [109], liver X 
receptors [109-111]and PPARs [112-114]. 
 
Biosynthesis 
Cholesterol can be synthesized from acetyl-coenzyme A via its conversion to 
hydroxymethylglutaryl-coenzyme A, which is the primary cholesterol 
precursor.  Through a series of reaction, it can be converted to different types 
of cholesterols.  As acetyl-CoA is the main product of glycolysis, citric acid 
cycle and β oxidation of fatty acids, the cholesterol biosynthesis can be 
affected by fatty acid level and glucose concentrations[98].  The biosynthesis 
of cholesterol is controlled via the regulation of hydroxymethylglutaryl-
coenzyme A reductase. 
 
2.2 Approaches to studying genetic variants of coronary artery disease 
Linkage analysis is a powerful tool to identify the genomic regions that contain 
genes predisposing to diseases based on family studies.  It maps genetic loci by 
comparing the observations of familial individuals[115].  Linkage analysis has 
been greatly successful in the identification of major genes for monogenic 
22 
 
diseases [116] such as autosomal recessive hypercholesterolemia[117].  Thus, it 
has been widely utilized for candidate gene studies, where variants in genes 
known to regulate the development of disease traits are investigated.  A number of 
significant variants for monogenic disease have been discovered by linkage 
analysis, including the apolipoprotein E gene [118].   
 
However, this approach is limited in the context of studying the genetic basis of 
CAD.  Unlike Mendelian/monogenetic diseases, CAD is a complex multifactorial 
disease.  Its etiology follows the common disease common variant 
hypothesis[119], which posits common interacting variants and their interactions 
with environmental factors underline most of common diseases.  In other words, 
CAD candidate genes could be numerous; the effects of common variants tend to 
be small when averaged across a population; the frequency of common variants 
could be relatively high (1% to 50%).  Linkage analysis was challenged to 
identify weak genetic variants of CAD due to the characteristics of complex 
diseases.  In the attempt to address this problem, Neil and Kathleen showed a 
thorough perspective[120]. The authors believed that the most important flaw of 
linkage analysis was the restricted sample size for conferring risk variants [120, 
121].  Taking an allele of moderate frequency (0.1-0.5) as an example, linkage 
analysis for loci conferring genotypic relative risk of 2 or less required more than 
2,500 families, which was practically unachievable.  Moreover, it did not provide 
a good prediction of the probability of allele transmission[120].  Hence, a flaw of 
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linkage analysis is its inability to accurately identify variants with weak and 
moderate effects. 
 
Association analysis can overcome these drawbacks as it is based on the tests of 
correlation between genetic variations and diseases[122].  It possesses the 
advantages of being hypothesis-free and high powered.  It has been demonstrated 
that the number of samples required for association analysis was 80% to 95% less 
than that for linkage analysis [120].  Furthermore, it has a better prediction of 
allele transmission compared to linkage analysis.  The advantages of association 
analysis have become more valuable with the identification of numerous variants 
(> 100,000) conducted by Hapmap and 1000 Genome projects.  It allows for the 
exhaustive search of genetic variants on a genome wide scale.  Therefore, 
association analysis provides a much more effective way to unveil the genetic 
basis of CAD. 
 
2.3 Genome wide association studies of coronary artery disease and its risk 
factors lipids 
In this section, I will review the progress of GWAS of CAD as well as lipid 
traits and highlight the major findings.   
 
2.3.1 GWAS of CAD 
Genome wide association studies have identified multiple genetic variants 
associated with CAD.  Most of the associations have been replicated in 
independent studies, indicating that the findings are genuine novel 
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associations.  The main GWAS findings for CAD are summarized in Table 
1[123]. 
 
To date, 39 susceptibility loci have been identified to be associated with CAD 
(Table 3).  Among them, approximately 68% of susceptibility single 
nucleotide polymorphisms (SNPs) in GWAS are in or near a protein-coding 
genes but the rest of them are distant from known protein-coding genes.  9p21 
is one such example.  It is the most consistent and strongest association.  It has 
been discovered in Caucasians in 2007and the associations have also been 
reported in East Asians but not in African-Americans [124-126].  The 9p21 
risk factor is independent of any established cardiovascular risk factors for 
CAD.  The risk allele would increase the risk of CAD by 10%-30%.  However, 
the role of 9p21 in CAD remains obscure as the 9p21 region is absent of any 
known protein-encoding genes[127].  The nearest genes are the cyclin-
dependent kinase 2A (CDKN2A) and 2B (CDKN2B).  A study on 9p21 
variants has demonstrated an impact on the expression of CDKN2A and the 
proliferation of CDKN2A and CDKN2B in vascular smooth muscle cells 
[128].  It was discovered that the 9p21 region contains an antisense non-
coding RNA gene that may constitute a regulator of epigenetic modification 
and thus modulate the risk of CAD [129, 130].  Recently, it has been reported 
that the risk of CAD conferred by 9p21 variants might be mitigated by a 
prudent diet high in raw vegetables and fruits [131]. 
 
25 
 
Among those SNPs near protein-coding genes, some of genes are linked to 
CAD-associated risk factors or phenotypes, such as LDLR, proprotein 
convertase subtilisin/kexin-type 9 (PCSK9) and sortilin 1 (SORT1), which are 
involved in cholesterol metabolism (Table 3).  By studying genes with strong 
associations but no established functional effects on CAD, several biological 
mechanisms have been suggested. One such example is the role of the 
chemokine gene CXCL12 in inducing inflammation and hence leading to 
CAD [132].  However, some variants discovered by GWAS lacked biological 
evidences on CAD, which is one of frequent drawbacks of GWAS. Whether 
such variants and the suggestive genes are causally involved in the etiology of 
CAD will require further experimental studies.  
 
As with all findings of association studies, there are genetic variants with 
genome-wide significance that could not be replicated successfully in other 
studies.  For example, the association of 6q25.1 with CAD has been identified 
by the Welcome Trust Consortium and it could not be not validated in a 
German MI family study [133]. This inconsistency may be due to true false 
association or caused by unknown interactions which attenuate associations in 
different study populations. In the above example, the variants at 6q25.1 were 
mapped to the gene encoding mitochondrial isozyme C1-tetrahydrofolate 
synthase.  This gene is involved in homocysteine metabolism, which is related 
to the early development of heart and blood vessel disease. Therefore, 
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examining the biological evidences underlying the associations is an 
important approach to validate the associations.  
 
Ethnicity is another important factor in the discovery of genetic variants as 
genetic constitution would differ between different ethnic groups.  Some 
SNPs may be unique to a particular ethnic group.  The genetic variant 
rs4299376 (Table 3) is such an example, monomorphic only in Asians (JPT + 
CHB) but polymorphic in the rest of populations. As most of the GWAS were 
conducted in Caucasians, there is an increasing need and trend to conduct 
GWAS for the Asian populations.   In 2011, the first GWAS of CAD in 
Chinese was conducted with a discovery population of 460[134].  In the study, 
they identified a new susceptibility locus C6orf105 (rs6903956) for CAD and 
validated it in 3,240 cases and 4,353 controls.  This association has been 
replicated in Singaporean Chinese [135].  The genetic variant rs6903956 has 
also been shown to significantly associate with angiographic characteristics of 
coronary atherosclerosis risk [136].  The susceptibility locus C6orf105 has 
been reported to encode proteins that regulates tissue factor pathway inhibitor 
mRNA expression and anticoagulant activity of the inhibitor in response to 
androgen, thus lead to increased risk of thrombosis and CAD[137].  In 2012, a 
meta-analysis of two Chinese GWAS of CAD was conducted in a larger 
sample size of 1,515 cases and 5,019 controls [138].  The study failed to 
replicate the association of rs6903956 but identified four new susceptibility 
loci and validated them in 15,000 CAD cases and 12,000 controls.  The four 
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loci were rs2123536 nearTTC32-WDR35, rs1842896 near GUCY1A3, 
rs9268402 in the upstream of C6orf10-BTNL2 and rs7136259 in ATP2B1.  
Among them, rs2123536 (P=0.0038, OR=1.10) and rs7136259 (P=0.035, 
OR=1.03) have previously shown nominal significance with CAD in the 
Coronary Artery Disease Genome Wide replication And Meta-Analysis 
(CARDIoGRAM) consortium study [139, 140].   
 
2.3.2 GWAS of lipids 
The GWAS of lipids was initiated by the Diabetes Genetics Initiative in 
2007[141].  The first GWAS was performed in 1,464 type 2 diabetes patients 
and 1,467 matched controls.  The research group has identified a SNP in 
glucokinase regulatory protein for TG with genome wide significance [141].  
This newly identified gene was follow-up and found to exert its effect by 
regulating the glucokinase activity in the liver [142].  This group then 
collaborated with the FUSION study and SardiNIA study to conduct a meta-
analysis of 8816 individuals for lipid levels [16].  Twenty three loci have 
shown genome wide significant associations with lipid traits [16].  Among 
them, eleven loci have previously been implicated in lipid associated 
pathways (ABCA1, APOA5-A4-C3-A1 cluster, APOE-C1-C4 cluster, APOB, 
CETP, LCAT, LDLR,LIPC, LIPG , LPL, PCSK9) , which provides 
compelling internal validation of GWAS technique.  Twelve newly identified 
loci included GALNT2, SORT1, CILP2, B3GALT4, B4GALT4, GCKR, 
GRIN3A, MLXIPL, MMAB, and TRIB1.  Subsequently, the sample size of 
lipid GWAS was increased from a few thousand to tens of thousands. .  As a 
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result, the power of to detect genetic variants was improved. Many additional 
loci have been identified [143-147].  Benefitting from global collaboration, 
the meta-analysis of hundreds of thousands of samples has enabled the 
extensive exploration and refinement of loci associated with lipid levels.  One 
study conducted by the Global Lipid Genetics Consortium has examined the 
genetic determinants of lipid levels in more than 100,000 individuals of 
European ancestry and has identified 95 genome wide significant loci.  Of the 
95 loci, 59 have been newly identified and some of them are known lipid 
regulators such as CYP7A1, NPC1L1 and SCARB1 [148].  They also 
examined the relevance of GWAS loci in non-Europeans and suggested that 
most but not all of the 95 loci shared the same genetic effect on lipid levels 
across global populations.  Another study comprising 188,578 European 
ancestry and 7,898 non-European ancestry individuals has also identified 157 
loci, among which 62 loci were new [149].  The large number of susceptibility 
loci poses a big challenge for future causal and functional studies.  Therefore, 
prioritizing loci on the basis of relevant pathways, mRNA targets, functional 
variants and literature is of great importance. 
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Table 3 Main GWAS findings for CAD (reproduced from a review paper [123, 140, 150-153]) 
Locus Lead SNP 
Risk allele 
frequency 
OR per risk allele 
mean (CI) 
Replications 
in other 
studies
*
 
Mapped genes 
CAD associated risk factors or 
phenotypes 
Reference 
1p13 rs599839 0.78 1.11 (1.08-1.15) Y SORT1 LDL-C [133, 154] 
1p32.2 rs17114036 0.91 1.17 (1.13-1.22) Y PPAP2B 
Enhanced Vascular Inflammation 
and Permeability 
[133, 139, 
155] 
1p32.3 rs11206510 0.82 1.08 (1.05-1.11) Y PCSK9 LDL-C [154] 
1q41 rs17465637 0.74 1.14 (1.09-1.20) Y MIA3 
 
[133] 
2p21 rs4299376 0.32 1.07 (1.04-1.11) N ABCG5ABCG8 LDL-C [156] 
2p24.1 rs2123536 0.39 1.12(1.08-1.16) N TTC32-WDR35  [138] 
2q33.1 rs6725887 0.15 1.14 (1.09-1.19) N WDR12NBEAL1 Early onset  [154] 
3q22.3 rs9818870 0.18 1.12 (1.07-1.16) Y MRAS 
 
[157] 
4q32.1 rs1842896 0.76 1.14(1.10-1.19) N GUCY1A3 
 
[138] 
6p21.31 rs17609940 0.75 1.07 (1.05-1.10) N ANKS1A 
 
[139] 
6p21.32 rs9268402 0.59 1.16(1.12-1.20) N C6orf10-BTNL2 
 
[138] 
6p21.33 rs3869109 0.55 1.14 N HLA-CHLA-B 
 
[158] 
6p24.1 rs12526453 0.67 1.10 (1.06-1.13) Y PHACTR1 Coronary calcification [154] 
6p24.1 rs6903956 0.07 1.65 (1.44-1.90) N C60rf105 
 
[134] 
6q23.2 rs12190287 0.62 1.08 (1.06-1.10) Y TCF21 
Disruption of a miR-224 binding site 
and miRNA-mediated regulation 
[139, 159] 
6q25.3 rs3789220 0.02 1.51 (1.33-1.70) N LPA Lipoprotein (a) [160] 
6q26 rs10455872 0.07 1.68 (1.43-1.98) N LPA Lipoprotein (a) [160] 
7q22 rs10953541 0.80 1.08 (1.05-1.11) N BCAP29DUS4L 
 
[161] 
7q32 rs11556924 0.62 1.09 (1.07-1.12) Y ZC3HC1 
 
[139] 
8q24 rs17321515 0.53 1.06 (1.03-1.10) N TRIB1 Triglycerides [16] 
9p21.3 rs10757274 0.46 1.29 (1.23-1.36) Y ANRIL 
Abdominal, intracranial aneuryms, 
IF-γ signaling 
[124, 125, 
133] 
9q34 rs579459 0.21 1.10 (1.07-1.13) Y ABO IL-6, E-selectin [139, 162] 
*Replications refer to whether it reached genome wide significance in other studies in GWAS context. Y: yes; N: no.
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Table 3(continued) Main GWAS findings for CAD (reproduced from a review paper [123, 140, 150-153]) 
Locus Lead SNP 
Risk allele 
frequency 
OR per risk allele 
mean (CI) 
Replications 
in other 
studies
*
 
Mapped genes 
CAD associated risk factors or 
phenotypes 
Reference 
10p11 rs2505083 0.38 1.07 (1.04-1.09) N KIAA1462 
 
[161] 
10q11 rs1746408 
  
Y CXCL12 
Endothelial regeneration, attenuation 
of neutrophil migration 
[133] 
10q23 rs1412444 0.42 1.09 (1.07-1.12) Y LIPA Endothelial function [161] 
10q24 rs12413409 0.89 1.12 (1.08-1.16) Y 
CYP17A1-CNNM2-
NT5C2 
Intracranial aneurysms [139] 
11q22 rs974819 0.32 1.07 (1.04-1.09) N PDGFD 
 
[161] 
11q23 rs964184 0.13 1.13 (1.06-1.16) Y APOA5APOA1APOC3 Triglycerides, HDL-C [139] 
12q21.33 rs7136259 0.39 1.11(1.08-1.15) N ATP2B1 calcium ATPase [138] 
12q24 rs3184504 0.44 1.07 (1.04-1.10) Y SH2B3 LDL-C, Blood pressure [139] 
13q34 rs4773144 0.44 1.07 (1.05-1.09) N COL4A1/A2 
Type IV collagen chain of basement 
membrane 
[139] 
14q32 rs2895811 0.43 1.07 (1.05-1.10) N HHIPL1 
 
[139] 
15q25 rs3825807 0.57 1.08 (1.06-1.10) Y ADAMTS7 
Proliferative response to vascular 
injury 
[139, 162] 
17p11 rs12936587 0.56 1.07 (1.05-1.09) Y RASD1PEMTRAI1 
 
[139] 
17p13 rs216172 0.37 1.07 (1.05-1.09) N SMG6 
 
[139] 
17q21 rs46522 0.53 1.06 (1.04-1.08) N UBE2Z 
 
[139] 
19p13 rs6511720 0.89 1.18 (1.11-1.25) Y LDLR LDL-C [154] 
19q13 rs4420638 0.18 1.17 (1.08-1.28) Y APOE LDL-C [16] 
21q22 rs9982601 0.15 1.18 (1.12-1.24) Y SLC5A3-MRPS5-KCNE2 
 
[154] 
*Replications refer to whether it reached genome wide significance in other studies in GWAS context. Y: yes; N: no. 
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2.4 Detecting interactions 
Although GWAS have been extremely successful in the identification of genetic 
variants predisposing complex diseases, the total variance explained by the 
identified genetic variants is limited.  These identified variants cannot fully 
account for the heritability of diseases.  Gene-environment interaction and gene-
gene interaction are important factors that contribute to the missing heritability.  
The identification of interactions can facilitate the exploration of underlying 
mechanisms and pathways. Therefore, interaction studies have been a new 
frontier for genetic investigations of complex diseases.  However, few studies 
have been conducted using GWAS data.  There are several reasons for this.  First, 
it is challenging to recruit a sample size that is sufficiently large to detect 
significant interactions and capture possible genetic interactions.  A useful rule of 
thumb is that a sample size required for the detection of an interaction is at least 4 
times larger compared to that for the detection of a main effect[163].  The sample 
size for interactions in GWAS is more critical because of the requirement of a 
stringent significance level.  Second, it is challenging to compute such large 
number of tests, especially for gene-gene interactions. If the number of genotyped 
SNPs is 500,000, the number of tests for gene-gene interactions will be 
250,000,000,000, which would require months to complete the computation. 
Although it is computationally feasible, it is time-consuming.  In addition, the 
large amount of data obtained would also be difficult to analyze.  Fourth, 
interactions in the absence of main effect are thought to be a ubiquitous 
phenomenon in nature [164-167].  As prior knowledge of the discovered genetic 
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variants is usually absent for the majority of situations, it leads to difficulties in 
the explanation of statistical interaction in biological context.  Therefore, a 
judicious strategy is essential for successful interaction analysis in the GWAS 
context.  There are two main ways to prioritize genetic variants.  The first is to 
select genetic variants based on their strength and the statistical significance of 
their main effects[168] such as using index SNPs from the GWAS catalog.  The 
alternative way is to select genetic variants located in the genes associated with 
traits of interest.  Independent statistical significance for the main effect is not 
required for these genetic variants.   
 
To date, no genome wide environment interaction association studies have been 
conducted for CAD.  This may be due to the variable nature of environmental 
factors and the large sample size required for complex diseases.  There is only one 
research group studying the gene-gene interactions for MI using a candidate 
genetic variants approach [169].  They selected genetic variants with marginal 
significance and association with cardiovascular endpoints such as lipid levels for 
examination.  However, their data failed to find any significant interaction effect 
for MI.  The null finding may be a result of inappropriate selection of genetic 
variants or simply an underpowered study.  Most of the published interaction 
studies have focused on the intermediate traits of CAD, especially lipid traits.  Ma 
et al. used genotyped data from 9,713 European individuals and identified an 
interaction between HMGCR and a locus near LIPC which affects HDL-C 
concentrations (Bonferroni corrected P=0.002) [170].  This interaction has been 
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validated in European American cohorts from the Framingham Heart Study 
(P=0.002), the Multi-Ethnic Study of Atherosclerosis (P=0.006), African 
American (P=0.004) and Hispanic American (P=0.04).  Regarding gene-
environment interaction, Dumitrescu et al. conducted gene-environment 
interaction using 23 lipid-associated SNPs from previous GWAS,  and suggested 
that serum vitamins A and E may modify lipid concentrations in the Population 
Architecture using Genomics and Epidemiology (PAGE) study[171].  Another 
study has demonstrated that alcohol may modify the effect of rs671 on 
triglycerides levels in Chinese [172].   
 
2.5 Strategies of genome wide association studies 
In this section, I will review factors influencing the performance of GWAS and 
the analytical strategies of GWAS. 
 
2.5.1 Genotype calling 
GWAS is based on SNP arrays, predominately manufacture by Illumina 
(www. illumina. com) and Affymetrix (www. affymetrix. com/).  Regardless 
of array types, all genotypes are determined by fluorescent intensity using 
genotype calling algorithms implemented in the accompanying software of the 
genotyping platform.  For a given subject and a SNP, the genotype calling 
algorithms help estimate the probability of three genotypes: common 
homozygote, heterozygote and rare homozygote.  It applies a certain cut-off to 
the raw intensity data and decides whether the genotype is accepted, namely 
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―called‖.  Genotypes under the cut-off will be assigned as ―missing‖.  Hence, 
genotype calling algorithms can strongly affect genotype call rate and the 
quality of genotype data.  If the cut-off is set low and the separation of three 
genotypes is poor, erroneous genotypes could be assigned.  As hundreds of 
thousands of SNPs are dealt with in GWAS, it is impossible to inspect raw 
allele intensities and develop a universally correct genotype calling algorithm.  
Therefore, it is crucial to scrutinize the separation of genotypes, often 
presented in cluster plots, for top hits associated with traits. Moreover, the 
genotype call rate can subject to the minor allele frequency (MAF) of SNP 
because rare SNPs often show lower probabilities of rare homozygotes and 
thus introduce bias.  Hence, rare variants (MAF <0.1) are normally excluded 
for GWAS.   
 
2.5.2 Quality control 
Quality control (QC) is essential to control biases in genetic association 
studies and reduce the number of false-positive and false-negative 
associations.  It consists of SNP QC and sample QC.  
 
SNP QC 
SNP QC of GWAS data comprises at least four steps: 1) elimination of SNPs 
with a very low minor allele frequency, 2) elimination of SNPs with excessive 
missing genotypes, 3) elimination of SNPs with significantly different 
genotyped call rates between control and case, and 4) elimination of SNPs 
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demonstrating a significant departure from Hardy Weinberg equilibrium 
(HWE) [173].   
 
It is difficult to correctly determine genotyping calls for rare SNPs based on a 
small sample size.  Even if the genotyping calls are correct, the association 
signals are more likely to be false-positive because the results are only based 
on a few individuals.  Hence, the removal of rare SNPs is essential to reduce 
false-positive associations.  Furthermore, SNPs with excessive missing 
genotypes are problematic as they may be caused by poor separation of 
genotypes, indicating non-reliable genotype calls.  In addition, SNPs with 
significant differences in genotype call rate between controls and cases can be 
poorly genotyped and result in confounding associations.  However, the 
criteria to filter out these SNPs differ from study to study.  Caution should be 
exercised when excluding SNPs as every marker is potentially a disease 
variant.  
 
The Hardy Weinberg equilibrium is a principle proposed by Hardy and 
Weinberg, stating that allele frequencies in a population are constant from 
generation to generation in the absence of evolutionary effects.  The effects 
include non-free mate, mutation, selection, genetic drift and migration.  The 
Hardy Weinberg equilibrium is normally examined using Pearson’s chi-
squared test.  In quality control, it is utilized to check if the samples have any 
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selection bias [174], which can be real selection bias or that due to genotyping 
errors.   
 
Sample QC 
Sample QC of GWAS data comprises of at least four steps: 1) identification of 
samples with discordant sex information with reported sex, 2)identification of 
samples with excessive heterozygosity and sample missingness, 3) 
identification of related samples, 4) identification of  samples with divergent 
ancestry or discordant ethnic with reported ethnic [173].   
 
The ascertained sex is generated by evaluating X-chromosome heterozygosity.  
Compared to women, men have only one copy of X-chromosome.  Hence, the 
genotypes of X-chromosome markers of male will be called as missing, 
namely a heterozygosity rate of 1, while the heterozygosity of females is 
impossible to be 1 unless the reading can be explained by sample 
contamination or wrong labeling.   
 
DNA sample quality has a large impact on genotype call rate and genotype 
accuracy.  This is reflected in genotype failure rate and heterozygosity rate.  
Genotype failure rate is the ratio of the missing number of SNPs per 
individual and total genotyped SNPs. 
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Heterozygosity rate is defined as the (N-O)/N, where N is the number of non-
missing genotypes and O is the observed number of homozygous genotypes.  
Excessive or reduced heterozygote genotypes indicate sample contamination 
or inbreeding.  Normally, the genotype failure rate is plotted against the 
heterozygosity rate.  Samples which exceed the 3-fold standard deviation are 
removed.   
 
Related samples with first degree familial relationship or second degree 
relationship can introduce bias of association analysis because their genotypes 
are over-represented, which fails to be a fair reflection of the general 
population.  To identify related samples, a method called identity by descent 
(IBD) can be utilized to calculate the shared allele proportion for each pair of 
samples[173].  This method performs best when only independent SNPs are 
included [175].  A value of IBD=1 denotes hundred percent allele sharing, 
meaning duplicates or monozygotic twins.  A value of IBD=0.5 denotes first 
degree familial relationship, including full sibling, homozygote and parent 
offspring.  A value of IBD=0.25 denote second degree familial relationship, 
including uncles, aunts, half-sibling, cousins and grandparent-grandchild.  
 
2.5.3 Population stratification 
Population stratification is a significant complication in association studies, 
especially case-control studies, where the identified association could be due 
to the underlying population structure but not a disease associated locus.  Two 
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most widely used approaches to address this problem include genomic control 
(GC) and principle component analysis (PCA).   
 
Genomic control  
Genomic control is a nonparametric method estimating the inflation of the test 
statistics.  It works by using independent markers that are not linked with the 
studying trait to estimate the inflation of the association test statistic caused by 
population stratification [176, 177].  Genomic control factor λGC summarizes 
the inflation of test statistic and could be used to compensate the population 
structure.  It is defined as the ratio of the median χ2 association statistic across 
whole genome SNPs divided by its theoretical median (0.456) under the null 
distribution.  Normally, a value of λGC≈1 implies no stratification and values 
of λGC<1. 05 are generally considered benign although it could be affected by 
sample size proportionally [176, 178].  To note, although genomic control can 
correct the population stratification by adjusting association statistic at each 
marker using a uniform overall inflation factor (λGC), it neglects an important 
situation that some markers may differ in allele frequencies more than 
others[179].  It is insufficient to correct the population stratification simply by 
a uniform inflation factor and it is also superfluous for markers devoid of such 
differences.  To address the limitations, Principle Component Analysis is used 
in tandem with genomic control.  
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Principle Component Analysis 
Principle Component Analysis (PCA) is a multivariate statistical tool that can 
utilize genotype data to produce independent continuous axes of variation, 
accounting for as much variability as possible.  The axes of variation help 
reduce the data to much smaller dimensions and enable explicit detection and 
correction of population stratification[179].  PCA can detect the presence of 
any population structure by plotting one principle component (PC) against 
another.  For example, HapMap genotype data can be used as reference to 
detect continental level ancestry differences.  Tested samples will be clustered 
according to ancestry alongside with corresponding HapMap samples.  
Notably, principle components do not always reflect population structure as it 
could be affected by family relatedness[180], long range LD[181] and assay 
artifacts[182].  These problems can be solved by removing familial samples, 
regions of long range LD and low quality data, respectively.  In my studies, 
identity by state analysis, 5 conservative regions and quality control of SNPs 
and samples were conducted to eliminate the confounding.   
 
2.5.4 Imputation and frequentist test 
Imputation is a mathematical approach that can predict un-genotyped variants 
based on linkage disequilibrium (LD) using genotyped data.  Generally, each 
sample will be phased and the haplotypes are modeled as a mosaic of the 
haplotypes in a reference panel.  The missing genotypes are imputed 
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accordingly and the probability of predicted genotype certainty is given.  
IMPUTE is a widely used software to achieve this[183].  
 
Regarding to the accuracy of imputation, several groups have tested it by 
comparing the imputed data and genotyped data on the same SNPs.  One of 
the groups masked 5% of the genotypes at the locus and imputed these 
genotypes.  The imputed data showed a correct imputation rate > 99% [12].  
Another group [13] also contrasted imputed genotypes with experimental 
genotypes by genotyping >500 SNPs in the lab.  Their results also showed 
excellent concordance between imputed genotypes and experimental 
genotypes. 
 
The statistical analysis including imputed genotypes differs from experimental 
genotypes.  To better take account for the uncertainty of each genotype, a 
well-established statistical theory for missing data problems is usually used, 
which is the frequentist test[184].  It partitions the data into observed data and 
missing data, weights the contribution of each possible genotype by its 
imputation probability and generates data likelihood score for each possible 
genotype.  The frequentist test can maximize the data likelihood for 
association tests.  This approach can be implemented in SNPTEST 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/old/snptest. html).   
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Imputation is useful in many aspects.  First, it can help boost the power up to 
10% compared to analysis in genotyped only SNPs[185], especially for rare 
SNPs, which are harder to tag[184].  Furthermore, it provides a high-
resolution view of associated regions and facilitates direct identification of a 
causal SNP[186].  In addition, it makes meta-analysis easier by equating the 
set of SNPs in each cohort, which may be genotyped in different arrays.  In 
this manner, the combined dataset provides a greater power for each SNP.  
Several new loci for different traits have been identified by this approach 
[187-192].  Finally, it allows sporadic missing data imputation and correction 
of genotyping errors. 
 
2.5.5 Meta-analysis 
Meta-analysis is a statistical method that allows the quantitative combination 
of data from multiple studies.  It helps better summarize the results based on 
the combined data and evaluates the consistency of the results across multiple 
datasets.  Most importantly, it facilitates the increase of power and the 
coverage of testing SNPs, especially for variants with a low frequency (1%-
5%), which may escape from detection due to low power.  To achieve this, 
imputation is the key part of meta-analysis as it bridges different studies by 
using a reference panel.  The options of reference panel include Hapmap 
(www. hapmap. org) and 1000 Genome (www. 1000genomes. org).  
Nowadays, 1000 Genome is more widely used as it is sequencing based and 
has a greater coverage of variants.   
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2.5.6 Bonferroni correction 
In statistical hypothesis testing, type I and type II errors represent two kinds of 
errors: rejecting null hypothesis when it is true and accepting null hypothesis 
when it is false, respectively.  Both type I and type II errors can be affected by 
sampling bias.  For example, when recruiting an unrepresentative small 
sample, type I error will occur.  When the difference is true in population but 
not seen in sample, type II error will occur.  Bonferroni correction is applied 
to limit the probability of committing a type I error.  It adjusts the significance 
level of 0.05 by dividing it by the number of independent statistical tests 
performed.  However, Bonferroni correction does not limit the probability of a 
type II error.  Thus, a more representative sample will help reduce both errors 
by increasing sample size.  Notably, Bonferroni correction is conservative and 
need to be applied with caution since few of SNPs will be significant after 
correction.   
 
2.6 Mendelian randomization and implications of causality 
Epidemiological research has identified many biomarkers such as lipids as being 
associated with CAD.  Considering the strength and reproducibility of the 
associations and the possible mechanisms through which these biomarkers could 
affect CAD, several of them were thought to be causal.  Subsequent investigations 
were initiated to block such causal factors for the therapy of CAD, but sometimes 
the results did not always confer to the expected outcome based on epidemiology 
observations.  Given such large number of biomarkers, the uncertainty of the 
43 
 
causality and the high cost of drug development, it is vital to discriminate the 
causation from association in order to identify beneficial drug targets.   
 
2.6.1 Mendelian randomization 
Mendelian randomization (MR) is a method that utilizes genetic variants as 
robust proxies for modifiable risk factors to assess and qualify the potential 
causal relationship of disease outcome.  It has advantages such as having no 
confounding and no reverse causation compared to observational 
epidemiology studies.  To draw conclusion from Mendelian randomization, 
several important assumptions should be fulfilled.  First, the genetic variants 
cannot have pleiotropic effect, which means that the genetic variants should 
only significantly influence the disease of interest but have no effect on other 
phenotypes.  This is because pleiotropy would confound the association 
between the biomarker and disease[193].  The true causal effect of the variant 
on disease may be counteracted by pleiotropic effect, leading to null findings.  
Alternatively, the positive association may be due to pleiotropic effect and 
mistakenly interpreted as causality.  Second, the genetic variant employed 
should ideally be independent and not in any linkage disequilibrium with 
other loci.  A typical scenario is that SNP A is in high LD with SNP B that 
influences the expression of gene B.  If the SNP B is causally associated with 
the disease outcome, it would be wrong to conclude that SNP A is the causal 
factor of disease.  Third, genetic variant should associate with disease of 
interest in the same direction predicted by the association between genetic 
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variant and biomarker[193].  In addition, if the effect of a single genetic 
variant may be too small, a combination of several genetic variants can be 
analyzed.  However, it increases the possibility of potential pleiotropic effects.  
To study a complex disease such as CAD, sufficiently large sample size is 
required to detect small effects.  In my studies, a small MR study was 
conducted to examine the causality of lipid traits for MI.   
 
2.6.2 Causality of HDL-C for MI 
Although the association of HDL-C with MI has widely replicated for many 
years, the causal interference between HDL-C and MI remains unclear and 
inconclusive.  In the randomized trials, a causal relationship between high 
HDL-C and low MI risk has not been proven.  As the null findings could be 
results of reverse causality or confounding, several MR studies have been 
conducted.  Recently, Voight and colleagues have identified a genetic variant 
that only substantially affects HDL-C but no other lipid traits or non-lipid 
cardiovascular risk factors.  They utilized the genetic variant LIPG Asn396Ser 
to do MR in more than 115,000 participants from 6 prospective cohorts and 14 
case-control studies of cardiovascular risk factors.  The results suggested that 
the rise of HDL-C concentration may not uniformly translate to the protection 
of MI [194].  Furthermore, drug designed to increase HDL-C failed to show 
any reduced risk of MI.  For example, treatment with torcetrapib, which can 
substantially raise HDL-C concentrations, failed to achieve predicted benefit 
for the risk of MI [195].  These findings imply that HDL-C is merely a 
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biomarker for some unknown underlying factors that lowers the risk of MI 
and increase of HDL-C might not be an effective therapeutic target for MI.  
However, a firm conclusion cannot be drawn as these negative results could 
have been due to the poor selection of drug targets or molecules.  In animal 
studies, HDL particles appeared to exhibit direct anti-atherogenic properties 
[196].  Another large scale MR study conducted in 2014 (62,199 participants 
and 12,099 coronary heart disease events) showed possible causal role of 
HDL-C for MI [197].  Therefore, the causality of HDL-C for MI requires 
further investigations.  
 
2.6.3 Causality of LDL-C for MI 
The causality of LDL-C, the so-called ―bad cholesterol‖, has been well 
established.  There are several evidences long before MR studies.  In family 
studies, families carrying LDL-C receptor mutations that remarkably 
increased LDL-C concentrations had a higher risk of CAD [198].  In a large 
scale GWAS, variants associated with LDL-C concentrations have been 
shown to significantly associate with the risk of MI [148].  Consistent with the 
association results, the studies on LDLR knockout mice also reported that the 
lack of LDLR potentially leads to atherosclerosis [199].  Moreover, several 
MR studies have also been conducted to confirm the causality of LDL-C for 
MI [194, 197, 200].  An excellent study was published in Lancet in 2012, 
which included20,913 MI cases and 95,407 controls.  Thirteen SNPs 
exclusively associated with LDL-C were employed to generate genetic score.  
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The results showed concordant trends between the estimates from 
observational studies (a 1SD increase in LDL-C concentration associated with 
OR=1.54) and the estimates from genetic score (OR=2.13, P= 2x10
-10
).   
Drugs specifically aimed at lowering LDL-C levels have been developed.  
Statin is the most widely used drug in clinical therapies.  It lowers LDL-C 
concentrations by inhibiting hydroxyl-3-methylglutaryl coenzyme A reductase 
(HMGCR).  Several clinical trials have demonstrated the protective effect of 
statins on the risk of CAD [201, 202].  The causality of LDL-C for CAD has 
encouraged the development of new drugs.  In 2006, a rare variant in PCSK9 
was reported to lower LDL-C below population average (21-38 mg/dl) and 
reduce incidence of MI by 40%-80% [203].  New drugs targeting PCSK 9 are 
currently under investigation in clinical trials for their potential to decrease MI 
risk [204, 205]. 
 
2.6.4 Causality of TG for MI 
Fasting TG [206-208] and non-fasting TG [209-211] have both showed 
significant associations with prevalent of CAD [210].  Evidence for the causal 
role of TG in MI continues to grow till this day.  In 2010, a collaborative 
analysis of 101 studies assessed the index variant rs662799 in APOA5 for TG 
in relation to the risk of MI.   It found a significant association of rs662799 in 
APOA5 with MI (OR=1.18, P=2.6x10
-7
).  In 2013, another MR study using 
this variant demonstrated that the variant not only displayed a significant 
association with increased non-fasting TG but also an increased odds ratio for 
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the risk of MI (OR=1.87, P<0.001)[212].  Similar findings have been reported 
when multiple variants influencing TG were studied in combination.  One 
impressive study was conducted in a large sample size exceeding 180,000 
individuals by employing 185 common variants associated with plasma lipids 
with genome wide significance to examine the role of TG in the risk of 
MI[206].  They also concluded that triglyceride-rich lipoproteins are likely to 
causally influenced risk of MI.  However, therapies designed to lower TG 
levels have not succeeded in reducing the risk of MI to date [213]. 
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Chapter 3: Study populations and methods 
In this chapter, I will describe the study populations used in my studies, the 
quality control details of SNPs and samples, and present the analytical methods 
used for genome wide data and population genetics. 
 
3.1 Study design and population 
3.1.1 Singapore Chinese Health Study (Used in Studies I, II and III) 
The Singapore Chinese Health Study (SCHS) is a population-based 
prospective cohort which began in 1993 and has a recruitment of 63,257 
residential Singaporean Chinese between age 45-74 by 1998 [214].  The study 
subjects were restricted to the major dialect groups of Chinese in Singapore: 
the Hokkiens, who originated from southern Fujian Province, and the 
Cantonese, who came from central Guangdong Province (both provinces are 
in the southeastern China).  At recruitment, subjects were interviewed face-to-
face at their home by trained interviewers (N=2) using a well-structured 
quesionarie, which focused on the information of basic demographics, 
smoking status, alcohol consumption,  usual physical activity, menopausal 
status (women only), medical history, family history and a 165-item, semi-
quantitative food frequency section[214] and the development of a Singaore 
Food Composition Table based on raw and cooked foods allows for the 
computation of personal intakes of 96 nutritive/non-nutritive dietary 
ingredients in study subjects.  The Singapore Food Composition Table lists 
the contents of roughly 100 ingredients in almost 900 foods in the Singapore 
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Chinese diet.  All participants were given written informed consents.  This 
study was approved by the National University of Singapore (NUS) 
Institutional Review Board (IRB). 
 
This cohort conducted the first followed-up interviews between 1999 to 2004 
and second follow-up interviews between 2006 to 2010.  In the second follow-
up interviews, MI and cardiovascular heart disease (CHD) death were checked 
for all participants through Singapore Registry of Births and Deaths, the 
Hospital Discharge Database or diagnosed by the review of a cardiologist 
based on the Multi-Ethnic Study of Atherosclerosis criteria (availabe at 
http://www.mesa-nhlbi.org/manuals.aspx).  Each verified MI or CHD case 
were matched with two SCHS pariticipants who were alive and free of CHD 
at the time of diagnose or death of the case for sex, dialect group, year of birth 
and year of recruitment.  A total number of 762 subjects have been diagnosed 
as MI until 2013.  This subset of SCHS formed our discovery population.  It 
would be called as SCHS in the following documents. 
 
3.1.2 Singapore Prospective Study (Used in Studies II and III) 
The Singapore Prospective Study (SP2) is a population based, cross-sectional 
study.  It began with the invitation of 10,445 subjects from 4 population based, 
cross-sectional surveys conducted from 1982 to 1998 in Singapore to 
participate in a repeat examination from 2004 to 2007.  The 4 studies were 
Thyroid and Heart Study 1982-1984[215], the National Health Survey 
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1992[216], the National University of Singapore Heart Study 1993-
1995[217]and the National Health Survey [218], which all include a random 
sampling of individuals from Singaporean population.  Among 10,445 invited 
subjects, 517 subjects were deceased at the time of follow-up, which was 
shown in the Registry of Births and Deaths in Singapore, 6 subjects emigrated 
and 85 subjects had discordant identity card number with records.  All these 
subjects were excluded for downstream analysis.   
Subjects were contacted to make an appointment for interview at their homes.  
Three home visits were made on 3 occasions, including at least one weekday 
and one weekend.  A total number of 2,673 subjects were noncontactable.  
Among the contactable subjects, 30 (0.3%) subjects refused to paticipate.  
Hence, a total number of 7,742 subjects were recruited, comprising 5,499 
Chineses, 1,405 Malays and 1,138 Asian Indians.  These subjects were invited 
to attend health examination and collection of biospecimens shortly after the 
home visit.  In summary, 74.1% of 7,742 subjects completed the questionaire 
and 49.4% of 7,742 (N=5,157) attended the health examination. 
 
Interviewer-adminstered questionaires were conducted subsequently.  Data on 
demographic, life style factors (alcohol consumption and smoking status) and 
medical history (hypertension, diabetes mellitus and hyperlipidemia) were 
collected.  Among the participants, 5,094 provided fasting blood samples (10 
hours).  Approximately half of them were genotyped using Illumina 
genotyping arrays.  Informed consent was obtained from all participants.  This 
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study was approved by the respective IRBs of NUS and Singapore General 
Hospital. 
 
3.1.3 Singapore Eye Study (Used in Studies II and III) 
The Singapre Eye Studies were population based, cross-sectional studies, 
designed to assess various ocular disorders.  It recurited adults age from 40 to 
80, residing in the southern west of Singapore, which is a fair representation 
of the Singapore population in terms of age distribution, housing type and 
socioeconomic status according to the 2000 Singapore Census.  The 
Singapore Eye Studies includes three ethnical sub-studies.  They were the 
Singapore Malay Eye Study (SiMES) commenced in 2004 ,Singapore Chinese 
Eye Study (SCES) commenced in 2007 and Singapore Indian Eye Study 
(SINDI) commenced in 2007[219].  The three studies were all conducted by 
the Singapore Eye Research Institute (SERI).  The ethnicity of Malay, 
Chinese and Indian were defined by a criteria set from Singapore Census[220].  
It is also indicated on the National Registration Identity Card.  All subjects 
were selected using age-stratified (10 year age group) random sampling 
strategy from a computer-genenrated list provided by the Ministry of Home 
Affairs.  The final sampling for SiMES, SCES and SINDI were 3,280 (78.7% 
participant rate of 4,168 eligiable participants), 3,400 (75.6% response rate of 
4,497 eligiable participants), 3,300 (72.8% response rate of 4,533 eligiable 
participants)[221] with initial sampling frame 5,600, 6,350,6,350, respectively.  
All the selected subjects underwent an extensive and standardized 
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examination procedure and detailed questionaires[219, 222], including marital 
status, education, occupation, current housing status, lifestyle factors, history 
of smoking, current medications and systemic medical and surgical history. 
All subjects known to have diabetes were administered to assess the level of 
glycosylated haemoglobin (HbA1c), diabetic retinopathy and blood pressure.  
Non fasting venous blood samples were collected for laboratory analysis 
including serum lipids, HbA1c, creatinine, random glucose and DNA.  All 
participants gave their written informed consents.  The study followed the 
principles of the Declaration of Helsinki and was approved by the SERI IRB.  
The detailed methodology of the three studies have been previously 
published[219, 222, 223]. 
 
3.1.4 Singapore Coronary Artery Genetics Study—Study I 
Singapore Coronary Artery Genetics Study (SCADGENS) is an ongoing 
multiethnic study, designed to assess the genetic determinants of CAD.  The 
subjects were recruited from consecutive patients who visited the National 
University Heart Centre for angiography. Coronary artery stenosis 
wasestimated by experienced cardiologists. Subjects who had 
angiographically proven coronary artery stenosis of at least 50% in at least 
one vessel were selected as CAD cases.  MI diagnoses were gathered through 
medical records showing diagnostic patterns on electrocardiogram and 
enzyme changes.  In SCADGENS, some CAD minor cases (30%-50% 
blockage)  and CAD- (20%-30% blockage) were recruited because the 
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blockage of arteries is visually measured and the final estimation of blockage 
were known only after the recruitment.  These CAD minor and CAD- cases 
were excluded from our studies.   
 
At recruitment, a face-to-face interview was conducted by a well-trained 
research nurse using a questionnaire that asked for information related to 
demographic, alcohol consumption ,smoking status, physical activities and 
medical history (hypertension, diabetes mellitus and hyperlipidemia).  
Informed consents were obtained from all pariticpants.  The study was 
approved by the National Health Group Domain Specific Review Boards 
(NHG DSRB). 
 
3.2 Anthropometric measurements 
Anthropometric measurements were taken similarly for all cohorts.  Height (in 
meter) was measured without shoes by using a wall-mounted stadiometer.  
Subjects were weighted (in kilogram) in light cloths and without any objects by 
using a digital scale.  Body mass index (BMI) was derived according to height 
and weight (BMI=weight/height
2
).  Waist circumference (cm) was measured at 
midpoint between the last rib and the iliac crest and hip circumference (cm) was 
measured at trochanter of the femur. 
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3. 3 Laboratory measurements 
3.3.1 Singapore Chinese Health Study 
One year after recruitment began, blood samples (20ml) were collected from a 
random 3% sample of the cohort participants and expanded to entire cohort 
from 2000-2005.  Most blood samples were collected in the morning and the 
information of last meal was recorded.  The blood samples were kept in dry 
ice immediately after collection.  They were seperated and stored at -80 °C.  
The final number of  blood samples collected before the incident of disease 
during the first home visits were 28,439. 
 
Non-fasting total cholesterol (CHOL), HDL-C, LDL-C and TG were 
measured in the Department of Laboratory Medicine, National University 
Hospital.  CHOL and  HDL-C were measured at baseline with the enzymatic, 
colorimetirc method with sterol esterase, cholesterol oxidase, and 4-
aminoantipyrine using the Siemens Advia 2400 instrument in SCHS.  LDL-C 
was directly measured by elimination/catalase method using Siemens Advia 
2400.  TG was measured using the enzymatic, colorimetric method with 
glycerol-3-phosphate oxidase and 4-aminoantipyrine.   
 
SBP and DBP were measured during home visits by trained doctors or nurses 
using Omron Automatic Digital Blood Pressure Monitors (HEM 705CP) after 
at least 5-minute rest.  Each participant had three blood pressure 
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measurements, with a 3-min interval between measurements.  The mean value 
of the three  readings was used in the data analysis. 
 
Serum C-reactive protein (CRP) was measured using a particle enhanced 
immunoturbidimetric method implemented on Roche Cobas Intergra 400 plus 
( Roche Diagnostics, Rotkreuz, Switzerland).  Creatinine was measured using 
enzymatic method with creatininase (Siemens Advia 2400).  HbA1c was 
evaluated using ion-exchange HPLC method (Biorad Variant II). 
 
3.3.2 Singapore Prospective Study 
Venous blood was drawn and collected at the time subjects visting clinics for 
health examination.  All the subjects were examined in the morning and after 
a 10-hour overnight fast.  Serum total cholesterol, triglycerides and high 
density lipoprotein cholesterol were measured by using an automated 
autoanalyzer (ADVIA 2400; Siemens).  Low density lipoprotein was 
calculated by using the Friedewald formula. 
 
Blood pressure was taken by using automated blood pressure monitor 
(Dianamap Pro 100V2; Criticon, Norderstedt, Germany) after 5-minute rest.  
Generally two readings were taken unless the difference of the two readings 
were greater than 10 mm Hg for systolic blood pressure (SBP) or 5 mm Hg  
diastolic blood pressure (DBP).  The mean of the closest 2 readings was 
calculated.  Hypertension was defined as a history of hypertension or SBP > 
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140 mmHg or DBP > 90 mmHg.  Participants known to be on lipid-lowing 
therapy or with self-reported hypercholesterolemia were excluded from 
analysis for all studies. 
 
Plasma glucose and creatinine were assessed using enzymatic methods 
(ADVIA 2400).  CRP was measured in the same method used in SCHS.  
Insulin levels were measured using immunoassay (Abbott ASYM Abbott 
Laboratories, Chicago, IL). 
 
3.3.3 Singapore Eye Study 
A 40ml non-fasting venous blood was collected for all pariticpants.  For 
SiMES, plasma lipids were measured using enzymatic methods with Advia 
2400 Chemistry System (Siemens Medical Solutions Diagnostics, Deerfield, 
IL, USA).  For SINDI and SCES, plasma lipids were measured with 
turbidimetric inhibition immono assays using Roche-Cobas® CE analyser 
(Roche Diagnostics, Germany).  SBP and DBP measurement and the 
definition of hypertension were similar to SP2, as described above.  T2D was 
defined as participants with a history of diabetes mellitus or HbA1c levels ≥ 6.  
5% in non-fasting blood samples. 
 
3.4 Genotyping 
SCHS was genotyped on Illumina ZHONGHUA Bead 8 Array version 1 
(900,015SNPs) (San Diego, California, the United States).  SCADGENS was 
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genotyped on Illumina ZHONGHUA Bead 8 Array version 2 (894,956 SNPs).  
The Chinese samples from SP2 (N=3,066) were genotyped using the Illumina 
HumanHap 1Mduov3 (N=1,016), HumanHap 610Quad (N=1,467) and Hap550 
arrays (N=583).  The Chinese subjects from SCES (N=1,642), the Malay subjects 
from SiMES (N=3,072) and the Asian-Indians from SINDI (N=2,953)were 
genotyped using HumanHap 610Quad arrays.  . 
 
3.5 Quality control 
For each cohort used in our studies, quality control (QC) was conducted similarily.  
In general, SNP QC was conducted to remove SNPs that did not meet the 
following criteria: 1) monomorphic or rare variants (minor allele frequency 
<0.01), 2) SNPs with an excessive missing genotype (>0.05), 3) SNPs 
demonstrating a significant deviation from Hardy-Weinberg Equlibrium (HWE, 
P< 10
-4
~10
-6
),  4) SNPs with missing information of strand.  Imputed SNPs were 
additionally filtered out following two criteria: 1) posterior call less than 0.99, 2) 
info score calcuated in frequentist test less than 0.80.  Based on the remaining 
SNPs, sample quanlity control was conducted.  Samples with 2%~5% missing 
data and excessive heterozygosity of more or less than 3 fold of mean were 
removed.  One sample from the pairs of first relatives was excluded based on two 
rules, which are first to remove control prior to case and second to remove sample 
with lower call rate.  Besides, samples with discordant ethnic relationship and 
discrepancy reported gender with genetically inferred gender were removed 
unless strong clarification.  The detailed cut-off varied from study to study. 
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3.5.1 Quality control of SCHS 
Only SCHS was used for lipid association analysis (Study II) as the lipid 
measurements of SCADGENS are still ongoing at the time of this thesis 
writing.  We did not use lipid data from SP2, SCES, SiMES and SINDI for 
GWAS association analysis as a international consortium is concurrently 
using it for a trans-ethnic meta-analysis. The number of SCHS for genotyping 
was 2,136 and the sample of SCHS passed QC was 2,003.  The number of 
SNPs pass genotype calling algorithms was 895,493.  The SNP and sample 
quality control of SCHS was summarized in Table 4.  The post-QC including 
genotyped and imputed SNPs  was conducted in SCHS samples passing the 
first sample QC (N=2,003).  The process was summarized in Table 5. 
 
3.5.2 Quality control of SCHS-SCADGENS  combined dataset 
The GWAS of SCHS (N=2,003) was conducted but it was underpower to 
detect genome wide association variants.  SCADGENS (N=511) was added to 
increase the power.  The quality control of SCHS-SCADGENS combined 
dataset (N=2,514) were summarized in Table 6.  A post QC was perfomred to 
reduce the mistakenly removed SNPs due to poor quality samples (Table 7). 
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3.5.3 Quality control of Singapore eye studies and SP2 
The genotyping and quality control of Singapore eye studies and SP2 were 
conducted by Genome institute of Singapore (GIS). The quality control details 
of Singapore eye studies and SP2 aresummarized in Table 8. 
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Table 4 Quality control of SCHS 
SNP QC in 2,136 samples for 895493 SNPs 
QC criteria  Excluded (N) Remaining (N) 
Non-autosomal SNPs set aside 24,461 871,032 
Low call rate (<95%) 467 870,565 
gross departures of HWE for controls, defined as PHWE<10
-6
 406 870,159 
Minor allele frequency smaller than 0. 01 67,524 802,635 
SNP has no info about strand according to the marker file 1 802,634 
Sample QC in 2,136 samples for 802634 SNPs 
QC criteria Excluded (N) Remarks  
Poor sample call rate (<98%) 10  
Excess heterozygosity, which can be indicative of sample contamination 
(mean±3SD)   
20 
 
Excessive identity-by-state, which suggests related / duplicated samples
 
25+42 
25: first degree relatives 
42: monozygotic duplicates 
Discordant ethnic membership from the reported ethnicity  2  
2
nd
 degree relatives, causing formation of small outlier clusters 17  
Departure of SCHS population 17  
Total number of samples remaining 2,003 
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Table 5 Post QC SNP of SCHS in 2,003 samples 
Genotyped SNPs Excluded (N). Remaining(N) Excluded (N) Remaining (N) Excluded (N) Remaining (N) 
Control HDL-C LDL-C TG 
Total genotyped SNPs  872,243  872,243  872,243 
Exclude after Maf<0.1 68,154 804,089 68,154 804,089 68,154 804,089 
Exclude after HWE<10
-5
 485 803,604 485 803,604 485 803,604 
Exclude after call rate <95% 407 803,197 407 803,197 407 803,197 
Exclude after info <0.5 5 803,192 0 803,197 0 803,197 
Total imputed SNPs   35,825,886   35,825,886   35,825,886 
Exclude after Maf<0.1 29,783,261 6,042,625 29,783,261 6,042,625 29,783,261 6,042,625 
Exclude after HWE<10
-5
 138 6,042,487 138 6,042,487 138 6,042,487 
Exclude after call rate <95% 1,216,276 4,826,211 1,216,276 4,826,211 1,216,276 4,826,211 
Exclude after info <0.8 52,459 4,773,752 51,848 4,774,363 52,883 4,773,328 
MI case HDL-C LDL-C TG 
Total genotyped SNPs   872,243   872,243   872,243 
Exclude after Maf<0.1 68,809 803,434 68,809 803,434 68,809 803,434 
Exclude after HWE<10
-5
 254 803,180 254 803,180 254 803,180 
Exclude after call rate <95% 432 802,748 432 802,748 432 802,748 
Exclude after info <0.5 0 802,748 0 802,748 0 802,748 
Total imputed SNPs   35,825,886   35,825,886   35,825,886 
Eexclude after Maf<0.1 29,784,480 6,041,406 29,784,480 6,041,406 29,784,480 6,041,406 
Exclude after HWE<10
-5
 133 6,041,273 133 6,041,273 133 6,041,273 
Exclude after call rate <95% 1,233,557 4,807,716 1,233,557 4,807,716 1,233,557 4,807,716 
Exclude after info <0.8 59,271 4,748,445 57,103 4,750,613 58,673 4,749,043 
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Table 6 Quality control of SCHS-SCADGENS combined dataset 
SNP quality control (2,647 samples and 900,015 SNPs initially) 
QC criteria Removed (N) Remaining (N) 
Non-overlapping SNPs between two versions 5,059 894,956 
SNPs with no applicable allele information 25 894,931 
SNPs have identical position 4,466 890,465 
Non-autosomal SNPs  27,587 866,148 
Low call rate (<95%) 726  
Gross departures of HWE for controls, defined as pHWE<10
-6 
430  
Minor allele frequency smaller than 0.01 66,521 798,574 
SNP has no info about strand according to the marker file 1 798,573 
 SNPs failed the chi-square test of allele count between SCHS and SCADGENS 9 798,564 
Sample quality control (2,647 samples and 798,573 SNPs initially) 
QC criteria Removed (N) Remaining (N) 
Identity-by state (IBD) analysis to identify internal control samples for sample loading checking 42 2,605 
Poor sample call rate (<98%) 14 2,591 
Excess heterozygosity, which can be indicative of sample contamination (mean±3SD)   31 2,561 
Excessive identity-by-state, which suggests related (based on 2561samples)
 
37 2,524 
Discordant ethnic membership from the reported ethnicity (based on 2524 samples)  15 2,509 
2
nd
 degree familiar relationship, causing formation of small outlier clusters 34 2,393 
Departure of SCHS population 82 
Exclusion of CAD minor & CAD- samples 14 2,379 
CAD only samples 208 2,171 
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Table 7 SNP QC on 890,465 SNPs and 2,379 SCHS-SCADGENS samples 
QC criteria Removed (N) 
Non-autosomal SNPs set aside 24,317 
Low call rate (<95%) 720 
Gross departures of HWE for controls, defined as pHWE<10
-5 1,016 
Minor allele frequency smaller than 0. 01 67,367 
Different MAF (3 fold) in cases among top SNPs (10
-5
) due to sampling bias or batch effect 123 
Total number of unique SNPs remaining 796,922 
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Table 8 Detailed quality control procedures of SP2, SiMES, SINDI and SCES 
  SP2 SiMES SINDI SCES 
SNP quality control             
Illumina SNP chip 1M Duo 610 Quad 550 610 Quad 610 Quad 610 Quad 
No. of genotyped only SNPs 1,185,068 620,881 561,466 620,881 620,881 538,429 
No. of imputed only SNPs 1,231,463 1,795,716 1,855,129 1,313,443 1,348,697 1,926,240 
Total Imputed and genotyped SNPS 2,416,531 2,416,597 2,416,595 1,934,324 1,969,578 2,464,669 
SNPs with allelic discrepancies 62 - - - 
SNPs with positional discrepancies between 
observed data and HapMap reference panels 
79 13 15 13 - 12 
SNPs with MAF < 1% 153,908 189,571 197,610 49,165 27,882 265,554 
SNPs with call-rate < 95% 225,135 392,044 404,878 424,293 502,323 424,924 
HWE outliers (p-value < 10
-4
) 761 1,668 275 4,481 5,868 648 
SNPs with poor imputation information score < 0.5 4 6 81 1 0 5 
No. of SNPs that pass QC filters 2,071,812 1,834,625 1,810,065 1,560,745 1,527,744 1,773,537 
Sample quality control              
Ethnicity Chinese Malay 
Asian-
Indian 
Chinese 
Total samples genotyped 2,031 2,662 583 3,072 2,953 1,949 
Extreme heterozygous samples and/or samples with 
low call-rate
†
 
32 17 0 37 34 11 
Related samples and/or duplicates/contaminations 58 229 13 279 326 41 
Discordant ethnic membership 20 26 7 170 39 6 
Gender discrepancies 31 24 1 44 16 2 
Remaining samples 1,890 2,366 562 2,542 2,538 1,889 
Samples with BMI information 1,868 2,220 335 2,522 2,531 1,866 
† Low call-rate defined as < 95% call-rate and extreme heterozygosity defined as < 0.25 or > 0.35. 
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3.6 Imputation 
To facilitate meta-analysis, each cohort performed genotype imputation except 
SCADGENS.  The whole genome was phased and additional genotypes were 
imputed with IMPUTE (v2) on 1000 Genome Asian data.  The imputed genotypes 
were filtered using a posterior probability of at least 0.99 and a call-rate of at least 
95% for all imputed SNPs.  The imputed data was only utilized in Chapter 
5.SCHS was imputed in 2013 and SCADGENS was imputed in 2014. 
 
3.7 Methods for population stratification analysis 
3.6.1 Genomic control 
Genomic control factor λGC was calculated as the ratio of the median χ2 
association statistic across whole genome SNPs divided by its theoretical 
median (0.456) under the null distribution. 
 
3.6.2 Principle Component Analysis 
In our studies, quality control of SNPs and samples were applied before PCA.  
Identity by state analysis was performed to remove samples with 1
st
 degree 
familial relationship.  Five conserved region of SNPs were excluded from 
analysis, including chr5:43,964,243-51,464,243, chr6:24,892,021-36,892,022, 
chr8:1-12,655,629, chr11: 84,322,352-86,322,352 and chr11: 45,043,424-
57,243,424based on build 37.  The quality controlled SNPs without 5 
conserved regions were subsequently pruned across whole genome using pair-
wise comparison in PLINK (v1.07) to remove SNPs with an R
2
 greater than 
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0.2 within a 50-SNP window.  The remaining 99,885 independent autosomal 
SNPs were computed to generate principle components in the 194 reference 
samples of the HapMap project (Africa (YRI, N=53), Europe (CEU, N=56), 
Asia (CHB, N=43; JPT, N=53)) for the purpose of detecting discordant ethnic 
membership from reported ethnicity. 
 
PCA of SCHS 
PCA was performed to identify the admixed samples or samples with mis-
specified ethnic memberships using HapMap samples from Europe, Africa, 
China and Japan ancestries as reference.  Shown in Figure 2, all of the SCHS 
samples were perfectly separated except 2 cases in the plot of PC1 vs. PC4, 
which were reported as Chinese.  However, they lied in between Japanese and 
Chinese, indicating that they can be the mixture of Chinese and Japanese.  
Therefore, these 2 samples were excluded, leaving 2,037 samples remaining. 
 
To identify samples with departure of SCHS population, second PCA was 
conducted among 2,037 samples.  Shown in Figure 3A, 44 samples exceeded 
3 or more SD from the mean of PC1-5.  Checking with IBS analysis, 27 of 44 
samples were second degree relatives, which may probably cause the 
formation of small outlier clusters.  By using the same removal criteria of first 
degree removal criteria (described in section 3.5), 17 samples were removed.  
The rest 10 samples came back to the population clusters.  Finally, 17 true 
outliers were removed, leaving 2,003 samples, including 719 cases and 1,284 
controls.  To make sure all the admixed samples were removed, PCA was 
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conducted again using the remaining 2,003 samples.  The results were 
summarized in Figure 3B, showing a homogenous distribution. 
 
Figure 2 Plots of the principle components (PC) of 2,039 MI samples to identify the admixed 
samples or samples with misspecified ethnic memberships with 194 Hapmap samples (YRI 
(N = 53), CEU (N = 56), CHB (N = 43) and JPT (N = 53)) on 98,357 common SNPs.  2,039 MI 
samples: Cases (red), controls (white); CEU (yellow); CHB (blue); JPT (green); YRI (purple).  
Samples which are identified as admixed or misspecified have been circled. 
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Figure 3 Plots of the principle components (PC) of 2,003 MI samplesCases are 
represented by red dots, controls are represented by yellow dots.  Pairs of samples which 
are identified as second degree familiar relationship have been circled.  A: 2,037 samples; 
B: 2,003 samples  
B.  
 
 
A.  
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PCA of SCHS-SCADGENS combined dataset 
Similar to the PCA of SCHS, PCA was first conducted to identify samples 
with non-Chinese ancestry.  Figure 4 showed that different ethnicities were 
perfectly separated except for 2 cases in the plot of PC1 vs.PC2, in which two 
Indians were deliberately introduced for the purpose of negative control.  In 
the plot of PC1 vs.PC3, 11 outliers were the CAD/MI cases from 
SCADGENS.  In the plot of PC1 vs.PC4, 2 outliers from SCHS cases were 
between Japanese and Chinese, which were the same two samples identified 
by the PCA of SCHS.  They were likely to be the mixture of Chinese and 
Japanese.  Therefore, these 15 samples were excluded, with 2,509 samples 
remaining.  The consistent ethnicity among 2,509 samples was confirmed by 
another PCA shown in Figure 4B.   
 
The remaining 2,509 samples were subsequently examined for the departure 
of SCHS-SCADGENS population by PCA on 2,509 samples.  Shown in 
Figure 5, 83 samples deviated from the centered cluster (cut off: PC1<-0.04 or 
PC2>0.05 or PC2<-0.05 or PC3>0.06 or PC3<-0.1 or PC4<-0.15 or PC5>0.1).  
Of these, 18 samples were identified as second degree familial relationship 
from 8 families by IBD analysis.  One sample from each family was kept 
based on the same removal criteria of first degree removal criteria (described 
in section 2.5).  The second PCA was conducted to confirm the homogenous 
distribution of SCHS-SCADGENS.   We observed 50 more samples that 
deviated from the centered cluster (cut off: PC2<-0.06, PC2>0.057, Absolute 
(PC3) <0.057, Absolute (PC4) <0.06, Absolute (PC5) <0.057).  Twelve 
70 
 
samples with second degree familial relationship were removed due to the 
formation of small cluster and 26 true outliers were removed, leaving 2,396 
samples.  By similar process, additional two PCA were conducted.  In total, 2 
samples were removed, leaving 2,393 samples.  Figure 5B exhibited 
homogenous distribution in SCHS-SCADGENS.  In conclusion, 34 samples 
with second degree familial relationship and 82 true outliers were excluded in 
PCA.  The final sample size was 2,393 samples, consisting of 1,243 SCHS 
control, 694 SCHS cases, 234 SCADGEN MI, 208 SCADGEN CAD only and 
14 SCADGEN CAD minor or CAD- samples.  
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A.   
 
 
B.   
 
Figure4 Plots of the principle components (PC) to identify the admixed samples or 
samples with misspecified ethnic memberships with 194 Hapmap samples (YRI (N
= 53), CEU (N = 56), CHB (N = 43) and JPT (N = 53)) in 2,524 samples on 99,885 
common SNPs.  Cases, control, CEU, CHB, JPT and YRI are represented by red, white 
yellow, blue, green and purple dots, respectively.  Samples which are identified as 
admixed or misspecified have been circled.  A.  PCA plots of 2,524 samples.  B.  PCA 
plots of 2,509 samples. 
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A.   
 
B.   
 
Figure 5 Plots of the principle components (PC) to confirm to identify the admixed 
samples in 2,393 samples on 99,885 common SNPs.  SCHS cases, controls, SCADGEN 
CAD cases, CAD-, CAD-MI, CAD and MI cases, CAD minor cases, CAD minor and MI 
cases are represented by pink, brown, red dots, yellow, blue, green dots, purple dots, grey 
dots, respectively.  A. 2,509 samples B.  2,393 samples 
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3.8 Methods for association analysis 
Logistic or linear regression were implemented in PLINK to examine the 
association.  If imputed genotypes were included in analysis, frequentist test was 
implemented in SNPTEST to test the association.  In all analyses where the 
underlying genetic model is unknown, an additive model was used with the 
assumption that the presence of two minor alleles will increase two times higher 
risk of disease compared to the risk increased by the presence of one minor allele. 
The detailed models were described in the respective chapter for each study.  A P-
value threshold of 5 x 10
-8
 was applied to declare genome-wide significance for 
all genome wide association analysis. 
 
For analysis of more than two cohorts, meta-analysis was applied using fixed 
effect inverse variance model, which assumes the effect of SNP in different 
cohort is identical.  The results were calculated in STAT v11.0 using following 
function and equation:  
1) meta-beta=(betacohort1/ S.Ecohort1
2 
+ betacohort2/ S.Ecohort2
2
)/(1/S.Ecohort1
2 
+1/ 
S.Ecohort2
2
) 
2) meta-statistic= meta-beta/ (1/(1/S.Ecohort1
2 
+1/ S.Ecohort2
2
))
0.5
 
3) meta-P=2x(1-normal(abs(meta-stat))) 
 
3.9 URLs 
Whole genome association analysis package, PLINK: http://pngu.  mgh.  harvard.  
edu/~purcell/plink/ 
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Whole genome association analysis package, SNPTEST V1.  1.  5: 
https://mathgen.  stats.  ox.  ac.  uk/genetics_software/snptest/old/snptest_v1.  1.  
5.  html 
Whole genome association analysis package, SNPTEST v2.  5: https://mathgen.  
stats.  ox.  ac.  uk/genetics_software/snptest/snptest.  html 
Genotype imputation program, IMPUTE 2: https://mathgen.  stats.  ox.  ac.  
uk/impute/impute_v2.  html 
Genotype transformation program, GTOOL: http://www.  well.  ox.  ac.  
uk/~cfreeman/software/gwas/gtool.  html 
Statistical computer software, R:http://www.  r-project.  org/ 
Regional plots drawing package, Locus zoom: https://statgen.  sph.  umich.  
edu/locuszoom/genform.  php?type=yourdata 
SNP annotation and proxy search SNAP: 
http://www.  broadinstitute.  org/mpg/snap/ldsearchpw.  php 
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Chapter 4: Genome wide scan of single nucleotide polymorphisms associated 
with coronary artery disease 
4.1 Introduction 
In Singapore, 27.3% of the deaths were due to cardiovascular disease [225].  It 
implied that one out of three deaths in Singapore was due to cardiovascular 
disease or 15 people died from cardiovascular disease every day.  To address this 
health burden, effective preventive efforts are needed urgently.   
 
Since 2007, GWAS has proven itself as a useful tool due to its advantages of 
offering high power and high resolution compared to conventional approaches.  
Until now, 30 loci have been discovered and verified to be associated with CAD 
by GWAS[226].  However, most GWAS were conducted in Caucasians.  In Asia, 
where the diet and genetic constitution of the population is relatively different 
from their western counterparts and within the region itself, fewer studies have 
been carried out.  More studies should, therefore, be conducted on the Asian 
population, taking into account both environmental and genetic aspects.  Given 
that there are only 2investigations of CAD in Chinese and limited knowledge of 
CAD in Chinese, we aimed to discover new susceptibility loci and new genetic 
variants underlying CAD in Singaporean Chinese population.   
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4.2 Methods 
4.2.1 Study design and genotyping  
SCHS and SCADGENS were used as discovery populations.  The study 
design, genotyping and quality control were described in Chapter 3.  After 
quality control, 796,922 SNPs and 2,379 samples remained.  The final sample 
size was consisted of 1,243 SCHS controls, 694 SCHS MI cases, 234 
SCADGENS MI cases and 208 SCADGENS CAD cases.  To investigate if 
208 SCADGENS CAD samples affect the results, the association analysis was 
conducted for 2,379 and 2,171 samples.  But only the results of 2,379 samples 
were presented below. The procedures of genome wide scan of SNPs 
associated with CAD were summarized in Figure 6. 
 
4.2.2 Selection of index SNPs for MI 
SNPs associated with MI were drawn from the GWAS catalog using 
keywords ―coronary artery disease‖, ―coronary heart disease‖, ―myocardial 
infarction‖ and ―myocardial infarction (early onset)‖.  Only SNPs that were 
part of genotyped SNPs on Illumina HumanOminZhongHua-8 Beadchip were 
extracted. Finally, 28 index SNPs of MI were selected. 
 
4.2.3 Statistical tests 
Genome-wide association analysis was performed by using PLINK (v1.07) to 
implement a logistic regression model where age, gender and the first five 
principal components were included as covariates.  The Manhattan plot of –
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log10P was generated using R to summarize the association results.  The 
quantile-quantile plot was generated using R to evaluate the significance of 
observed genome wide association compared to expected association.  The 
genome wide significance was set at 5x10
-8
.  As SCHS and SCADGENS were 
genotyped at two different times, Mantel extension test was applied to identify 
the SNPs with batch effect or sampling bias.  The quantile-quantile plot for 
Mantel extension test was generated accordingly.  SNPs (N=123) that deviated 
from the expected P value were excluded from analysis.   
 
 
Figure 6 Flow chart of genome wide scan of SNPs associated with CAD 
 
4.3 Results 
4.3.2 Association with MI 
The association of MI was analyzed in 2,379 samples on 796,822 SNPs.  The 
genomic control parameter for MI was 0.999.  As shown in Table 9and Figure 
7, there was no significant SNP reaching genome wide significance level but 
SNPs showed suggestive associations (10
-8
<P<10
-5
).  Among the top 10 genes 
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of SNPs, five of them were related to RNA expression.  The most significant 
signal was rs1144814 with a P value of 2.87x10
-06 
from gene RP11-978I15.10, 
whose product is antisense mRNA.  Most of the genes showed little 
relationship with MI but there were two genes that showed some functional 
relations with MI.  One was vascular endothelial growth factor A, where SNP 
rs3025035 is located and showed suggestive association with MI.  The other 
one is fibronectin type III domain containing 3B (FNDC3B), where the 3’ 
UTR variant rs12897 is located and showed suggestive association with MI.   
 
Regional plots of top 10 hits were plotted to examine the possibility of true 
associations by checking whether any nearby SNPs in LD exhibited similar 
associations to different extent.  As can been seen from Figure 8, rs35724622 
was a singleton, suggesting that it was a false positive association.  Most of 
the SNPs had other SNPs in LD clustered showing reduced associations with 
MI except rs3025035, rs12455933 and rs10081999. 
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Table 9 List of top 10 SNPs in 2,379 samples 
SNP CHR Position Nearest genes Context OR SE P 
MAF 
SCADGENS SCHS 
CAD MI MI Control 
rs1144814 1 247,783,890 RP11-978I15.10(antisense RNA)  0.75 0.06 2.87E-06 0.43 0.41 0.40 0.48 
rs3025035 6 43,751,359 VEGFA Intron 1.48 0.08 4.01E-06 0.16 0.16 0.18 0.13 
rs12455933 18 39,269,404 KC6 (RNA gene) Intergenic 1.49 0.09 4.42E-06 0.17 0.17 0.16 0.12 
rs35724622 
(kgp17090
42) 
1 145,831,160 NBF10 Intron 0.75 0.06 5.46E-06 0.38 0.34 0.40 0.45 
rs6878810 5 78,034,805  LHFPL2, ARSB 
 
Intergenic  0.76 0.06 5.63E-06 0.43 0.43 0.42 0.49 
rs10081999  
(kgp53365
45) 
1 161,273,648 MPZ Intergenic  1.62 0.11 6.90E-06 0.10 0.13 0.10 0.07 
rs4801364 19 57,223,816 FJ997633(anti-sense RNA) Intron 1.45 0.09 1.19E-05 0.15 0.17 0.17 0.12 
rs730845 19 57,224,390 FJ997633(anti-sense RNA) Intron 1.45 0.09 1.36E-05 0.15 0.17 0.17 0.12 
rs2870104  
(kgp61388
11) 
19 57,252,896 FJ997633(anti-sense RNA) Intron 1.37 0.07 1.71E-05 0.23 0.26 0.24 0.19 
rs12897 3 172,115,902 FNDC3B 3’UTR 0.75 0.66 1.76E-05 0.25 0.28 0.26 0.31 
VEGFA: vascular endothelial growth factor A; KC6: keratoconus gene 6; NBF10: neuroblastoma breakpoint family, member 10; LHFPL2: lipoma HMGIC 
fusion partner-like 2; ARSB: arylsulfatase B; MPZ: myelin protein zero; FNDC3B:fibronectin type III domain containing 3B 
 
 
Figure 7 Summary of genome wide association of 2,379 samples on 796,922 SNPs. The left panel was the Manhattan plot of 2,379 samples on 
796,922 SNPs.  The right panel was the Q-Q plot of 2,379 samples on 796,922 SNPs 
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Figure 8 Regional plots of top 10 hits. The SNP was marked by purple diamond.  The 
surrounding SNPs coloured based on their r
2
 with index SNP from the 1000 genome Asia 
reference panel 
 
 
 
 
a. b. 
c. d. 
e. f. 
g. h. 
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4.3.1 Index SNPs influencing MI 
Twenty eight known MI or CAD associated SNPs were replicated in our data 
of 2,171 samples and 2,379 samples (Table 10).  Five reported SNPs 
(rs4977574 in CDKN2B, rs10757274 in CDKN2B, rs4380028 in ADAMTS7, 
rs579459in ABO, rs1332844 in PHACTR1 ) showed moderate association 
evidence in the dataset of 2,171 samples (P<0.05).  Similarly, they also 
showed association in 2,379 samples but one more SNP rs9349379 in 
PHACTR1 showed significant association in 2,379 samples, indicating an 
increase of power.  The Chinese specific variant rs6903956 was not 
significant in our dataset but showed a consistent trend as reported.  All 
significant index SNPs exhibited a consistent risk direction with reported 
effect direction.   
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Table 10 Association of 28 known CAD loci with CAD 
No SNP CHR Mapped gene 
N=2,171 N=2,379 MAF 
PUBMED 
ID 
Population 
OR P OR P 
SCADGENS SCHS 
CAD MI MI control 
1 rs4977574 9 CDKN2B 1.22 0.0016 1.22 0.0010 0.49 0.44 0.50 0.47 21378990 Europeans 
2 rs10757274 9 CDKN2B 1.21 0.0020 1.21 0.0012 0.49 0.44 0.50 0.47 22751097 Chinese 
3 rs4380028 15 ADAMTS7  0.86 0.017 0.85 0.0087 0.41 0.43 0.41 0.45 21378988 Europeans 
4 rs579459 9 ABO  1.20 0.025 1.21 0.012 0.21 0.21 0.20 0.18 21378990 Europeans 
5 rs1332844 6 PHACTR1 0.72 0.010 0.77 0.027 0.08 0.06 0.05 0.07 21378988 Europeans 
6 rs9349379 6 PHACTR1 0.88 0.053 0.88 0.043 0.29 0.33 0.27 0.32 22751097 Chinese 
7 rs1333042 9 CDKN2B 0.91 0.16 0.89 0.057 0.29 0.28 0.35 0.35 23364394 Koreans, Japanese 
8 rs12524865 6 TCF21 1.07 0.27 1.11 0.083 0.47 0.46 0.48 0.48 22751097 Chinese 
9 rs7136259 12 ATP2B1 -MRPL2P1 0.88 0.06 0.93 0.22 0.40 0.34 0.33 0.36 22751097 Chinese 
10 rs12200560 6 FHL5 - RPS7P8 1.12 0.19 1.11 0.23 0.14 0.15 0.16 0.14 22319020 Europeans 
11 rs974819 11 MTND1P36 -MIR4693 0.96 0.49 0.93 0.25 0.33 0.38 0.36 0.38 21378988 Europeans 
12 rs2259816 12 HNF1A 1.07 0.30 1.07 0.26 0.49 0.47 0.47 0.46 19198612 Europeans 
13 rs6903956 6 ADTRP 1.20 0.17 1.16 0.26 0.06 0.09 0.05 0.05 21378990 Chinese 
14 rs11556924 7 ZC3HC1 0.91 0.44 0.89 0.35 0.05 0.07 0.06 0.07 21378990 Europeans 
15 rs3782889 12 MYL2 0.93 0.32 0.95 0.42 0.29 0.28 0.27 0.28 23364394 Koreans, Japanese 
16 rs501120 10 LINC00840 - CXCL12 0.96 0.57 0.95 0.46 0.31 0.33 0.33 0.34 17634449 Europeans 
17 rs17465637 1 MIA3 0.95 0.43 0.96 0.46 0.35 0.35 0.37 0.38 21378990 Europeans 
18 rs3729639 16 E2F4;EXOC3L1 1.26 0.30 1.16 0.50 0.02 0.01 0.03 0.02 21347282 African American 
19 rs646776 1 CELSR2 1.01 0.93 1.07 0.56 0.08 0.06 0.06 0.06 21378988 Europeans 
20 rs16893526 6 FAM46A - IBTK 0.98 0.83 0.96 0.60 0.14 0.19 0.17 0.18 21606135 Europeans 
21 rs599839 1 PSRC1 0.99 0.93 1.05 0.65 0.10 0.08 0.07 0.07 21378990 Europeans 
22 rs9268402 6 C6orf10 0.99 0.82 0.97 0.68 0.37 0.36 0.38 0.38 22751097 Chinese 
23 rs2229238 1 IL6R 0.97 0.73 0.97 0.68 0.19 0.19 0.19 0.19 22319020 Europeans 
24 rs8055236 16 CDH13 1.00 0.99 1.02 0.88 0.12 0.11 0.10 0.10 17554300 Europeans 
25 rs9818870 3 MRAS 1.01 0.98 1.06 0.89 0.01 0.01 0.01 0.00 19198612 Europeans 
26 rs3869109 6 HCG27 - USP8P1 1.01 0.83 0.99 0.89 0.40 0.42 0.44 0.43 22319020 Europeans 
27 rs1263173 11 APOA5 - APOA4 1.01 0.90 1.00 0.95 0.29 0.30 0.31 0.31 21347282 African American 
28 rs2943634 2 NYAP2 - MIR5702 1.04 0.71 1.00 0.98 0.07 0.07 0.09 0.08 17634449 Europeans 
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4.4 Discussion 
We examined the association with MI on 796,922 SNPs in 2,379 samples.  
Although there were evidences of index association signals in a consistent 
direction with reported literatures, we failed to observe any genome wide 
significant associations for MI. Nevertheless, a few loci did emerged with 
suggestive significance of 10
-8 
<P< 10
-5
.   
 
The vascular endothelial growth factor A (VEGFA) is one of the most important 
stimulator of angiogenesis.  Increased circulating VEGFA levels have been found 
in subjects with hyperlipidemia and hypercholesterolemia [227, 228].  Significant 
associations have been observed between lipid levels and VEGFA [229, 230].  In 
a recent large scale meta-analysis of lipids, rs998584 in the downstream region of 
VEGFA has shown genome wide significant associations with HDL-C and TG 
[149].  A GWAS study of coronary heart disease has reported an association with 
SNP rs6905288 in VEGFA (P=7x10
-8
) [158].  The two SNPs and lead SNP 
rs3025035 were independent SNPs in low LD.  However, these two SNPs were 
not genotyped in our array.   
 
There were two other loci also showing relevant biological association with MI.  
One is the fibronectin type III domain containing 3B (FNDC3B).  It is 
predominantly expressed in white adipose tissue, especially in the stromal 
vascular cells.  Its expression is increased in the early stage of adipogenesis, 
which is an important process in the pathology of MI.  An intronic variant 
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rs9647379 in FNDC3B has been identified as a heart rate associated loci [231].  
The other one is LHFPL2-ARSB.  Lipoma HMGIC fusion partner-like 2 
(LHFPL2) is a tetraspan transmembrane protein.  ARSB is an arylsulfatase in 
lysosome.  The two adjacent genes LHFPL2 and ARSB were suggested to exhibit 
positive associations with MI related risk factors such as blood pressure and 
hemoglobins [232-234]. 
 
Our study has several limitations.  Firstly, we had limited power to detect genome 
wide significant SNPs due to small sample size.  Given 2,379 unmatched samples, 
we only have 80% power to detect variants with MAF of at least 0.33 and effect 
size of at least 1.31. However, it is not unreasonable as many of the top hits in 
other GWAS do fulfill this, even the Chinese GWAS as well. More importantly, 
we lacked additional independent samples to validate the variants at a level of 
suggestive significance.  Notably, we included participants without MI but with 
CAD in our analysis as the results obtained from 2,137 samples consisting of 
controls plus   MI cases and 2,379 samples (controls plus MI and CAD) were 
similar except for lower power in the former.  Secondly, true susceptibility 
variants may be excluded due to batch effect or sampling bias.  SCHS and 
SCADGENS were two cohorts recruited at different time.  Although it is ideal to 
genotyped SCHS and SCADGENS at the same time to eliminate batch effect, 
SCADGENS was genotyped as the additional cohort to boost the power of SCHS.  
Thirdly, we had restricted coverage of SNPs which may result in the discovery of 
singletons.  The four SNPs identified by Lu et al in Chinese were not genotyped 
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in our array.  The problem could be solved by imputations with 1000 Genome 
reference panel.  However, we did not conduct association analysis for imputed 
genotypes as the underpowered issue will not be resolved by imputation.  With 
the ongoing recruitment of SCADGENS samples, more cases will be the 
supplement to our new sample size and increase the power of detection.   
 
4.5 Summary 
We tested the genome wide association of MI on 796,922 SNPs in 2,379 samples.  
Several index SNPs showed evidences of associations in a consistent direction 
with reported literatures.  No genome wide statistically significant associations for 
MI were observed but a few loci showed suggestive significant associations and 
biological relationships with MI. 
 
Key findings from Study I: 
1. The genome wide association analysis failed to detect any genome wide 
association with MI. 
2. Several well-established genes such as VEGFA, LHFPL2-ARSB, and 
FNDC3B that are involved in pathogenesis of MI were found to be 
associated with MI at a suggestive significance level. 
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Chapter 5: Genome wide scan of single nucleotide polymorphisms associated 
with serum lipid concentrations 
5.1 Introduction 
Atherosclerosis, an underlying pathology of CAD, is also characterized by lipid 
deposition in the arteries and initiated with abnormal uptake of LDL-C by 
monocyte and macrophage [237, 238].  Since the 1950s, lines of evidence have 
demonstrated that abnormal lipid levels are the major contributors to 
atherosclerosis [239-242].  HDL-C, LDL-C and TG are all independently 
associated with CAD risk [201, 210, 211]. Specifically, it has been estimated that 
every 1 % increase of HDL-C would reduce ~2% risk of CAD[243] and 1% 
decrease of LDL-C would reduce ~1% risk of CAD[244].  Lipid levels are 
generally accepted as crucial intermediate traits of CAD and essential targets for 
therapeutic interventions.  
 
Blood lipid levels can be affected by smoking, diet and physical activity.  It also 
varied between individuals and different ethnicities.  However, compelling studies 
have suggested that blood lipids are highly heritable. Studies consistently showed 
that the estimates of heritability could be 40-70% for TC, 30-80% for both HDL-
C and LDL-C, and 20-55% for TG [245-251].  Furthermore, genetic variants that 
affect lipid concentrations have shown to be associated with increased risk of 
CAD, such as rare variants in LDL receptor (LDLR) and apolipoprotein B (APOB) 
and common variants in the apolipoprotein E (APOE) [252].  Hence, it is 
important to elucidate the genetic determinant of blood lipid levels.  The 
87 
 
discovery and identification of lipid traits associated loci and genes may facilitate 
the controls and therapies of diseases. 
 
According to the GWAS catalog, only two GWAS of HDL-C and three for TG 
have been conducted in Asia to date.  The first GWAS in Asia was conducted in 
individuals with Japanese ancestry in 2009 and 2010 for HDL-C and TG, 
respectively [253, 254].  Knowledge on the genetic determinants of lipids in Asia 
is limited. Recently, a meta-analysis of 188,578 individuals with European 
ancestry has identified 95 loci significantly associated with blood lipids [148] and 
suggested that susceptibility loci were ethnically transferable as the majority of 
susceptibility loci have been successfully replicated in 7,898 individuals with 
non-European ancestry.  However, the identified genetic variants only account for 
10-12% of the total variance. This indicated that the understanding of genetic 
determinants underlying blood lipid levels is incomplete.  Moreover, non-
replication in subjects with non-European ancestry could be a result of ethnic-
specific causal variants, different LD or lack of statistical power.  Hence, we 
aimed to examine the transferability of known susceptibility loci in European-
ancestry and discover new independent SNPs in a Singaporean Chinese 
population.  
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5.2 Methods 
5.2.1 Study design and population 
The study design was summarized in Figure 9. The discovery population was 
the Singapore Chinese Health Study (SCHS).   Any significant findings from 
conditional analyses were further replicated in SP2 and SCES.  
 
 
Figure 9 Flow chart of genome wide scan of SNPs associated with serum lipid 
concentrations 
 
5.2.2 Laboratory measurements 
Non-fasting HDL-C , LDL-C and triglycerides (TG) were measured in  SCHS. 
The lipid concentrations were transformed using ranking based inverse 
transformation. 
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5.2.3 Genotypes and quality control 
SCHS was genotyped on Illumina HumanOmniZhongHua-8 beadchipv1 (San 
Diego, California, the United States).  The quanlity control of SCHS was 
summarized in Table 11.   
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Table 11 Summary of quality control 
N=2,003 
Genotyped SNPs 
Excluded 
(N) 
Remained 
(N) 
Excluded 
(N) 
Remained 
(N) 
Excluded 
(N) 
Remained 
(N) 
Controls HDL-C LDL-C TG 
Total genotyped 
SNPs 
  872,243   872,243   872,243 
After excluding 
MAF<0.1 
68,154 804,089 68,154 804,089 68,154 804,089 
After excluding 
HWE<10
-5
 
485 803,604 485 803,604 485 803,604 
After excluding  
Exclude after call 
rate <95% 
407 803,197 407 803,197 407 803,197 
After excluding  
Exclude after info 
<0.5 
5 803,192 0 803,197 0 803,197 
Total imputed SNPs   35,825,886   35,825,886   35,825,886 
After excluding 
MAF<0.1 
29,783,26
1 
6,042,625 29,783,261 6,042,625 29,783,261 6,042,625 
After excluding 
HWE<10
-5
 
138 6,042,487 138 6,042,487 138 6,042,487 
After excluding  
call rate <95% 
1,216,276 4,826,211 1,216,276 4,826,211 1,216,276 4,826,211 
After excluding  
info <0.8 
52,459 4,773,752 51,848 477,4363 52,883 4,773,328 
MI cases HDL-C LDL-C TG 
Total genotyped 
SNPs 
  872,243   872,243   872,243 
After excluding 
MAF<0.1 
68,809 803,434 68,809 803,434 68,809 803,434 
After excluding 
HWE<10
-5
 
254 803,180 254 803,180 254 803,180 
After excluding  
call rate <95% 
432 802,748 432 802,748 432 802,748 
After excluding 
info <0.5 
0 802,748 0 802,748 0 802,748 
Total imputed SNPs   35,825,886   35,825,886   35,825,886 
After excluding 
MAF<0.1 
29,784,480 6,041,406 29,784,480 6,041,406 29,784,480 6,041,406 
After excluding 
HWE<10
-5
 
133 6,041,273 133 6,041,273 133 6,041,273 
After excluding  
call rate <95% 
1,233,557 4,807,716 1,233,557 4,807,716 1,233,557 4,807,716 
After excluding  
info <0.8 
59,271 4,748,445 57,103 4,750,613 58,673 4,749,043 
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5.2.5 Imputation 
Additional genotypes of SCHS were imputed based on 1000 genome Chinese 
samples.  Details were described in Chapter 3. 
 
5.2.6 Linkage equilibrium 
The R
2
 between SNPs were retrieved from 1000 Genome Pilot 1 CHBJPT 
population panel using SNAP 
(http://www.broadinstitute.org/mpg/snap/ldsearchpw.php).  If SNPs were not 
founded in the database, the LD would be calculated in PLINK v1.07 by 
applying the ―ld‖ function.  
 
5.2.7 Examination of the relationships between SNPs associated with lipid 
concentrations and MI 
SNPs associated with lipid traits were extracted from GWAS catalog.  All the 
SNPs extracted have been reported at least twice and reached genome wide 
significance (P<5x10
-8
) in references. We selected 96 SNPs for HDL-C, 78 
for LDL-C and 79 for TG.  Those have been genotyped or imputed and 
showed significant associations with lipid trait (P<0.05) in SCHS were used 
as variables to examined the associations with MI.  The number was 14, 10, 
and 8 for HDL-C, LDL-C and TG, respectively.  These variants were 
subsequently filtered out based on the locations. The variant with the smallest 
P value was selected for each locus.  The allele coding was flipped according 
to the effect direction. A genetic risk score (GRS) was then generated by 
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summarizing the risk allele count of these independent significant trait-
associated SNPs in the same direction.  The GRS was employed as proxies of 
lipid traits to determine the causality between lipids and MI.  For HDL-C, 9 
out of 14 SNPs were selected, including rs1883025 in ABCA1, rs3764261 in 
CETP, rs737337 in DOCK6, rs11216126 in RPL15P15 - BUD13, rs1532085 
in LIPC, rs7241918 in LIPG, rs17482753 in LPL, rs7120118 in NR1H3 and 
rs7679 in PLTP.  For LDL-C, 5 out of 10 SNPs were selected, including 
rs2479409 in PCSK9, rs599839 in CELSR2, rs12916 in HMGCR, 
rs11668477 in LDLR, rs157580 in APOE.  For TG, 5 out of 8 SNPs were 
selected, including rs1260326 in GCKR, rs10105606 in LPL, rs4775041 in 
LIPC, rs3764261 in CETP, rs10401969 in CSPG3-CILP2-PBX4. The 
selection procedure was summarized in the flow chart below (Figure 10).  
 
 
Figure 10 The flow chart of examining the relationships between SNPs associated 
with lipid traits and myocardial infarction 
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5.2.8 Statistical tests 
Genome-wide association analysis was performed by using PLINK (v1.07) 
and SNPTEST (v1.1.5) in linear regression model where age, age
2
, gender, 
body mass index (BMI) and the first five principal components were included 
as covariates.  Using age
2
 can help to model the effect of age more accurately 
as the relationship between age and lipid traits is ―J‖ shape. The Manhattan 
plot of –log10 P was generated using R to summarize association results.  The 
quantile-quantile plot was generated using R to evaluate the significance of 
observed genome wide association compared to expected association. 
Although all the lipid levels were measured at baseline, the associations were 
analyzed for control and case separately to reduce the bias caused by the 
incident of CAD or MI.  For each SNP, evidence of association was combined 
using fix effect meta-analysis.  To discover independent novel new SNPs 
associated with traits, conditional analysis was applied to adjust the effect of 
known index SNPs, which were obtained from GWAS catalog.  The genome 
wide significance was set at 5x10
-8
.   
 
5.3 Results 
Genome wide association studies for lipid levels (HDL-C, LDL-C, and TG) were 
conducted to identify new SNPs associated with lipid levels and verify known 
index SNPs.  For each SNP, lipid concentrations were regressed onto allele counts 
in a linear regression model including age, age
2
, gender, BMI and 5 principle 
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components as covariates.  The associations of any new susceptibility SNPs were 
tested again on the condition of index SNPs of the corresponding traits. 
 
5.3.1 Associations of SNP withHDL-C, LDL-C and TG 
The genomic control parameter for HDL-C, LDL-C and TG were 1.006, 
1.023and 1.015, respectively.  It suggested that the QC were well carried out 
and population stratification and unmodeled relatedness had negligible impact 
on the association analyses, where at least one SNP exceeds the genome wide 
significance threshold of P<5x10
-8
.  Figure 11 and Table 12summarized the 
results of the association analyses of HDL-C, LDL-C and TG in 2,003 SCHS 
samples.  
 
HDL-C 
As shown in Table 12, two loci have been previously implicated in the 
involvement of lipid metabolism and showed strong evidences for 
associations, including regions near LIPC (strongest association at rs2043085, 
P=6.21x10
-10
, HDL-C concentration decrease 0.20 mmol/L per G allele) and 
regions near CETP (strongest association at rs3764261, P= 1.27x10
-9
, HDL-C 
concentration decrease 0.27mmol/L per T allele).  Another SNP rs2740488 in 
ABCA1 showed a suggestive association with HDL-C with P value of 
2.90x10
-07
 (β= -0.20, S.E=0.04).  
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Among the significant SNPs in the LIPC region, SNP rs422137 and SNP 
rs1532085 were genotyped and demonstrated a moderate LD (R
2
 = 0.536) in 
2,003 SCHS.  The imputed SNPs rs2043085 and rs261291 were in high LD 
with rs1532085 (R
2
>0.9), which have been repeatedly reported in several 
genome wide association studies [24, 26-28] while the other genotyped 
genome wide SNP rs422137 has not been reported.  To examine if rs422137 
was an independent SNP associated with HDL-C, conditional analysis was 
conducted subsequently and the results were summarized in Section5.3.2. 
 
LDL-C 
As can be seen from Table 12, all the SNPs with genome wide significance 
were from TOM40-APOE-PRVL2-APOC1P1-APOC1 cluster in chromosome 
19. Of them, 14 out of 18 were imputed SNPs.The lead imputed SNP was 
rs769446, with P value of 2.79x10
-28
.  The C allele (frenquency, 9%) was 
associated with significantly lower levels of circulating LDL-C.  This SNP 
was in high LD with genotyped SNPs rs7265473 (β=0.65, P=1.10x10-24) and 
rs445925 (β=0.57, P=4.16x10-21).  A cluster of SNPs were also highly 
correlated with this signal, including rs7412, rs445925, rs769446, 
rs1160983,rs111784051 (R
2
 ≥0.5).  Two other clusters of SNPs rs483082 and 
rs438811showing strong association were lead by rs75627662 (β=-0.29, 
P=5.61x10
-10) and rs61679753 (β=-0.70,P=1.40x10-26).  The rs61679753 
included the rest of SNPs and was in perfect LD with genotyped SNP 
rs7254892 (R
2
=1).  
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None of the identified significant SNPs have been reported before except 
rs7412.  Not all SNPs were highly correlated with the index SNP rs7412.  
Therefore, it is worthy to perform conditional analysis to determine whether 
any SNPs in the cluster independently influenced LDL-C.  Theresults are 
reported in Section 5.3.2. 
 
TG 
In Table 12,  SNPs in APOA5-BUD13-ZNF259 cluster in chromosome 11 
showed genome wide significance associations with TG.  This locus has 
demonstrated lines of prior evidences for association with TG cholesterol 
concentrations.  
 
The strongest SNP was rs662799 with a P value of 4.87x10
-11
 (β=-0.26, 
S.E=0.04).  Among the 21 significant SNPs, 11 SNPs have been previously 
reported in GWAS.  The new SNPs were rs2072560, rs10750096, rs7483863, 
rs6589564, rs7930786, rs180326, rs1974718, rs180349, rs9326246, 
rs3825041.  However, these SNPs were in relatively high LD with the lead 
SNP rs662799 (R
2
>0.6).  
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Figure 11 Summary of genome wide association analysis of HDL-C. The Manhattan 
plot summarizes the genotyped and imputed genome wide association results in the left 
panel. Loci that were lead SNPs reported in GWAS catalog with p<10
-5
 in our dataset are 
in green. The right panel display quantile-quantile plot for test statistics. The red line 
corresponds to test statistics. 
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Table 12 Top SNPs associated with lipid levels (P< 5x10-8) in SCHS 
Gene SNP CHR Position 
Controls Cases Meta 
β S.E P β S.E P β S.E P 
SNPs associated with HDL-C 
LIPC rs2043085
*
 15 58,680,954 -0.18 0.04 9.08E-06 -0.24 0.05 1.17E-05 -0.2 0.03 6.21E-10 
LIPC rs1532085 15 58,683,366 -0.18 0.04 1.15E-05 -0.23 0.05 1.60E-05 -0.2 0.03 1.04E-09 
CETP rs3764261 16 56,993,324 -0.25 0.06 5.68E-06 -0.3 0.07 4.70E-05 -0.27 0.04 1.27E-09 
CETP rs17231506
*
 16 56,994,528 0.25 0.06 8.90E-06 0.31 0.08 4.45E-05 0.27 0.04 1.98E-09 
LIPC rs261291
*
 15 58,680,178 0.18 0.04 7.66E-06 0.21 0.05 6.41E-05 0.19 0.03 2.16E-09 
LIPC rs422137(kgp8075989) 15 58,709,182 -0.19 0.04 5.96E-06 -0.21 0.05 8.67E-05 -0.2 0.03 2.19E-09 
CETP rs12149545
*
 16 56,993,161 0.25 0.06 9.20E-06 0.3 0.08 6.30E-05 0.27 0.05 2.75E-09 
CETP rs183130 (kgp6695323) 16 56,991,363 0.25 0.06 7.87E-06 0.29 0.07 8.86E-05 0.27 0.04 3.09E-09 
CETP rs247617
*
 16 56,990,716 0.25 0.06 8.20E-06 0.29 0.08 9.53E-05 0.27 0.05 3.43E-09 
CETP rs247616
*
 16 56,989,590 0.25 0.06 1.06E-05 0.3 0.08 8.14E-05 0.27 0.05 3.92E-09 
CETP rs12720926
*
 16 56,998,918 0.18 0.04 4.00E-05 0.22 0.06 2.66E-04 0.19 0.04 4.47E-08 
SNPs associated with LDL-C 
TOM40 rs769446
*
 19 45,408,628 -0.57 0.08 5.11E-14 -1.13 0.13 5.24E-19 -0.72 0.06 2.79E-28 
TOM40 rs61679753
*
 19 45,400,747 -0.56 0.08 1.73E-13 -1.09 0.13 2.08E-17 -0.70 0.07 1.40E-26 
APOE rs7412
*
 19 45,412,079 -0.54 0.08 4.8E-13 -1.03 0.12 9.67E-17 -0.68 0.06 9.24E-26 
APOE rs72654473 (kgp8411531) 19 45,414,399 0.52 0.07 1.51E-12 0.99 0.12 4.19E-16 0.65 0.06 1.10E-24 
PRVL2 rs7254892(kgp807278) 19 45,389,596 0.60 0.08 7.27E-14 1.02 0.14 1.16E-13 0.71 0.07 1.84E-24 
APOC1P1 rs141622900(kgp11202561) 19 45,426,792 0.51 0.07 3.29E-12 0.90 0.12 6.17E-14 0.62 0.06 6.03E-23 
TOM40 rs1160983
*
 19 45,397,229 -0.60 0.08 7.96E-13 -1.06 0.15 2.63E-13 -0.71 0.07 6.70E-23 
APOE rs445925 19 45,415,640 0.44 0.07 2.52E-10 0.89 0.12 1.02E-14 0.57 0.06 4.16E-21 
APOC1 rs390082
*
 19 45,416,831 -0.44 0.07 2.86E-10 -0.89 0.12 1.06E-14 -0.57 0.06 4.81E-21 
TOM40 rs111784051
*
 19 45,402,262 -0.54 0.09 3.41E-09 -1.31 0.16 1.17E-15 -0.72 0.08 1.34E-19 
PRVL2 rs283809
*
 19 45,387,057 -0.47 0.07 8.4E-11 -0.61 0.12 1.44E-07 -0.51 0.06 1.06E-16 
PRVL2 rs283808
*
 19 45,387,034 -0.48 0.07 8.38E-11 -0.61 0.12 1.45E-07 -0.51 0.06 1.07E-16 
PRVL2 rs283810
*
 19 45,388,241 -0.44 0.07 3.72E-10 -0.61 0.11 4.91E-08 -0.49 0.06 2.22E-16 
PRVL2 rs283813
*
 19 45,389,174 -0.43 0.07 4.83E-10 -0.61 0.11 3.74E-08 -0.48 0.06 2.22E-16 
PRVL2 rs406456
*
 19 45,382,717 0.38 0.07 2.12E-08 0.38 0.10 0.00014 0.38 0.06 1.25E-11 
*imputed SNPs 
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Table 12(continued) Top SNPs associated with lipid levels (P< 5x10-8) in SCHS 
Gene SNP CHR Position 
Controls Cases Meta 
β S.E P β S.E P β S.E P 
SNPs associated with LDL 
APOE rs75627662
*
 19 45,413,576 -0.23 0.05 3.21E-05 -0.43 0.09 5.49E-07 -0.29 0.05 5.61E-10 
APOE 
rs438811
*
 
19 
45,416,741 -0.21 0.05 0.000102 -0.40 0.08 1.46E-06 -0.26 0.04 4.31E-09 
APOE rs483082
*
 19 45,416,178 -0.20 0.05 0.000173 -0.40 0.08 1.41E-06 -0.26 0.05 7.97E-09 
SNPs associated with TG 
APOA5 rs662799
*
 11 116,663,707 -0.24 0.07 0.000207 -0.27 0.05 5.43E-08 -0.26 0.04 4.87E-11 
APOA5 rs651821 11 116,662,579 -0.24 0.07 0.000255 -0.27 0.05 6.21E-08 -0.26 0.04 6.88E-11 
BUD13 rs7350481
*
 11 116,586,283 -0.27 0.07 0.000119 -0.25 0.05 1.85E-06 -0.26 0.04 9.18E-10 
ZNF259 rs6589566
*
 11 116,652,423 -0.30 0.08 9.87E-05 -0.24 0.05 6.15E-06 -0.26 0.04 3.01E-09 
APOA5 rs2266788 11 116,660,686 0.31 0.08 4.78E-05 0.23 0.05 1.31E-05 0.25 0.04 3.79E-09 
APOA5 rs2072560
*
 11 116,661,826 -0.30 0.08 7.85E-05 -0.23 0.05 0.00001 -0.25 0.04 4.23E-09 
ZNF259 rs10750096
*
 11 116,656,788 -0.30 0.08 8.62E-05 -0.23 0.05 1.28E-05 -0.25 0.04 5.99E-09 
ZNF259 rs7483863
*
 11 116,652,491 -0.30 0.08 0.000104 -0.23 0.05 0.000013 -0.25 0.04 7.06E-09 
ZNF259 rs2160669
*
 11 116,647,607 -0.30 0.08 0.000112 -0.23 0.05 1.28E-05 -0.25 0.04 7.41E-09 
BUD13 rs6589565
*
 11 116,640,237 -0.29 0.08 0.000116 -0.23 0.05 1.38E-05 -0.25 0.04 8.2E-09 
BUD13 rs10790162
*
 11 116,639,104 -0.29 0.08 0.00012 -0.23 0.05 0.000014 -0.25 0.04 8.5E-09 
BUD13 rs6589564
*
 11 116,624,153 -0.29 0.08 0.00013 -0.23 0.05 1.34E-05 -0.25 0.04 8.55E-09 
BUD13 rs7930786
*
 11 116,624,727 -0.29 0.08 0.00013 -0.23 0.05 1.34E-05 -0.25 0.04 8.6E-09 
ZNF259 rs964184
*
 11 116,648,917 -0.30 0.08 9.28E-05 -0.22 0.05 2.57E-05 -0.24 0.04 1.35E-08 
BUD13 rs1558861
*
 11 116,607,437 -0.27 0.08 0.000433 -0.23 0.05 0.000009 -0.24 0.04 1.58E-08 
BUD13 rs180326 11 116,624,703 -0.29 0.08 0.000105 -0.22 0.05 2.75E-05 -0.24 0.04 1.58E-08 
BUD13 rs1974718
*
 11 116,606,766 -0.26 0.08 0.000473 -0.23 0.05 1.13E-05 -0.24 0.04 2.15E-08 
BUD13 rs180349
*
 11 116,611,827 -0.28 0.08 0.00024 -0.22 0.05 2.04E-05 -0.24 0.04 2.21E-08 
BUD13 rs9326246
*
 11 116,611,733 -0.28 0.08 0.000229 -0.22 0.05 2.41E-05 -0.24 0.04 2.52E-08 
BUD13 rs1558860
*
 11 116,607,368 -0.26 0.08 0.000476 -0.22 0.05 1.52E-05 -0.24 0.04 2.97E-08 
BUD13 rs3825041
*
 11 116,631,707 -0.28 0.08 0.000168 -0.21 0.05 4.28E-05 -0.24 0.04 3.68E-08 
BUD13 rs180327
*
 11 116,623,659 -0.29 0.07 8.75E-06 -0.17 0.05 0.000459 -0.21 0.04 5.36E-08 
*imputed SNPs 
 
100 
 
5.3.2 Conditional analysis of top genetic loci 
To examine if any SNPs in the significant loci were independently associated 
with HDL-C, LDL-C or TG, conditional analyses were performed for HDL-C, 
LDL-C and TG.   
 
Condition analysis for HDL-C 
For LIPC, the analysis was conditioned on six previously reported index SNPs:  
rs10468017(imputed SNP, β=0.11, P=0.008),  rs261334(imputed SNP, β=0.09, 
P=0.006), rs2043085 (imputed SNP, β=-0.20, P=6.21x10-10),  
rs1532085(genotyped SNP, β=-0.23, P=1.04x10-9),  rs1800588 (genotyped 
SNP, β=0.11, P= 0.001),  rs4775041(genotyped SNP, β=-0.09, P= 0.02).  For 
CETP, the analysis was conditioned on five previously reported index SNPs 
rs3764261 (P=1.27x10
-9
), rs12708980 (P= 0.03), rs1532624 (P=1.71x10
-7
) 
rs180077 (P= 2.47 x10
-4
) rs1864163 (P= 7.53x10
-3
).  
 
After adjustment, the P value of index SNP rs1532085 in LIPC dropped to 
zero (Figure 12) and the P value of other SNPs in CETP region became non -
significant after conditioning. However, two clusters of SNPs remain showing 
suggestive associations with HDL-C (Table 13and Figure 13).  One of them, 
rs8025065, showed a suggestive genome wide significance of 1.82x10
-07
 
before adjustment and remained nominally significance in both controls and 
cases after conditional adjustments.  We attempted to replicate it in SP2 and 
SCES.  However, this SNP only had imputed genotypes and had a bad call 
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rate.  The other cluster of SNPs was led by the SNP rs4622454 (β=-0.18, P= 
2.95x10
-04
) with an improved beta and P value after conditional adjustments.  
The replication of rs4622454 was conducted in SP2 but failed.  
 
Condition analysis for LDL-C 
The analysis was conditioned on previously reported index SNPs in TOM40-
APOE-PRVL2-APOC1P1-APOC1 region, including rs7412(β=-
0.68,P=9.24x10
-26), rs4420638(β=0.09,P=0.13), rs157580(β=0.11,P=0.002), 
rs445925(β=0.57, P=4.16x10-21), rs2075650(β=0.14,P=0.02), 
rs10402271(β=0.04, P=0.39), rs6859(β=0.04, P=0.31), rs283813(β=-0.48, 
P=2.22x10
-16), rs519113(β=0.06, P=0.24), rs395908(β=0.04, P=0.39), 
rs6857(β=0.14, P=0.03).  The significant associations of SNPs in this region 
with LDL-C were eliminated and no peaks of SNPs were observed after 
conditional adjustment.  
 
Condition analysis for TG 
The analysis was conditioned on five index SNPs in APOA5-BUD13-ZNF259, 
including rs7350481(β=-0.26, P=9.18x10-10), rs1558861(β=-0.24, P=1.58x10-
08
), rs964184(β=-0.24, P=1.35x10-08), rs651821(β=-0.26, P=6.88x10-11), 
rs10892151(β=-0.36, P=0.02).  There were no SNPs that remained significant 
after conditional adjustment. 
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Table 13 Top 10 SNPs near LIPC in condition analysis 
SNP Position 
Allele MAF 
 
Before conditioning After conditioning 
A B Controls Cases β S.E P β S.E P 
rs4622454 58,646,332 C T 0.15 0.14 
Meta -0.09 0.05 0.04 -0.18 0.05 2.95E-04 
Control -0.03 0.06 0.57 -0.11 0.06 0.08 
Case -0.20 0.08 7.98E-03 -0.31 0.08 1.92E-04 
rs62001733 
(kgp34299) 
58,662,090 A C 0.16 0.16 
Meta -0.08 0.04 0.06 -0.17 0.05 4.99E-04 
Control -0.02 0.06 0.76 -0.10 0.06 0.11 
Case -0.19 0.07 8.24E-03 -0.29 0.08 2.54E-04 
rs192329* 58,645,914 G C 0.11 0.11 
Meta -0.07 0.05 0.17 -0.18 0.06 1.07E-03 
Control 0.004 0.06 0.95 -0.10 0.07 0.16 
Case -0.20 0.08 0.02 -0.32 0.09 3.88E-04 
rs149645347* 58,660,731 G A 0.04 0.04 
Meta -0.23 0.09 9.05E-03 -0.29 0.09 1.12E-03 
Control -0.18 0.11 0.11 -0.19 0.11 0.09 
Case -0.34 0.15 0.02 -0.49 0.15 1.41E-03 
rs8025065* 58,711,206 G C 0.32 0.33 
Meta -0.18 0.03 1.82E-07 -0.13 0.04 1.22E-03 
Control -0.16 0.04 3.27E-04 -0.11 0.05 0.04 
Case -0.22 0.06 1.06E-04 -0.19 0.07 7.24E-03 
rs410251* 58,643,839 T C 0.12 0.12 
Meta -0.06 0.05 0.19 -0.17 0.05 1.98E-03 
Control 0.02 0.06 0.73 -0.08 0.07 0.27 
Case -0.21 0.08 0.01 -0.31 0.09 3.31E-04 
rs11629557 
(kgp3182186) 
59,704,651 A G 0.06 0.06 
Meta -0.18 0.07 5.59E-03 -0.20 0.06 2.37E-03 
Control -0.20 0.08 0.02 -0.22 0.08 5.92E-03 
Case -0.15 0.11 0.17 -0.15 0.11 0.16 
rs7164367 59,797,154 G T 0.25 0.25 
Meta -0.11 0.04 4.63E-03 -0.11 0.04 2.94E-03 
Control -0.12 0.05 0.01 -0.12 0.05 0.01 
Case -0.09 0.06 0.16 -0.10 0.06 0.10 
rs72740818* 58,654,303 G C 0.15 0.14 
Meta -0.06 0.05 0.18 -0.14 0.05 3.93E-03 
Control -0.01 0.06 0.83 -0.09 0.06 0.16 
Case -0.15 0.08 0.05 -0.25 0.08 3.05E-03 
rs185074288* 59,702,243 G A 0.06 0.07 
Meta 0.16 0.06 9.55E-03 0.18 0.06 4.10E-03 
Control 0.21 0.08 9.73E-03 0.23 0.08 3.46E-03 
Case 0.09 0.11 0.38 0.09 0.10 0.37 
*imputed SNPs 
 
103 
 
 
 
Figure 12 Regional plots for index SNP rs1532085.  The SNP of interest was denoted 
by the purple diamond.  Upper panel showed the regional plot before adjustment for 
index SNPs on LIPC.  Lower panel showed the regional plot after adjustment for index 
SNPs on LIPC. 
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Figure 13 Regional plots for rs8025065, rs4622454 and rs149645347.The interested SNP was 
shown in purple diamond. Left panel showed the regional plot before adjustment for index SNPs 
on LIPC.  Right panel showed the regional plot after adjustment for index SNPs on LIPC.  
a. 
 
b. 
 
c. 
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5.3.3 Index SNPs influencing lipid levels 
As shown in Table 14, 66 out of 174 genotyped index SNPs were significantly 
associated (P<0.05) with HDL-C, LDL-C and TG and shared the same trend 
of risk as GWAS catalog reported.  Of these, two SNPs (rs1532085 in LIPC 
and rs3764261 in CETP) showed genome wide significant associations with 
HDL-C and one SNP (rs7412 in APOE) demonstrated a strong genome wide 
association with LDL-C.  Likewise, three SNPs (rs651821 in APOA5, 
rs7350481 in APOA1-APOC3-APOA4-APOA5 cluster and rs1558861 in 
LOC440069) were statistically associated with TG reaching genome wide 
significance.  Several SNPs were associated with more than one lipid traits.  
For SNPs rs3764261 in CETP, rs10503669, rs328 and rs12678919 in LPL, 
rs964184 in APOA cluster and rs4775041 in LIPC, they demonstrated inverse 
associations with HDL-C and TG, which was consistent with the reported 
relationship between HDL-C and TG.  For rs2954029, its effect on LDL-C 
and TG had the same direction in accordance with the known relationship 
between LDL-C and TG. 
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Table 14 Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position 
Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
1 rs1532085 15 58,683,366 G 0.57 
HDL-C -0.20[0.03] 1.04E-09 
LIPC 
20686565 Europeans 
TG -0.02[0.03] 0.61 20686565 Europeans 
2 rs3764261  16 56,993,324 C 0.84 
HDL-C -0.27[0.04] 1.27E-09 
CETP 
20686565 Europeans 
TG 0.14[0.05] 0.004269 20686565 Europeans 
3 rs1532624* 16 57,005,479 A 0.29 HDL-C 0.18[0.04] 1.71E-07 CETP 19060911 Europeans 
4 rs1883025 9 107,664,301 T 0.23 HDL-C -0.17[0.04] 7.71E-06 ABCA1 20686565 Europeans 
5 rs11216126 11 116,617,240 C 0.23 HDL-C 0.17[0.04] 7.87E-06 Intergenic 21909109 Koreans 
6 rs2083637* 8 19,865,175 G 0.21 HDL-C 0.17[0.04] 1.24E-05 LPL 19060911 Europeans 
7 rs10503669*  8 19,847,690 A 0.11 
HDL-C 0.21[0.05] 4.15E-05 
LPL 
21909109 Koreans 
TG -0.20[0.05] 3.11E-04 21909109 Koreans 
8 rs17482753 8 19,832,646 T 0.11 HDL-C 0.21[0.05] 4.72E-05 LPL 20031538 Europeans 
9 rs328*  8 19,819,724 G 0.11 
HDL-C 0.20[0.05] 6.66E-05 
LPL 
18193044 Europeans 
TG -0.18[0.05] 0.001081 22171074 Chinese 
10 rs325* 8 19,819,328 C 0.11 HDL-C 0.20[0.05] 6.88E-05 LPL 20864672 Europeans 
11 rs12678919*  8 19,844,222 G 0.11 
HDL-C 0.20[0.05] 7.74E-05 
LPL 
20686565 Europeans 
TG -0.20[0.05] 3.25E-04 20686565 Europeans 
12 rs1800775 16 56,995,236 C 0.51 
HDL-C -0.12[0.03] 2.47E-04 
CETP 
20031564 Europeans 
TG 0.06[0.03] 0.10 17463246 Europeans 
13 rs737337 19 11,347,493 T 0.74 HDL-C 0.13[0.04] 3.04E-04 DOCK6,LOC55908 20686565 Europeans 
14 rs16940212* 15 58,694,020 T 0.26 HDL-C 0.13[0.04] 3.40E-04 Intergenic 21909109 Koreans 
15 rs12686004 9 107,653,426 G 0.84 HDL-C 0.16[0.04] 3.65E-04 ABCA1 21909109 Koreans 
16 rs964184*  11 116,648,917 C 0.79 
HDL-C 0.13[0.04] 6.28E-04 ZNF259, 
APOA5,APOA4,APOC3, 
APOA1 
20864672 Europeans 
TG -0.24[0.04] 1.35E-08 20686565 Europeans 
LDL-C -0.02[0.04] 0.68 20686565 Europeans 
17 rs1800588 15 58,723,675 T 0.38 HDL-C 0.11[0.03] 1.39E-03 LIPC 18193044 Europeans 
18 rs2156552* 18 47,181,668 T 0.80 HDL-C 0.12[0.04] 1.97E-03 LIPG 20864672 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
19 rs4939883* 18 47,167,214 C 0.80 HDL-C 0.11[0.04] 5.74E-03 LIPG 19060911 Europeans 
20 rs261334* 15 58,726,744 C 0.68 HDL-C -0.09[0.03] 6.04E-03 LIPC 20864672 Europeans 
21 rs4149268 9 107,647,220 T 0.30 HDL-C -0.09[0.03] 6.46E-03 ABCA1 18193043 Europeans 
22 rs1864163* 16 56,997,233 A 0.13 HDL-C -0.13[0.05] 7.53E-03 CETP 18193043 Europeans 
23 rs605066* 6 139,829,666 T 0.33 HDL-C 0.09[0.03] 8.28E-03 CITED2 20686565 Europeans 
24 rs10468017* 15 58,678,512 T 0.18 HDL-C 0.11[0.04] 8.30E-03 LIPC 19060906 Europeans 
25 rs7241918 18 47,160,953 T 0.86 HDL-C 0.12[0.05] 8.79E-03 LIPG 20686565 Europeans 
26 rs7240405* 18 47,159,090 G 0.86 HDL-C 0.12[0.04] 9.16E-03 LIPG 20031538 Europeans 
27 rs9891572* 17 2,428,508 T 0.35 HDL-C -0.08[0.03] 9.68E-03 Intergenic 19060910 Europeans 
28 rs6065906* 20 44,554,015 C 0.03 
HDL-C -0.23[0.09] 0.01 
PLTP 
20686565 Europeans 
TG 0.01[0.10] 0.93 20686565 Europeans 
29 rs7679 20 44,576,502 T 0.97 
HDL-C 0.22[0.09] 0.01 
PLTP 
19060906 Europeans 
TG 0.00[0.10] 1.00 19060906 Europeans 
30 rs4775041 15 58,674,695 G 0.82 
HDL-C -0.09[0.04] 0.02 
LIPC 
18193043 Europeans 
TG -0.11[0.04] 0.01 18193043 Europeans 
31 rs7120118 11 47,286,290 T 0.23 HDL-C -0.09[0.04] 0.02 NR1H3 19060910 Europeans 
32 rs9987289* 8 9,183,358 G 0.99 
HDL-C 0.33[0.15] 0.03 
PPP1R3B 
20686565 Europeans 
LDL-C 0.09[0.16] 0.57 20686565 Europeans 
33 rs7412* 19 45,412,079 T 0.08 LDL-C -0.68[0.06] 1.00E-19 APOE 23067351 African 
Americans 34 rs629301* 1 109,818,306 T 0.94 LDL-C 0.27[0.07] 1.86E-04 CELSR2,PSRC1,SORT1 20686565 Europeans 
35 rs646776 1 109,818,530 T 0.94 LDL-C 0.26[0.07] 2.77E-04 CELSR2 19060911 Europeans 
36 rs12740374* 1 109,817,590 T 0.06 LDL-C -0.26[0.07] 3.21E-04 CELSR2, PSRC1, SORT1 19060906 Europeans 
37 rs660240 1 109,817,838 T 0.06 LDL-C -0.26[0.07] 3.21E-04 CELSR2 20864672 Europeans 
38 rs599839 1 109,822,166 G 0.07 LDL-C -0.22[0.07] 8.14E-04 CELSR2,PSRC1 18262040 Europeans 
39 rs2479409 1 55,504,650 G 0.70 LDL-C 0.13[0.04] 8.94E-04 PCSK9 20686565 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
40 rs635634* 9 136,155,000 T 0.18 LDL-C 0.14[0.05] 1.51E-03 ABO 20686565 Europeans 
41 rs157580 19 45,395,266 G 0.54 
HDL-C -0.05[0.03] 0.31 
TOMM40, APOE 
19060911 Europeans 
LDL-C 0.11[0.03] 1.69E-03 19060911 Europeans 
42 rs2954021* 8 126,482,077 G 0.53 LDL-C -0.11[0.03] 1.69E-03 TRIB1 20864672 Europeans 
43 rs3846662 5 74,651,084 G 0.54 LDL-C 0.11[0.03] 2.05E-03 HMGCR 19060911 Europeans 
44 rs3846663* 5 74,655,726 T 0.54 LDL-C 0.11[0.03] 2.05E-03 HMGCR 19060906 Europeans 
45 rs12654264* 5 74,648,603 T 0.54 LDL-C 0.11[0.03] 2.15E-03 HMGCR 18193044 Europeans 
46 rs12916 5 74,656,539 T 0.46 LDL-C -0.11[0.03] 2.33E-03 HMGCR 20864672 Europeans 
47 rs2954029*  8 126,490,972 T 0.52 
HDL-C -0.08[0.03] 1.00 
TRIB1 
20686565 Europeans 
LDL-C -0.10[0.03] 3.19E-03 20686565 Europeans 
TG -0.10[0.03] 0.004469 20864672 Europeans 
48 rs7703051* 5 74,625,487 A 0.54 LDL-C 0.10[0.03] 3.54E-03 HMGCR 18802019 Europeans 
49 rs2738459 19 11,238,473 C 0.71 LDL-C -0.09[0.04] 0.02 LDLR 20864672 Europeans 
50 rs11668477 19 11,195,030 G 0.15 LDL-C -0.10[0.05] 0.03 LDLR 19060910 Europeans 
51 rs11206510 1 55,496,039 T 0.95 LDL-C 0.16[0.08] 0.05 PCSK9 20864672 Europeans 
52 rs651821 11 116,662,579 T 0.72 TG -0.26[0.04] 6.88E-11 APOA5 22171074 Chinese 
53 rs7350481* 11 116,586,283 C 0.77 TG -0.26[0.04] 9.18E-10 
APOA1,APOC3,APOA4,A
POA5 cluster 
20139978 Japanese 
54 rs1558861* 11 116,607,437 T 0.78 
LDL-C 0.03[0.04] 0.43 LOC440069, BUD13, 
APOA5,APOA4,APOC3 
20864672 Europeans 
TG -0.24[0.04] 1.58E-08 18193046 Europeans 
55 rs780094 2 27,741,237 T 0.45 
TG 0.12[0.03] 3.14E-04 
GCKR 
19060911 Europeans 
LDL-C -0.02[0.03] 0.52 18179892 Europeans 
56 rs10096633* 8 19,830,921 T 0.11 TG -0.19[0.05] 3.91E-04 LPL 20139978 Japanese 
57 rs1260326 2 27,730,940 T 0.47 TG 0.12[0.03] 5.54E-04 GCKR 20686565 Europeans 
58 rs2001945* 8 126,477,978 C 0.54 TG -0.10[0.03] 3.04E-03 Intergenic 21909109 Koreans 
59 rs326* 8 19,819,439 G 0.21 TG -0.12[0.04] 3.64E-03 LPL, C8orf35, SLC18A1 18193046 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
60 rs17321515* 8 126,486,409 G 0.52 TG -0.10[0.03] 3.87E-03 TRIB1 18193044 Europeans 
61 rs10105606 8 19,827,848 C 0.79 TG 0.12[0.04] 4.61E-03 LPL 20864672 Europeans 
62 rs780092 2 27,743,154 G 0.37 TG -0.09[0.04] 8.96E-03 GCKR 21909109 Koreans 
63 rs10761731* 10 65,027,610 T 0.30 TG -0.10[0.04] 9.11E-03 JMJD1C 20686565 Europeans 
64 rs442177* 4 88,030,261 T 0.59 TG 0.09[0.03] 0.01 AFF1 20864672 Europeans 
65 rs10892151* 11 117,531,731 T 0.02 TG -0.36[0.15] 0.02 
APOA1, APOC3, APOA4, 
APOA5, DSCAML1 
19074352 Europeans 
66 rs10401969 19 19,407,718 T 0.91 
TG 0.13[0.06] 0.03 SF4,CILP2,CSPG3,CILP2, 
PBX4 
20686565 Europeans 
LDL-C 0.03[0.06] 0.63 20864672 Europeans 
67 rs10195252* 2 165,513,091 C 0.08 TG -0.03[0.06] 0.61 COBLL1 20686565 Europeans 
68 rs1042034 2 21,225,281 T 0.27 
HDL-C -0.02[0.04] 0.50 
APOB 
20686565 Europeans 
TG 0.01[0.04] 0.74 20686565 Europeans 
69 rs10489615 1 230,304,988 G 0.23 HDL-C 0.04[0.04] 0.33 GALNT2 20864672 Europeans 
70 rs1084651 6 161,089,817 G 0.54 HDL-C 0.01[0.03] 0.79 LPA 20686565 Europeans 
71 rs10889353* 1 63,118,196 C 0.22 
LDL-C -0.04[0.04] 0.28 
DOCK7,ANGPTL3 
19060911 Europeans 
TG 0.00[0.04] 0.91 20139978 Japanese 
72 rs11136341* 8 145,043,543 G 0.12 LDL-C 0.05[0.05] 0.39 PLEC1 20686565 Europeans 
73 rs11220462* 11 126,243,952 A 0.37 LDL-C -0.02[0.04] 0.58 ST3GAL4 20686565 Europeans 
74 rs11613352* 12 57,792,580 T 0.08 
HDL-C -0.01[0.05] 0.79 
LRP1 
20686565 Europeans 
TG -0.01[0.06] 0.92 20686565 Europeans 
75 rs11649653 16 30,918,487 G 0.91 TG 0.04[0.06] 0.44 CTF1 20686565 Europeans 
76 rs1167998* 1 62,931,632 A 0.74 TG 0.00[0.04] 0.94 DOCK7 19060911 Europeans 
77 rs1168013* 1 62,996,838 G 0.74 TG 0.00[0.04] 0.94 DOCK7,ANGPTL3 20864672 Europeans 
78 rs11776767* 8 10,683,929 C 0.23 TG 0.02[0.04] 0.66 PINX1,XKR6 20686565 Europeans 
79 rs1178979 7 72,856,430 T 0.91 TG 0.01[0.06] 0.83 
BAZ1B, BCL7B, TBL2, 
MLXIPL 
20864672 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
80 rs11869286* 17 37,813,856 C 0.38 HDL-C 0.06[0.03] 0.24 STARD3 20686565 Europeans 
81 rs11902417* 2 21,198,900 A 0.72 HDL-C 0.04[0.03] 0.11 APOB 20864672 Europeans 
82 rs12027135* 1 25,775,733 T 0.25 LDL-C 0.04[0.04] 0.31 TMEM57,LDLRAP1 20686565 Europeans 
83 rs12449157 16 67,708,897 G 0.03 HDL-C -0.02[0.03] 0.50 GFOD2,LCAT 20864672 Europeans 
84 rs12670798* 7 21,607,352 C 0.53 LDL-C -0.02[0.03] 0.48 DNAH11 20686565 Europeans 
85 rs12967135* 18 57,849,023 A 0.16 HDL-C -0.09[0.03] 0.92 RPS3A,MC4R 20686565 Europeans 
86 rs1367117 2 21,263,900 G 0.85 LDL-C -0.09[0.05] 0.08 APOB 20686565 Europeans 
87 rs1495741 8 18,272,881 G 0.50 TG 0.03[0.03] 0.41 NAT2 20686565 Europeans 
88 rs1501908* 5 156,398,169 C 0.72 LDL-C -0.01[0.04] 0.86 TIMD4, HAVCR1 19060906 Europeans 
89 rs1689800* 1 182,168,885 G 0.26 HDL-C -0.06[0.03] 0.19 ZNF648 20686565 Europeans 
90 rs16942887 16 67,928,042 G 0.97 HDL-C -0.02[0.03] 0.57 LCAT 20686565 Europeans 
91 rs16996148* 19 19,658,472 T 0.07 
LDL-C -0.02[0.06] 0.80 
CILP2, PBX4 
18193044 Europeans 
TG -0.09[0.06] 0.17 18193044 Europeans 
92 rs17145738 7 72,982,874 T 0.09 
HDL-C 0.04[0.03] 0.48 
MLXIPL 
20686565 Europeans 
TG 0.04[0.06] 0.50 20686565 Europeans 
93 rs17216525* 19 19,662,220 T 0.07 TG -0.07[0.06] 0.28 NCAN,CILP2,PBX4 19060906 Europeans 
94 rs174546 11 61,569,830 T 0.67 
LDL-C 0.01[0.04] 0.75 
FADS1,FADS2,FADS3 
20686565 Europeans 
TG 0.04[0.04] 0.25 20686565 Europeans 
95 rs174547 11 61,570,783 T 0.33 
HDL-C -0.04[0.03] 0.46 
FADS1, FADS2, FADS3 
19060906 Europeans 
TG -0.04[0.04] 0.25 19060906 Europeans 
96 rs174548 11 61,571,348 G 0.65 
HDL-C 0.02[0.03] 0.34 
FADS1 
20864672 Europeans 
TG 0.02[0.04] 0.57 20864672 Europeans 
 
 97 rs174570 11 61,597,212 T 0.66 
HDL-C 0.01[0.03] 0.53 
FADS2, FADS3 
19060911 Europeans 
LDL-C 0.01[0.04] 0.72 19060911 Europeans 
98 rs1748195 1 63,049,593 G 0.26 TG 0.00[0.04] 0.94 ANGPTL3 18193043 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
99 rs1800961 20 43,042,364 T 0.02 HDL-C -0.04[0.03] 0.74 HNF4A 20686565 Europeans 
100 rs181362* 22 21,932,068 T 0.56 HDL-C -0.01[0.03] 0.17 UBE2L3 20686565 Europeans 
101 rs2068888 10 94,839,642 G 0.18 TG -0.01[0.04] 0.75 CYP26A1 20686565 Europeans 
102 rs2075292* 11 116,732,512 T 0.49 TG -0.03[0.03] 0.31 
APOA1,KIAA0999, 
LOC645044 
18193046 Europeans 
103 rs2081687* 8 59,388,565 C 0.78 LDL-C 0.02[0.04] 0.68 CYP7A1 20686565 Europeans 
104 rs2126259* 8 9,185,146 C 0.99 LDL-C 0.09[0.16] 0.57 PPP1R3B 20864672 Europeans 
105 rs2131925* 1 63,025,942 T 0.74 
LDL-C 0.05[0.04] 0.20 
ANGPTL3,DOCK7 
20686565 Europeans 
TG 0.00[0.04] 0.91 20686565 Europeans 
106 rs2144300 1 230,294,916 T 0.20 
HDL-C -0.03[0.03] 0.08 
GALNT2 
18193043 Europeans 
TG -0.03[0.04] 0.41 18193043 Europeans 
107 rs2228671 19 11,210,912 T 0.01 LDL-C -0.25[0.16] 0.12 LDLR 19060911 Europeans 
108 rs2240466 7 72,856,269 G 0.91 TG 0.01[0.06] 0.84 MLXIPL 19060911 Europeans 
109 rs2247056 6 31,265,490 T 0.19 TG -0.08[0.04] 0.07 HLA 20686565 Europeans 
110 rs2254287 6 33,143,948 G 0.74 LDL-C 0.06[0.04] 0.13 B3GALT4 18193043 Europeans 
111 rs2255141* 10 113,933,886 G 0.74 LDL-C 0.00[0.04] 0.94 GPAM 20686565 Europeans 
112 rs2271293 16 67,902,070 G 0.97 HDL-C 0.04[0.03] 0.57 CTCF, PRMT8 19060911 Europeans 
113 rs2286276 7 72,987,354 T 0.09 TG 0.04[0.06] 0.49 TBL2, MLXIPL 21909109 Koreans 
114 rs2293889* 8 116,599,199 G 0.87 HDL-C 0.01[0.03] 0.46 TRPS1 20686565 Europeans 
115 rs2304130 19 19,789,528 G 0.13 
LDL-C 0.01[0.05] 0.81 
NCAN,CILP2,ZNF101 
19060911 Europeans 
TG 0.04[0.05] 0.41 20864672 Europeans 
116 rs2338104* 12 109,895,168 G 0.38 HDL-C -0.02[0.03] 0.37 MMAB,MVK 19060906 Europeans 
117 rs255049 16 68,013,471 T 0.89 HDL-C -0.01[0.05] 0.76 LCAT 19060910 Europeans 
118 rs255052 16 68,024,995 G 0.89 HDL-C -0.05[0.04] 0.80 LCAT 18193043 Europeans 
119 rs2650000 12 121,388,962 C 0.58 LDL-C -0.05[0.03] 0.13 HNF1A 19060906 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
120 rs2652834* 15 63,396,867 G 0.99 HDL-C 0.11[0.04] 0.11 LACTB 20686565 Europeans 
121 rs2814944* 6 34,552,797 A 0.02 HDL-C 0.01[0.04] 0.39 C6orf106 20686565 Europeans 
122 rs2902940* 20 39,091,487 G 0.30 LDL-C 0.01[0.04] 0.74 MAFB 20686565 Europeans 
123 rs2923084 11 10,388,782 G 0.49 HDL-C 0.03[0.04] 0.53 ADM,AMPD3 20686565 Europeans 
124 rs2925979 16 81,534,790 T 0.42 HDL-C 0.04[0.04] 0.42 CMIP 20686565 Europeans 
125 rs2929282* 15 44,245,931 T 0.08 TG 0.04[0.06] 0.57 FRMD5 20686565 Europeans 
126 rs2972146* 2 227,100,698 T 0.93 
HDL-C -0.05[0.03] 0.20 
IRS1 
20686565 Europeans 
TG -0.05[0.07] 0.50 20686565 Europeans 
127 rs3136441* 11 46,743,247 C 0.60 HDL-C 0.02[0.03] 0.08 LRP4,NR1H3 20686565 Europeans 
128 rs3177928 6 32,412,435 G 0.98 LDL-C 0.02[0.12] 0.85 HLA 20686565 Europeans 
129 rs3757354 6 16,127,407 T 0.39 LDL-C -0.02[0.04] 0.57 IDOL 20686565 Europeans 
130 rs3764261 16 56,993,324 C 0.84 LDL-C 0.01[0.05] 0.90 CETP 20686565 Europeans 
131 rs3812316* 7 73,020,337 G 0.08 TG 0.03[0.06] 0.58 MLXIPL 18193046 Europeans 
132 rs386000* 19 54,792,761 C 0.60 HDL-C 0.12[0.03] 0.72 LILRA3,LILRB2 20686565 Europeans 
133 rs3890182 9 107,647,655 G 0.94 HDL-C 0.12[0.03] 0.05 ABCA1 20864672 Europeans 
134 rs3905000 9 107,657,070 G 0.94 HDL-C -0.02[0.03] 0.05 ABCA1 19060911 Europeans 
135 rs4129767* 17 76,403,984 A 0.36 HDL-C 0.00[0.03] 0.46 PGS1 20686565 Europeans 
136 rs439401 19 45,414,451 T 0.56 TG 0.00[0.03] 0.99 APOE,APOC1,APOC2 20686565 Europeans 
137 rs4420638 19 45,422,946 G 0.10 
HDL-C 0.09[0.03] 0.18 
APOE,APOC1,APOC2 
20686565 Europeans 
LDL-C 0.09[0.06] 0.13 20864672 Europeans 
TG 0.08[0.06] 0.17 17463246 Europeans 
138 rs471364* 9 15,289,578 T 0.98 HDL-C 0.00[0.03] 0.26 TTC39B 19060906 Europeans 
139 rs4731702* 7 130,433,384 T 0.31 HDL-C 0.04[0.03] 0.99 KLF14 20686565 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
140 rs4759375* 12 123,796,238 T 0.28 HDL-C -0.05[0.03] 0.24 SBNO1 20686565 Europeans 
141 rs4765127* 12 124,460,167 T 0.08 
HDL-C 0.05[0.03] 0.36 
CCDC92,ZNF664 
20686565 Europeans 
TG 0.05[0.06] 0.45 20686565 Europeans 
142 rs4844614 1 207,875,175 T 0.27 LDL-C -0.07[0.04] 0.08 CR1L 19060910 Europeans 
143 rs4846914* 1 230,295,691 A 0.21 
HDL-C -0.02[0.03] 0.16 
GALNT2 
20686565 Europeans 
TG -0.02[0.04] 0.63 20686565 Europeans 
144 rs4971516* 2 20,903,015 C 0.15 LDL-C -0.03[0.05] 0.60 APOB 21059979 Europeans 
145 rs515135* 2 21,286,057 C 0.93 LDL-C 0.03[0.07] 0.62 APOB 20864672 Europeans 
146 rs519113* 19 45,376,284 G 0.15 HDL-C -0.03[0.03] 0.28 PVRL2, TOMM40, APOE 21909109 Koreans 
147 rs581080* 9 15,305,378 C 0.91 HDL-C -0.02[0.03] 0.58 TTC39B 20686565 Europeans 
148 rs6029526* 20 39,672,618 A 0.82 LDL-C -0.02[0.04] 0.71 TOP1 20686565 Europeans 
149 rs603446* 11 116,654,435 T 0.30 TG -0.04[0.04] 0.29 
ZNF259, APOA1, APOC3, 
APOA4, APOA5, BUD13 
21909109 Koreans 
150 rs6102059* 20 39,228,784 T 0.55 LDL-C 0.02[0.03] 0.51 MAFB 19060906 Europeans 
151 rs643531* 9 15,296,034 A 0.97 HDL-C -0.03[0.03] 0.36 TTC39B 20864672 Europeans 
152 rs6450176 5 53,298,025 G 0.54 HDL-C -0.09[0.03] 0.33 ARL15 20686565 Europeans 
153 rs645040* 3 135,926,622 T 0.86 TG -0.09[0.05] 0.07 MSL2L1 20686565 Europeans 
154 rs6544366* 2 21,204,025 T 0.71 TG -0.05[0.04] 0.20 APOB 20864672 Europeans 
155 rs6589566* 11 116,652,423 A 0.80 LDL-C -0.01[0.04] 0.89 APOA1,APOC3,APOA5 18179892 Europeans 
156 rs6754295* 2 21,206,183 G 0.71 
HDL-C -0.05[0.03] 0.13 
APOB 
19060911 Europeans 
TG -0.05[0.04] 0.19 19060911 Europeans 
157 rs6756629 2 44,065,090 G 0.98 LDL-C 0.05[0.14] 0.71 ABCG5 19060911 Europeans 
158 rs676210 2 21,231,524 G 0.27 LDL-C -0.01[0.04] 0.77 APOB 23247145 Europeans 
*imputed SNPs 
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Table 14(continued) Known index SNPs associated with HDL-C, LDL-C, TG in SCHS (P<0.05) 
No SNP CHR Position Test 
allele 
TAF Trait β_meta[S.E] P_meta Reported Gene(s) PMID Population 
159 rs6867983 5 55,854,153 T 0.07 TG 0.13[0.07] 0.06 C5orf35 20864672 Europeans 
160 rs6882076 5 156,390,297 T 0.28 
LDL-C 0.02[0.04] 0.69 
TIMD4,HAVCR1 
20686565 Europeans 
TG -0.03[0.04] 0.43 20686565 Europeans 
161 rs693 2 21,232,195 G 0.94 
LDL-C 0.00[0.07] 1.00 
APOB 
19060911 Europeans 
TG -0.06[0.07] 0.39 18193044 Europeans 
162 rs6987702* 8 126,504,726 C 0.58 LDL-C 0.00[0.03] 0.97 TRIB1 19060911 Europeans 
163 rs7134375 12 20,473,758 C 0.76 HDL-C 0.06[0.03] 0.73 PDE3A 20686565 Europeans 
164 rs7134594 12 110,000,193 T 0.30 HDL-C -0.01[0.03] 0.10 MMAB,MVK 20686565 Europeans 
165 rs714052* 7 72,864,869 G 0.09 TG -0.01[0.06] 0.87 MIXIPL 20139978 Japanese 
166 rs7206971 17 45,425,115 A 0.25 LDL-C 0.07[0.04] 0.06 OSBPL7 20686565 Europeans 
167 rs7255436* 19 8,433,196 A 0.07 HDL-C -0.04[0.03] 0.32 ANGPTL4 20686565 Europeans 
168 rs7395662 11 48,518,893 G 0.42 HDL-C -0.05[0.03] 0.18 MADD, FOLH1 19060911 Europeans 
169 rs7557067* 2 21,208,211 G 0.69 TG -0.05[0.04] 0.20 APOB 19060906 Europeans 
170 rs7819412 8 11,045,161 G 0.94 TG 0.08[0.07] 0.25 XKR6, AMAC1L2 19060906 Europeans 
171 rs7941030 11 122,522,375 T 0.71 HDL-C -0.13[0.03] 0.89 UBASH3B 20686565 Europeans 
172 rs8017377 14 24,883,887 G 0.95 LDL-C -0.13[0.08] 0.09 CBLN3,KIAA0323 20686565 Europeans 
173 rs9686661* 5 55,861,786 T 0.11 TG 0.04[0.05] 0.46 ANKRD55,MAP3K1 20686565 Europeans 
174 rs9943753 12 109,840,940 G 0.54 HDL-C 0.09[0.03] 0.23 
MYO1H,KCTD10,UBE3B,
MMAB,MVK 
20864672 Europeans 
*imputed SNPs 
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5.3.4 Association of index SNPs with MI 
Nominally significant associations (P<0.05) with MI were observed for four 
index GWAS variants in four genes that have been previously associated with 
lipid traits (Table 15).  Variant rs1532085 in LIPC was associated with 
increased level of HDL-C concentrations with genome wide significance and 
showed a significant association with MI.  However, it is abnormal that an 
increased risk of MI was observed with elevated HDL-C concentration and 
decreased LDL-C concentration.  The rest of variants rs17482753 in LPL, 
rs11668477 in LDLR and rs10401969 in CSPG3-CLP2-PBX4 exhibited a 
protective effect of MI in concordance with the changes in lipids.   
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Table 15 Association of myocardial infarction (MI) with SNPs previously found to significantly impactlipid traits 
SNP CHR SNP BP 
Reported 
Gene(s) 
Effect 
allele 
Lipid MI 
HDL-C LDL-C TG 
OR P 
β P β P β P 
Association of MI with single nucleotide polymorphisms (SNPs) previously found to relate to HDL-C 
rs1532085 15 rs1532085 58,683,366 LIPC A 0.20 1.04E-09 -0.08 0.02 0.02 0.61 1.18 4.81E-03 
rs17482753 8 rs17482753 19,832,646 LPL T 0.21 4.72E-05 0.10 0.08 -0.19 3.95E-04 0.82 0.04 
Association of MI with single nucleotide polymorphisms (SNPs) previously found to relate to LDL-C 
rs11668477 19 rs11668477 11,195,030 LDLR G 0.05 0.27 -0.10 0.03 -0.11 0.03 0.83 0.03 
Association of MI with single nucleotide polymorphisms (SNPs) previously found to relate to TG  
rs10401969 19 rs10401969 19,407,718 
CSPG3, 
CILP2, 
PBX4 
G 0.01 0.82 -0.03 0.63 -0.13 0.03 0.78 0.02 
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5.3.5 Examination of causal relationship between lipid and MI 
Mendelian randomization was utilized to assess the causal relationships 
between lipid and MI/CAD.  The MR studies were carried out for a 
combination of several SNPs, separately. 
 
Evaluation of genetic risk score (GRS) 
Nine index variants of HDL-C were employed to generate GRS (mean=9.00, 
minimum=4, maximum=14).  Adjusted for age, age
2
, gender and BMI, the 
GRS of HDL-C showed a significant association with HDL-C (β=-0.02, 
P=1.89x10
-7
), explaining 17.66% of HDL-C variance.  Five index variants of 
LDL-C were used to generate GRS. The GRS of LDL-C exhibited the mean 
of 2.87 with the minimum GRS of 0 and the maximum GRS of 8.  The GRS 
of LDL-C showed a genome wide significance with P value of 1.36x10
-10
 
(β=0.09) and a small R2 of3.16%.  Five index variants of TG were selected to 
generate GRS.  The GRS of TG exhibited the mean of 6.4 with the minimum 
GRS of 2 and the maximum GRS of 10.  The GRS of TG demonstrated a 
genome wide significant P value of 1.55x10
-10
 and explained 4.84% of TG 
variance.  
 
Association of genetic risk score with myocardial infarction  
The association of the GRS of each trait with MI was examined. Adjusting for 
age, gender, BMI and smoking status, they all showed an expected direction 
of beta coefficient but none of them showed a statistically significant 
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association (HDL-C: β=-0.02, P=0.36; LDL-C:  β=0.06, P=0.148; TG: 
β=0.03, P=0.47). 
 
5.4 Discussion 
5.4.1 Association of SNPs with lipid traits 
The power to detect genome wide significant associations was larger in lipid 
traits studies compared to that in MI studies.  With the sample size of 2,003, 
we had approximately 80% power to detect genetic variants that has 
MAF >0.06 and effect size >0.20. Our study has discovered 51 SNPs in 
known loci for the associations of lipid traits with genome wide significance.  
Among them, approximately half of them are new SNPs which have not been 
reported before. However, no new independent variants were discovered with 
the genome wide significance after adjustment for all index SNPs.  
 
Although no variants reached genome wide significance after conditional 
analysis, there were some suggestive evidences for new variant associated 
with HDL-C. The variant rs8025065 has demonstrated a P value of 1.82x10
-07
 
before adjustment and remained significance with P value of 1.22x10
-03 
after 
conditioning.  The effect size changed from 0.18 to 0.13.  The attenuated but 
significant P value and effect size suggested that the effect of rs8025065 on 
HDL-C may partly work together with the index SNPs but has its independent 
role in HDL-C concentrations.  This SNP has twice higher MAF in SCHS 
than the MAF in Europe.  According to the 1000 Genome database, the MAF 
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in Europe is 0.17 while the MAF in Asia is 0.41.  The high MAF may 
facilitate our finding.  However, rs8025065 needs to be examined in a larger 
sample size. 
 
In this study, the plasma TG levels were measured in the non-fasting state. 
Fasting TG is normally measured as a biomarker for the prediction of CAD 
risk as it can be largely affected by diet.  The concentration of TG increases 
substantially after meal.  Fasting TG has shown significant association with 
prevalent of CAD [206-208].  However, non-fasting TG is more widely used 
recently.  Researchers argued that non-fasting TG is a more meaningful index 
because fasting state only represents a small proportion of time each day and 
therefore understates levels that are attained in the postprandial state.  
Moreover, most individuals consume 3 or more meals daily, which make them 
remain in the postprandial state  most time of the day since TG may take 8 –
12 h to return to fasting concentrations after eating.  A study published in 
JAMA [210]compared the effect of fasting and non-fasting TG on 
cardiovascular risk.  This group used the Women’s Health Study cohort, 
which consist of 26,509 initially healthy American women and followed over 
11 year for MI, stroke and cardiovascular death.  In the analysis, both fasting 
and non-fasting TG were associated with future cardiovascular risk after 
adjustment of age, blood pressure, smoking and hormone replacement therapy.  
However, the association weakened after adjustment for total cholesterol and 
HDL-C while non-fasting TG remained a strong independent factor for future 
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cardiovascular risk [210].  Another study, which was conducted in a 
prospective cohort of 7,587 women and 6,394 men in Copenhagen with 
follow up of 26 years [211] has also shown that non-fasting TG is 
significantly associated with future vascular events in both sexes. Although 
recruitment for our study took place before these publications, and 
measurement of non-fasting TG was due to convenience rather than by design, 
it turned out favorably that this is now being recognized as a better 
measurement.   
 
The limitation of our study is the small sample size.  Given a modest sample 
size of 2,003 subjects, we only have 80% power to detect SNPs with MAF 
0.01 when its effect size is at least 0.30.  True variants associated with lipid 
traits may not reach genome wide significance. Only those with strong effect 
and relatively high allele frequency were discovered. To increase the power 
for these variants, additional samples would be required. 
 
5.4.2 Index SNPs influencing lipids and MI 
We have successfully replicated 66 of the 128 SNPs that have been previously 
reported associated with lipid traits in SCHS at P<0.05. Six of them showed 
genome wide significant associations. The majority of them have been first 
discovered in Europe, including rs1532085 in LIPC, rs3764261 in CETP [16, 
255] , rs7412 in APOE [256].  Among them, rs1532085 and rs3764261 have 
been replicated in Asian population [148], and rs7412 and rs651821 were 
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firstly replicated in Chinese population, in which it has a relatively higher 
MAF.  The other three variants rs651821 in APOA5, rs7350481 in APOA and 
rs1558861 in BUD13 all have a relatively higher MAF in Asian population 
and have been firstly identified in Asian population (rs651821: 1999 Chinese 
individuals [172]; rs7350481:  Japanese individuals [254]; rs1558861: Asian 
Indians [257]). They were then replicated in European individuals [256].  Our 
study first replicates the associations of rs7412, rs651821, rs7350481 and 
rs1558861 in Chinese.  
 
Among the entire index genotyped SNPs, approximately half of them were not 
significant in our population.  This may be attributed to the differences of 
MAF between Asian and European populations.  For example, rs471364 in 
TTC39B has been discovered to be associated with HDL-C with a genome 
wide significance in 20,623 individuals of European ancestry [143].  It has a 
MAF of 0.12 in Europe while the MAF in SCHS is only 0.017, which is 
consistent with Asian data from the 1000 Genome Project.  Moreover, 
variants with small MAF and effect size are less likely to be detected using a 
relatively small sample size of 2,003, such as rs1800961 in HNF4A associated 
with HDL-C (MAF=0.01, β=-0.06).  
 
To understand the role of index SNPs that influence lipid traits in the risk of 
MI, the associations of index SNPs with MI were examined.  The results 
showed that rs1532085, rs17482753, rs11668477 and rs10401969 that were 
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associated with lipid traits were also associated with the risk of MI although 
the P value was marginal (Prs1532085=4.81x10
-03
, Prs17482753=0.04, 
Prs11668477=0.03, Prs10401969=0.02).  The observed effect of variants rs17482753 
in LIPL, rs11668477 in LDLR and rs10401969 in CSPG3-CLP2-PBX4 were 
in accordance with the current paradigm that particular lipid levels associate 
with the risk of MI.  Except for rs1532085 in LIPC, there are prior evidences 
for the potential roles of LDLR in regulating LDL-C levels and CSPG3-
CLP2-PBX4 in regulating TG levels.  Variants in the LDLR gene have been 
shown to be the causal factor of familial hypercholesterolemia [258] and CAD 
[148, 259, 260]. Consistent with the association results, studies conducted on 
LDLR knock-out mice have also shown that lacking LDLR can lead to 
atherosclerosis [199].  A recent paper in Nature showed that a candidate 
causal variant in TM6SF2, previously known as NCAN-CILP2-PBX4 or 
19p13 has significant influence on lipid levels and MI risk [261].  These 
evidences have suggested that rs17482753 in LIPC, rs11668477 in LDLR and 
rs10401969 in CSPG3-CLP2-PBX4 could influence the risk of MI via certain 
lipid metabolic pathways. 
 
It is noteworthy that one of the findings, rs1532085 exhibits an increased 
HDL-C concentration, a reduced LDL-C concentration and increased risk of 
MI, which is not the paradigm of the relationship between lipid traits and the 
risk of MI.  In a recent GWAS study of 94,595 Europe individuals, Willer et 
al reported that the A allele of rs1532085 has statistically associated with 
increased TG concentration, HDL-C concentration and total cholesterol 
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concentration.  It suggested that rs1532085 may have different effect sizes on 
lipid profile or have a pleiotropic effect on unknown factors.  
 
5.4.3 Causal relationship 
To uncover the causal relationship between lipid traits and MI, we generated a 
genetic risk score variants that have significant impact on lipid traits as 
unbiased proxies.  The genetic risk score analysis did not showed any 
significant results.  Although the causal relationship between LDL-C and MI 
has been well established [194, 198, 200], we failed to replicate it.  The reason 
could be the few variants included in the genetic score and that too little 
variance of LDL-C was explained by the GRS.  Moreover, the sample size is 
small.  These were also the reasons for the failures of causation of HDL-C and 
TG.  
 
5.5 Summary 
In this study, we examined the associations of genome wide SNPs with lipid traits, 
including HDL-C, LDL-C and TG.  We have successfully replicated 66 index 
SNPs and discovered 51 SNPs associated with lipid traits with genome wide 
significance.  However, no SNPs remained genome wide significance after 
conditional analysis but there were suggestive evidences for rs8025065, which 
requires further investigation.  To understand whether the index SNPs that are 
associated with lipid traits (the intermediate traits of MI) could affect MI, their 
associations with MI were examined.  Four SNPs (rs1532085 in LIPC, 
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rs17482753 in LIPL, rs11668477 in LDLR and rs10401969 in CSPG3-CILP2-
PBX4) have demonstrated associations with lipid traits and MI.  We failed to 
determine the causality of HDL-C, LDL-C and TG for MI.  
 
The key findings from Study II were: 
1. Fifty one SNPs have been identified to associate with lipid traits but none of 
them stands after condition analysis. 
2. SNPs that have previously reported to be associated with lipid traits have 
been successfully replicated in SCHS.  Among them, rs17482753 in LIPL, 
rs11668477 in LDLR and rs10401969 in CSPG3-CILP2-PBX4 also 
demonstrated significant associations with MI (P<0.05)  
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Chapter 6: Interactions between genetic variants of peroxisome proliferator 
activated receptor delta and epithelial membrane protein 2 on high density 
lipoprotein cholesterol levels in the Singaporean Chinese—Study III 
6.1 Introduction 
HDL-C has been overwhelmingly demonstrated as a key factor that is inversely 
and independently associated with the risk of cardiovascular disease in 
epidemilogical studies[262, 263].  The protective effect of HDL-C has been 
attributed to its role in reverse cholesterol transport[264, 265], which results in the 
movement of cholesterol from tissues to liver.  PPARs,well-known lipid-activated 
transcriptional factors,play crucial roles  in the regulation of key molecules in 
reverse cholesterol transport such as ATP-binding cassette A1.  PPARs have  3 
isoforms ( α, δ, γ), which are structually correlated but different in their 
expression profiles and their target genes.  PPAR α is abundantly expressed in the 
liver and enterocytes.  Its activation increases HDL-C [266, 267].  PPAR γ is  
predominantly expressed in adipose tissue [268] and plays an important role in 
cholesterol homeostasis.  It controls ATP-binding cassette A1 (ABCA1) and 
caveolin 1, thus contributing to variations in HDL-C levels [269-271].  Unlike 
PPAR α and γ,  PPAR δ is ubiquitously expressed but only at low levels in the 
liver.  High-affinity ligand studies of PPAR δ have revealed that IT is a key 
regulator of HDL-C levels through its action on  the number of its particles and 
not size[272].  Taken together, PPARs are important factors influencing HDL-C 
levels, which are associated with many diseases such as type 2 diabetes and 
atherosclerosis. 
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Given the substantial roles of PPARs on lipids , various agonist of PPARs have 
been synthesized and the biological effects of PPAR agonists on lipid and 
cardiovascular diseases have been tested in vivo and in vitro.  For example, the 
PPAR δ agonist MBX-8025 and GW501516 have been studied in randomized 
trials in humans, showing an effect of increased HDL-C and reduced LDL-C[273, 
274].  Moreover , much effort has been put into the identification of novel genetic 
variants in PPARs for association with a variety of lipid-related diseases.  Several 
rare variants in PPARs have been reported to associate with high density 
lipoprotein[275-277].  The L162V(rs1800206) polymorphism in PPAR α is a 
misssense variant that has been reported to associate with the levels of 
apolipoprotein AІ (apoAІ)[275], apoliprotein B (apoB)[278, 279], apoCIII, LDL-
C[278, 279] and HDL-C[275].  The P12A(rs1801282) polymorphism in PPAR γ 
has been discovered[280] and showed a statistically significant association with 
type 2 diabetes but not lipid levels[281].  Another variant +T294C (rs2016520), in 
PPAR δ, has been intensively studied by Skogsberg et al in 2003, showing that 
carriers of minor allele C had significantly higher LDL-C concentration[276] and 
lower HDL-C [277] in male populations.  Similar results have been presented in a 
sample size of 967 Geman in 2006[282].  However, a reversible severe HDL-C 
deficiency, a phenomenon called ―disappearing HDL syndrome‖[283-286], has 
been observed in subjects with previously normal HDL-C levels but extremely 
low HDL-C levels after PPAR agnoist treatment.  More importantly, the severe 
HDL-C deficiency is reversible when the treatment stopped.  It implies PPARs 
may interacti with some other factors to regulate HDL-C levels.  Until now 
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several interaction studies have been conducted among three PPAR isoforms 
experimentally and statistically[277, 287].  A gene-gene interaction between the 
PPARδ polymorphism rs2016520 and the PPARα polymorphism rs1800206 was 
found to influence the plasma LDL-C concentration[277].  However, there have 
been no previous studies to explore how genetic variants in the three PPAR 
isoforms have interacted with other SNPs across the genome to impact HDL-C 
levels, we set out in this studyto fill this knowledge gap using a Chinese 
population in Singapore.  
 
6.2 Methods 
6.2.1 Study design and study populations 
The study design was summarized in Figure 14. SCHS (N=2,003) was used as 
discovery population. SP2 (N=2,099), SCES (N=1,872), SiMES (N=2,541) 
and SINDI (N=2,538) were used as replication population.  The study design, 
genotyping, quality control and lipid mesurements were detailedly described 
in Chapter 3. In this study, all participants known to be on lipid-lowing 
therapy were adjusted in our analysis.  
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Figure 14 Flow chart of interaction study between PPARs and SNPs across genome 
 
6.2.2 Candidate SNP selection 
The locations of PPARs were obtained from Ensembl Genome Brower 
(http://www.ensembl.org/index.html ).  The SNPs ± 100kb of  PPARs were 
extracted by Haploview 4.2 using CHB+JPT analysis panel(Version 3 Release 
R2).  The number of SNPs for PPAR α, δ, γ were 227, 110 and 163, 
respectively.  Among the 500 PPAR SNPs, 233 SNPs were overlapped with 
802,635 SNPs on Illumina ZhongHua array which passed the quality control.  
These genotyped SNPs were further pruned in (R
2
<0.2) by PLINK version 
1.07. Fifty three independent SNPs of PPARs (25 SNPs for PPARα, 10 for 
PPARδ, 18 SNPs for PPARγ) remained for analysis .  
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6.2.3 MicroRNA binding site prediction 
PolymiRTS Database 3.0 (http://compbio.uthsc.edu/miRSNP/) [288] was 
utilized to predict the effect of SNPs on miRNA taget sites in our study. 
 
6.2.4 LD pattern comparsion 
The online database SGVP (http://www.statgen.nus.edu.sg/cgi-
bin/gbrowse/sgvp/#search)[289] was utilized to compare the LD pattern 
around SNPs among different ethnic group.  
 
6.2.5 Statistical analysis 
Differences between means in demographic and biochemical parameters were 
evaluated by the t-test.  Differences in frequencies were evaluated by the chi 
square test.  Raw HDL-C levels were normalized by rank-based inverse 
normal transformation[290] in all cohorts (intHDL-C).  Samples with more 
than 3 SD of intHDL-C were excluded from analysis.  The number of outliers 
were 6 in SCHS, 5 in SCES, 5 in SP2, 6 in SiMES and 6 in SINDI.Body mass 
index (BMI) was derived from height and weight measurements 
(BMI=weight/height2).  Missing BMI values were imputed using multiple 
imputation [291].  Association analysis was conducted in PLINK version 1.07 
using linear regression model with age, age
2
, gender and BMI adjustment 
(P=9.43x10
-4
 after multiple test correction ).To note, using age2 can help 
more accurately model the effect of age as the relationships between age and 
lipid traits are non-linear.  SCHS was analyzed seperately according to MI 
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status and meta-analyzed using fix effect model.  The 801,660 genome wide 
SNPs (with the exclusion of 2 SNPs of missingness >0.05, 772 with 
MAF<0.01, 201 SNPs with HWE departure 1x10
-6 
among 802,635 SNPs and 
2,003 samples ) were pruned using PLINK, leaving 142,208 independent 
genome wide SNPs.  Interaction was first tested between 53 SNPs and 
142,208 independent genome wide SNPs in an additive model in SCHS 2,003 
samples.  This was executed in PLINK version 1.07 using a linear regression 
model by including the multicative term of 2 SNPs (each of the 53 PPAR 
SNPS*each of the 142,208 genomewide SNPs).Three rare double 
homozygotes of PPARδ and EMP2 were observed among the five cohorts 
(N=10,973). To reduce the possibility of a chance finding caused by rare 
double homozygotes, the interactions are presented in a dominant model with 
adjustment for age, age
2
, gender,  BMI, smoking status, priciple components 
(for non-Chinese cohorts) lipid-lowering medication and MI status if available. 
We defined the statistical significance as 6.63 x 10
-9
 based on 7,537,024 tests 
(53 PPAR SNPS*142,208 genomewide SNPs).  The replications were 
conducted in SCES, SP2, SiMES and SINDI using the same model.  Meta-
analysis was conducted in the two Chinese cohorts, SCES and SP2, using 
fixed effect model.  One way analysis of variance and Tukey’s honestly 
significant difference pos-hoc test were used for the multiple comparisons of 
genotypic mean HDL-C levels between different combined genotypes of 
rs2267668 (PPARδ) and rs7191411 (EMP2). 
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6.3 Results 
This study was conducted to discover new susceptibility loci within PPARs of 
HDL-C in SCHS.  Suggestive results were further replicated in SCES, SP2, 
SiMES and SINDI. 
 
6.3.1 Characteristics of populations 
As shown in Table 16, SCHS and SCES shared similar HDL-C level while the 
HDL-C of SP2 was significantly higher (P<0.00001).  The HDL-C of SiMES 
was slightly higher and the HDL-C of SINDI was significantly lower 
compared to that of SCHS.  For age, the majority of SCHS were much older 
than subjects in SCES, SiMES and SINDI while SP2 had a younger 
population.  Percentage of men was quite different across study cohorts. 
Therefore, age and gender were adjusted in subsequent analyses.  
  
132 
 
Table 16 Study demographic characterstics of the five Singaporean cohorts 
Studies 
SCHS 
(N=2,003) 
SP2 
(N=2,099) 
SCES 
(N=1,872) 
SiMES 
(N=2,541) 
SINDI 
(N=2,538) 
Ethnicity Chinese Chinese Chinese Malay Indian 
HDL-C 
(mmol/L) 
1.32 ± 0.32 1.40 ± 0.36 1.30 ± 0.40 1.35 ± 0.33 1.06 ± 0.31 
Age (years) 66.42 ±7.82 47.72 ±10.97 58.46 ±9.54 59.08 ±11.04 58.04±10.01 
Percent of men 
(%) 
63.95 41.78 51.34 49.43 51.14 
Percent of 
smoker (%) † 
42.49 16.72 26.94 39.64 26.96 
BMI (kg/m2)* 22.98 ± 3.35 22.74 ± 3.70 23.76 ± 3.54 26.38 ± 5.11 26.12 ± 4.98 
Lipid-lowering 
medication (%) 
n.a 8.10% 24.30% 15.90% 30.26% 
HDL-C, age and BMI are presented as mean ± SD 
*missing BMI values were imputed. 
†Smokers were defined as current smokers and ever smokers. 
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6.3.2 Associations of PPAR SNPs with HDL-C 
The association of 53 SNPs with HDL-C was determined by using linear 
regression analysis.  Although lipid measurements were made before any 
incidence of MI in the 719 cases, the analysis was nevertheless stratified by 
MI to eliminate any potential bias.  As shown in Table 17, only 2 SNPs 
demonstrated statistically significant associations with HDL-C (P<0.05) after 
adjustment of age, age
2
, gender and BMI.  One was rs2299869 in the intron of 
PPAR δ with a protective effect on HDL-C (P=9.96 x 10-4) in non-MI subjects 
(N=1,284) but it had no effect on HDL-C in MI incident subjects (N=719).  
Interestingly, the variant rs2299869 is unique in Asians and Americans with a 
relatively high MAF of 0.16 based on the data from 1000 Genome database 
(http://browser.1000genomes.org/index.html ).  The variant is absent in 
Europeans and Africans.  The other SNP rs932548, in the intron of PPAR α, 
consistently showed a corresponding lowering effect of 0.08 mmol/L HDL-C 
with every increase of risk allele copy in both non-MI and MI subjects.  
However, there were no substantial evidences of these two associations 
because they did not stand after multiple test correction since a P value 
smaller than <9.43x10
-4
 is required.  
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Table 17 Association of PPAR SNPs with HDL-C 
SNP CHR Position 
Minor 
allele 
MAF 
Non-MI incident 
(N=1,284) 
MI incident 
(N=719) 
Meta 
(N=2,003) 
Beta 
[S.E] 
P 
Beta 
[S.E] 
P 
Beta 
[S.E] 
P 
rs2299869 6 35383432 T  0.12 
-0.21 
[0.06] 
9.96E-04 
0.00 
[0.08] 
0.99 
-0.12 
[0.05] 
0.01 
rs932548 22 48200547 T  0.18 
-0.08 
[0.05] 
0.12 
-0.08 
[0.06] 
0.17 
-0.08 
[0.04] 
0.04 
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We attempted to replicate rs2299869 and rs932548 in two Chinese cohorts—
SP2 and SCES.  However, they all failed the quality control with more than 5% 
missing genotypes except rs932548 in SCES (call rate: 95.77%).  It showed a 
similar effect size but an opposite direction with P value of 0.061 (β=0.07, 
S.E=0.04).  The PPAR variants rs1800206, rs1801282 and rs2016520 that 
have previously shown associations with HDL-C in other studies were looked 
up in SCHS.  The SNP rs1800206 was monomorphic in Chinese while the 
other two were both not associated with HDL-C (Prs1801282=0.68, 
Prs2016520=0.58). 
 
6.3.3 Epistasis of PPARs variants on HDL-C 
In order to examine whether the effect of PPARs variants on HDL-C functions 
through gene-gene interaction, epistasis analysis was performed.  Pairwise 
SNP x SNP interactions on HDL-C between PPAR SNPs (N=53) and genome 
wide SNPs (N=142,208) were tested in 2,003 Singaporean Chinese subjects.  
We observed one gene-gene interaction between PPAR δ (rs2267668) and 
epithelial membrane protein 2(EMP2) (rs7191411affecting HDL-C (=-0.58, 
P=1.12x10
-10
).  To reduce the possibility of a chance finding caused by one 
double rare homozygote (HDL-C level=2.49mmol/L, N=1), the interaction 
was examined in a dominant model and remained significant (β=0.74, 
P=9.0x10
-03
 after Bonferroni correction).  The interaction between rs7191411 
(EMP2) and rs2267668 (PPAR δ) on HDL-C were subsequently examined in 
SCES, SP2, SiMES and SINDI.  The interaction was successfully replicated in 
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the meta-analysis of the two independent Chinese cohorts SCES and SP2 
(Table 18; P=0.01) but not in SiMES and SINDI (Table 18).  
Figure 15 showed that HDL-C decreased with increasing number of minor 
alleles from one SNP (either PPARδ or EMP2) led to a decreasing trend of 
HDL-C.  However, plasma HDL-C levels were increased among subjects 
harboring minor alleles from both SNPs.  The levels of HDL-C for each 
genotype combination are presented in Table 18 for the discovery and two 
replication Chinese cohorts.  
 
The EMP2 variant rs7191411 is 339 bases downstream of EMP2.  To explore 
potentially functional SNPs in close linkage disequilibrium (LD) with this 
SNP, we conducted a pairwise LD calculation across the chromosome of 
rs7191411. Two SNPs, rs12928798 (R
2
 = 0.97 in SCHS, R
2
 = 1 for Chinese in 
1000 Genome database in Chinese) and rs12596251 (R
2
 = 0.93 in SCHS, R2 = 
0.93 for Chinese in 1000 Genome database) were found to have a high LD 
with rs7191411.  Rs12928798 is located in the 3’UTR region while 
rs12596251 is an intronic SNP. The PPARδ SNP rs2267668 is located within 
the intronic region of PPARδ. No potentially functional SNPs in close LD 
with this SNP could be found in the genotyped SNPs. 
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Table 18 Main and interactive effect of rs2267668 (PPARδ) and rs7191411 (EMP2) SNPs on rank-based inverse normal transformated HDL-C 
(intHDL-C) 
 
 
Discovery Replication Meta-analysis 
  
SCHS SCES SP2 SiMES SINDI SCES+SP2 SCHS+SCES+SP2 
Ethnicity  Chinese Chinese Chinese Malay Indian Chinese Chinese 
N 
 
1,993 1,860 2,088 2,507 2,525 3,948 5,941 
MAF 
rs2267668 0.28 0.29 0.27 0.30 0.15 0.28 0.28 
rs7191411 0.06 0.07 0.07 0.07 0.11 0.07 0.07 
Model 1 
rs2267668 (PPARδ) 
Beta -0.03 -0.02 -0.03 0.02 0.05 -0.03 -0.03 
S.E 0.04 0.04 0.04 0.04 0.04 0.03 0.02 
P 0.41 0.59 0.44 0.57 0.20 0.38 0.25 
Model 2 
rs7191411 (EMP2) 
Beta 0.03 0.05 -0.01 -0.01 0.02 0.02 0.02 
S.E 0.06 0.06 0.05 0.05 0.04 0.04 0.03 
P 0.57 0.33 0.85 0.85 0.58 0.70 0.56 
Model 3 
rs2267668 (PPARδ) 
 
Beta -0.12 -0.06 -0.04 0.04 0.08 -0.05 -0.07 
S.E 0.04 0.04 0.04 0.04 0.05 0.03 0.02 
P 4.00E-03 0.14 0.27 0.35 0.07 0.08 1.00E-03 
rs7191411 (EMP2) 
 
Beta -0.30 -0.09 -0.06 0.05 0.06 -0.08 -0.15 
S.E 0.08 0.08 0.08 0.07 0.05 0.06 0.05 
P 2.73E-04 0.25 0.40 0.53 0.22 0.19 1.00E-03 
rs2267668xrs7191411 
(PPARδX EMP2 ) 
 
Beta 0.74 0.28 0.11 -0.11 -0.14 0.20 0.36 
S.E 0.12 0.11 0.11 0.10 0.10 0.08 0.07 
P 1.20E-09 0.01 0.31 0.29 0.15 0.01 4.82E-08 
Models 1 & 2: The main effect of PPARδ SNP/EMP2 SNP on intHDL-C were tested in a dominant model with adjustment of age, age2, gender, imputed 
BMI/BMI, principle component (for non-Chinese cohorts), smoking status , lipid-lowering medication status and MI status where available. 
Model 3:  Model 1 + Second SNP + multiplicative term of PPARδ SNP x EMP2 SNP. 
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 Figure 15 Interaction effect of rs2267668 (PPARδ) and rs7191411 (EMP2) on HDL-C in the three Chinese cohorts (SCHS+SCES+SP2) 
 
*† denote the significantly different HDL-C between any two group with the same symbol (P<0.05, two tailed)  
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Table 19 Genotypic mean HDL-C levels (mean ± SD) of the combined genotypes of rs2267668 (PPARδ) and rs7191411 (EMP2) in the discovery and 
replication Chinese cohorts 
Genotype* 
(rs2267668/rs7191411) 
AA/GG AA/GA AA/AA AG/GG AG/GA AG/AA GG/GG GG/GA GG/AA 
SCHS (Discovery) 
N 910 136 2 699 84 4 137 20 1 
HDL-C(mmol/L) 
1.34 ± 
0.32
ab
 
1.27 ± 
0.30
cd
 
1.19 ± 
0.61
e
 
1.30 ± 
0.32
fg
 
1.41 ± 
0.33
c
 
1.31 ± 
0.44
h
 
1.27 ± 
0.27
ij
 
1.56 ± 
0.44
adfi
 
2.49
bceghj
 
SCES + SP2 (Replication) 
N 1,798 259 13 1,330 230 8 283 45 2 
HDL-C(mmol/L) 1.36 ± 0.38 1.34 ± 0.35 1.22 ± 0.24 1.34 ± 0.38 1.39 ± 0.40 1.46 ± 0.26 1.33 ± 0.37 1.49 ± 0.40 
1.17 ± 
0.20 
Meta-analysis of SCHS+SCES+SP2 (Discovery + Replication) 
N 2,711 395 15 2,030 314 12 420 65 3 
HDL-C (mmol/L) 
1.35 ± 
0.36
a
 
1.32 ± 
0.34
b
 
1.22 ± 0.28 
1.33 ± 
0.36
c
 
1.39 ± 0.38 1.41 ± 0.32 
1.31 ± 
0.35
d
 
1.51 ± 
0.41
abcd
 
1.61 ± 
0.77 
* Mean value of HDL-C were compared across different genotypes. Significantly different HDL-C between any two group were denoted with the same 
symbol (Tukey test, P<0.05) 
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Figure 16 Comparisions of LD pattern within 200 kb flanking regions of rs2267668 and 
rs7191411 between Chinese and Indians, and between Chinese and Malays using SGVP 
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6.4 Discussion 
In this study, we first examined the association of 53 common variants in PPAR 
genes with HDL-C for their main effects. Subsequently, the interactions between 
PPAR variants and all independent genotyped SNPs elsewhere in the genome.  
No new variants in PPARs were significantly associated with HDL-C.  However, 
one statistically significant interaction has been identified between PPARδ 
(rs2267668) and EMP2 (rs7191411) which showed an increase of HDL-C in 
individuals carrying minor alleles from both SNPs. 
 
In the association analysis of PPAR SNPs with HDL-C, the power to detect 
variants (MAF=0.12~0.18) associated with HDL-C with an allelic effect size of 
0.08 to 0.21ranges between 0.95~0.99.  This implies that we have sufficient 
power to detect true associations.  The SNP rs2299869 might possibly interact 
with other unknown factors as it only showed a marginal significant association 
with HDL-C in the SCHS controls but not in the SCHS cases.  The SNP rs932548 
demonstrated similar effect size in SCHS controls cases and SCES but opposite 
directions between SCHS and SCES.  These results may be explained by 
unknown interactions in different cohorts.  
 
The EMP2 SNP tested in this study (rs7191411) is in high LD with rs12928798, 
which has been predicted to be a binding site of hsa-miR-4302 by PolymiRTS 
Database 3.0.  Therefore, the observed interaction effect of rs7191411 may be 
attributed to its high LD with the latter, which could influence the expression 
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levels of EMP2.  Subsequent in vivo and in vitro studies would be needed to 
elucidate the mechanism of how PPARδ and EMP2 interact to affect HDL-C 
blood lipid levels. 
 
The PPARδ and EMP2 interaction could be replicated in the meta-analysis of two 
independent Chinese but not in the Malays and Indians.  The effect of the 
interactions in all three Chinese cohorts were consistent (all showing positive 
betas), whereas there is no evidence for the interaction observed in Malays and 
Indians. One plausible explanation for the failure in the Malay replication could 
be due to the pattern of LD around the SNPs in different ethnic groups, in which 
the SNPs may be tagged to different causal SNPs. According to Singapore 
Genome Variation Project, a haplotype map of Chinese, Malay and Indian 
population groups in Southeast Asia, there is evidence of a different pattern of LD 
around rs2267668 (PPARδ) between Chinese and Indian population groups 
(Figure 16). However, we are not able to account for the failure of replication in 
the Malays. This would require additional investigations. 
 
PPARδ is a ubiquitously expressed transcription factor. Cellular and animal 
studies have shown that an agonist of PPARδ (GW501516) was able to affect 
lipid profile with an 80% increase in HDL-C compared to baseline level through 
its action on ATP binding cassette transporter subfamily A member 1 
(ABCA1)[272, 292].  Recently, several clinical trials have demonstrated that 
patients administered an agonist of PPARδ showed an elevation in HDL-C 
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concentrations and in the number of HDL-C particles [273, 274, 293].  The 
mechanism of PPARδ on HDL-C functions is through the protection of caveolin-1, 
an essential protein in reverse cholesterol transportation, from degradation [294].  
This protein has been reported to localize and interact with ABCA1 and their 
interaction is crucial for caveolin-1 regulation of cholesterol efflux [295].  
Interestingly, PPARγ has been reported to modulate the expression level of 
caveolin 1[105].  This suggests that PPARδ and PPARγ play important roles in 
cholesterol efflux through the regulation of caveolin-1 at the transcription and 
protein level. Importantly, EMP2 has been demonstrated to down regulate 
caveolin-1[296, 297].  Recently, a report in American Journal of Human Genetic 
has shown that the mutation in EMP2 can cause childhood-onset nephrotic 
syndrome, of which hyperlipedemia is one of the cardinal manifestations [298].  
Although the relationship between EMP2 and PPARs has never been studied, our 
study provides statistical evidence suggesting that EMP2 and PPARδ could 
interact to influence cholesterol efflux and thus modulate HDL-C.  The relevant 
biological roles of PPARδ and EMP2 in reverse cholesterol transport also 
provided some support to the possibility of such an interaction.  The overall 
impact of this interaction may not limit to the regulation of HDL-C concentrations.  
It could also fundamentally affect the cholesterol efflux capability in genetic level, 
which has been shown to be a more important factor in the prediction of 
cardiovascular disease than HDL-C concentrations [299].  
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In conclusion, our study provides genetic epidemiological evidences for the first 
time that PPARδ (rs2267668) could interact with EMP2 (rs7191411) influencing 
circulating HDL-C cholesterol.  A significant reduction of HDL-C was observed 
in subjects with minor allele(s) from either SNPs but an increase of HDL-C when 
minor alleles from both SNPs are present.   
 
6.5 Summary: 
The associations of genetic variants with HDL-C and the interactions 
(multiplicative term of two SNPs) between 53 independent PPAR SNPs (R
2
<0.2) 
and genome wide SNPs were tested using linear regression models.  Our study 
failed to discover any new SNPs with significant associations between PPAR 
SNPs and HDL-C after multiple-testing corrections.  One statistically significant 
interaction influencing HDL-C has been detected between PPAR δ variant 
rs2267668 and epithelial membrane protein 2(EMP2) downstream variant 
rs7191411 (=0.74, P=8.4x10-03 after multiple-testing correction).  The 
interaction was successfully replicated (meta-analysis=0.20, P=0.01) in the 
Singaporean Chinese population, including SCES (N=1,872) and SP2 (N=2,099) 
but not in the Malays (SiMES) and Indians (SINDI). 
  
145 
 
The key findings from Study III were 
1. No new SNPs showed significant association with HDL-C after multiple-
testing corrections. 
2. PPAR δ intronic variant rs2267668 showed a statistically significant 
interaction with EMP2 downstream variant rs7191411.  
3. The effect of PPAR δ variant rs2267668 on HDL-C was modified by 
EMP2 variant rs7191411 with the presence of minor allele from both 
SNPs being associated with an increase of HDL-C.  
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Chapter 7 Conclusion 
7.1 Main findings 
Genetic determinants are of fundamental importance for Mendelian and complex 
diseases such as CAD.  GWAS is currently the most popular and powerful tool to 
identify genetic variants associated with diseases.  To unravel the genetic basis of 
CAD, our aims were to discover susceptibility genetic variants associated with 
CAD and its quantitative intermediate traits (HDL-C, LDL-C and TG), to address 
one of the contributors to the phenomenon of missing heritability by including a 
gene-gene interaction analysis. 
 
In Study I, a total of 1,136 MI cases and 1,243 controls from the Singaporean 
Chinese were recruited, with the goal of discovering new susceptibility loci for 
CAD.  We observed suggestive associations of several SNPs in well-established 
genes implicated in the pathogenesis of CAD.  However, no new genetic variants 
exhibited genome wide significant association with MI due to the limited power 
of our study design.  Next, we conducted Study II, quantitative GWAS on the 
intermediate traits of CAD, namely HDL-C, LDL-C and TG.  The GWAS of 
lipids was carried out in 2,003 Singaporean Chinese stratified by their MI status 
and the results were meta-analyzed using the fix effect model.  We have 
successfully replicated 66 of the 174 genetic variants that were previously 
reported in Caucasians, thus demonstrating the transferability of these genetic 
variants across ethnic groups.  Significant genome wide associations have been 
discovered in 11 genetic variants for HDL-C, 18 for LDL-C and 22 for TG.  For 
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the purpose of identifying independent genetic variants, conditional analysis was 
conducted to adjust for the effect of index variants.  We found no evidence of 
genome wide significant associations for these variants after the conditioning but 
there were suggestive evidences for rs8025065 in LIPC, which requires further 
investigation.   
 
In study III, our aim was to find novel interactions that could potentially 
contribute to the missing heritability.  Based on a modest sample size of 2,003 
subjects, a gene-gene interaction study was carried out by selecting independent 
SNPs in PPARs, which are the key upstream regulators in the HDL-C metabolic 
pathway. We discovered a statistically significant interaction influencing HDL-C 
between the PPAR δ variant rs2267668 and EMP2 downstream variant rs7191411 
(β=0.74, P=1.20X10-09) after multiple-testing correction (corrected P significance 
threshold=1.18x10
-9
). The interaction has been validated (meta-analysis β=0.20, 
P=0.01) in the meta-analysis of two independent Chinese populations but not in 
the Malays and Indians.   
 
7.2 Directions for future works 
7.2.1 Increasing sample size to obatain a better power 
GWAS is a powerful tool used to identify susceptibility loci predisposing 
complex diseases.  The power of GWAS is limited by the sample size when 
multiple testing corrections are applied.  A larger sample size is essential to 
compensate for the multiple testing.  In Study I, it was too underpowered to 
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discover any genome wide signals. Approximately 80% power is obtained 
when the variants exhibit a minimum MAF and effect size of 0.33 and 1.31, 
respectively. In Study II, although many genome wide significant signals were 
detected, we did not observe any new susceptibility loci.  The possible 
explanations include a lack of power to discover SNPs with small effect and 
small frequency, or unknown interactions that reduce the effect of SNPs. 
Therefore, a sufficiently large sample size is essential for the success of 
GWAS.  With an increasing number of GWAS conducted, most of the 
frequent variants with strong effects would have been identified.  To detect 
common variants that have smaller effect and occur less frequently in 
populations, the requirement for sample size is more stringent.  We are 
currently recruiting patients for SCADGENS to boost the number of CAD 
cases and hence the power to detect genetic variants will be increased.  In the 
meantime, we are also actively seeking collaborations with other research 
groups who have undertaken GWAS in the East Asian cohorts which we can 
be utilized for meta-analysis or validation.   
 
7.2.2 Causality of lipid traits for MI 
The ultimate goal of any biomedical investigations is to improve our 
understanding of diseases and to translate the knowledge to develop effective 
therapies.  Before such a translation takes place, it is essential to rigorously 
establish the causality of any risk factor.  Among the three lipid traits—HDL-
C, LDL-C and TG, LDL-C is the only trait that has been proven to cause MI 
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[194, 197, 200].  Statin is the well-known drug used to lower LDL-C levels 
and thus reduce the risk of MI.  However, the causality of HDL-C and TG for 
MI remains obscure.  An important obstacle when determining causation is 
the fact that HDL-C and TG are inversely correlated.  This creates difficulties 
in the identification of genetic variants without pleiotropic effects so that 
genetic variants can be employed as surrogates for the corresponding lipid 
traits.  A recent Mendelian randomization study was conducted to investigate 
the causality of HDL-C for MI using a single SNP LIPG Asn396Ser [194] but 
failed to confirm the causality.  This could be have been due to the use of only 
one genetic variant as the proxy of HDL-C while the total variants of HDL-C 
explained by Asn296Ser could be restricted.  Therefore, it is preferable to 
conduct MR studies for a combination of several independent SNPs without 
pleiotropic effects.  This could be one possible avenue of future studies.   
 
7.2.3 Identification of interactions 
Interaction is an important contributor to missing heritability.  It is largely 
present in the biology of human. Interaction studies are a new frontier in the 
studies of human genetics in recent future. Although interaction analysis is 
challenged by underpowered issue, we can advance the understanding of 
interactions by clever selection strategies and effective analytical models. One 
aspect of interaction analysis is gene-environment interactions. The 
environmental factors include smoking, alcohol consumption, physical 
activities, diet and drugs.  Compared to the studies of environmental 
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exposures, the application of gene-gene interaction studies focuses more on 
the elucidation of mechanisms while environment interaction studies may 
have greater impact on public health as environmental factors are modifiable. 
Many interactions between genetic variants and environmental factors have 
been discovered. However, it has been difficult to translate these findings into 
clinical treatments due to the underlying complexity of these interactions 
because multiple genetic variants may be involved in the exposure to the 
environmental factors at the same time.  For example, variant rs3212986 was 
associated with the increased risk of lung cancer in never smokers (OR=2.11) 
but exhibit an opposite OR of 0.5 in smokers [300].  Another variant in let-7 
family-of-microRNAs demonstrated a 2.3-foled increased risk for lung cancer 
in smokers [301].  Despite these challenges, studies of interactions between 
drugs and genetic variants can facilitate the development of personalized 
therapy. We have conducted a gene-gene interaction study in Study III and 
identified a statistically significant interaction between PPAR δ and EMP2 
that influences circulating HDL-C concentrations.  The two molecules are 
related to each other through caveolin-1, which is involved in the cholesterol 
reverse transportation pathway.  This finding has provided insight into 
potential mechanisms that are involved in the etiology of CAD.  For such 
interaction findings from a population, it is vital to follow up with 
experimental studies.  For Study III, an immediate follow-up of this work 
could be to verify this interactive effect on HDL-C and then to examine their 
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relationships through in vitro and possibly in vivo investigations.  Similar 
studies may be an interesting topic in the future investigation.  
 
7.2.4 Identification of rare variants by next generation sequencing 
An important goal of human genetics is to identify genetic determinants for 
complex diseases. For a long time, researchers believe that common diseases 
are contributed by many common variants with small effects. Based on this 
hypothesis, GWAS has emerged as a powerful tool to identify common 
variants since 2007. To date, GWAS has identified more than 500 
independent significant genetic variants that are associated with complex 
diseases (see GWAS catalog 
http://www.genome.gov/gwastudies/index.cfm?pageid=26525384#searchFor
m ).  However, there is missing heritability that cannot be explained by strong 
significant common variants.  Furthermore, the total variance of disease is 
little explained (up to 5%~10%) by significant common variants discovered 
by GWAS.  In addition, few common causal variants have been identified in 
post-GWAS studies. These findings raise the doubt that common variants are 
the primary drivers for the etiology of diseases. In my opinion, I certainly 
believed that rare variants play a role in the etiology of complex diseases as 
several rare variants have been found to be associated with various complex 
diseases[302]. Nevertheless, it is currently still debatable whether common 
variants or rare variants are the primary genetic determinants for the etiology 
of complex diseases.  Common variants uncovered by GWAS have 
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substantially contributed to the understanding of new molecules or new 
mechanisms that involved in the etiology of diseases. The common variants in 
CDKN2A/2B are such an example that facilitates the discovery of antisense 
non-coding RNA gene that may constitute a regulator of epigenetic 
modification and thus modulate the risk of CAD [129, 130].  Regardless of 
this debate, whole genome and whole exon sequencing, which take 
advantages of next-generation sequencing technologies, could be the 
important avenue for future genetic studies of complex diseases.  It not only 
facilitates the identification of potentially causal common variants tagged by 
strong significant SNPs but also facilitates the discovery of rare variants. 
 
7. 4 Conclusion 
In summary, this dissertation has demonstrated the transferability of the majority 
of genetic variants identified in Caucasians across ethnicities to the Chinese.  
Several genetic variants associated with MI or lipid traits (HDL-C, LDL-C, and 
TG) have been identified in elucidation of the genetic basis of CAD.  The gene-
gene interaction identified in this dissertation has advanced our understanding of 
the complex etiology of CAD.  Further experimental studies of interactions will 
be necessary to unravel the mechanisms the mechanisms underlying CAD.  These 
findings highlight the global transferability of the majority of genetic variants and 
the potential new susceptibility of several loci for CAD.  The significant gene-
gene interaction, identified for the first time, provide new insight into the 
potentially new mechanisms influencing circulating HDL-C.  
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